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Abstract
Cancer is a complex disease with significant variability between cases, and
as a result, is one of the leading causes of death worldwide. Lung cancer
is a particularly difficult form of cancer to diagnose and treat, due largely
to the inaccessibility of lung tumours and the limited available treatment
options. There is a need for highly targeted, minimally invasive treatment
options that facilitate the complete removal of cancer from a patient while
minimising damage to non-malignant tissue.
The development of plasmonic gold nanoparticles has lead to their potential
use in a large range of disciplines, and in particular, they have shown
great promise for application in biomedicine. Plasmonic gold nanoparticles
possess many desirable characteristics, such as controllable size and shape
during synthesis, the biocompatible and inert nature of gold, the potential
functionalisation and surface modification prospects, and tunable surface
plasmon resonances, that make them excellent candidates for biological use.
These beneficial properties facilitate their use as contrast agents to further
enhance existing light-based biomedical techniques, such as photoacoustic
imaging and photothermal therapy, while possessing the ability to form
new combined treatments.
In this thesis, gold nanorods - a subset of gold nanoparticles - will be in-
vestigated as a means to mediate photoacoustic imaging and photothermal
therapy for combined lung cancer theranostics, while demonstrating their
ability to improve current clinical practice. Since gold nanorods can be syn-
thesised to be almost any size, and their aspect ratio governs their peak sur-
face plasmon resonance, there may be an optimal sized AuNR for use in bio-
medical modalities that absorbs light at a particular wavelength. Four dif-
ferent sized gold nanorods (widths of 10, 25, 40, and 50 nm) with similar as-
pect ratios and therefore similar surface plasmon resonances (815±26 nm)
were considered for use in photoacoustic imaging. It was shown that the
larger gold nanorods produced the highest photoacoustic amplitude at an
equivalent number of nanoparticles, but were the most toxic, while the
smallest gold nanorods were optimal at an equivalent total mass. The res-
ults indicate the importance for determining the dependence of total mass
or number of nanoparticles on cellular targeting and uptake in vivo.
Gold nanorods can also be used as photoabsorbers for therapeutic modalit-
ies, such as photothermal therapy. Conventionally, continuous wave lasers
are used to generate bulk heating in gold nanorods, that are situated in a
target region, and the diseased tissue is destroyed via hyperthermia. How-
ever, there are potential negative side-effects of heat-induced cell death,
such as the risk of damage to healthy tissue due to heat conducting to
the surrounding environment, and the development of heat and drug res-
istance. Therefore, the use of pulsed lasers for photothermal therapy was
investigated and compared with continuous wave lasers. It was shown that,
for continuous wave lasers, a larger number of gold nanorods in the absorb-
ing region resulted in increased cell death, whereas with pulsed lasers, the
location of the gold nanorods, with respect to the cells, was the most im-
portant factor governing laser-induced toxicity. Furthermore, gold nanor-
ods targeted to lung cancer EGFR receptors showed enhanced therapeutic
efficacy under pulsed laser illumination.
Finally, the potential for gold nanorods to enhance endobronchial ultra-
sound - an existing clinical procedure for guiding lung cancer needle biopsies
- was considered. This routine practice uses conventional B-mode ultra-
sound and a wide field of view to facilitate the locating of lymph nodes
and guide the staging of lung cancer. This technique could be further
improved with the use of gold nanorod-mediated photoacoustic imaging
with potentially minimal adaptation, since the underlying technology re-
quired to combine these modalities already exists. It was shown that in-
clusions of gold nanorods can be observed under pulsed laser illumination
using imaging and transducer parameters comparable to that of endobron-
chial ultrasound. The potential for this promising new multimodality was
demonstrated, with the aim of guiding future development.
Overall, the work presented in this thesis provided valuable insights into
the development of gold nanorods for biomedicine, and has demonstrated
the potential for improving new and existing theranostic modalities.
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Chapter 1
Introduction
Michael Faraday is often regarded as one of the first scientists to spark an interest in the
study of light interactions with small particles when he gave a lecture in 1857 that was
later awarded the Royal Society Bakerian Lecture prize [5]. In it, he explored a variety of
experiments regarding how light interacts with a range of different materials, including silver,
copper, platinum, tin, iron, mercury, rhodium, and iridium. His main interest, however, was
in the phenomena surrounding that of colloidal gold particles: “I do not pretend that they
are of great value in their present state, but they are very suggestive, and they may save much
trouble to any experimentalists inclined to pursue and extend this line of investigation”. He
was referring to the extraordinary ability of colloidal gold to reflect, refract and absorb light
of different colours based on a “mere variation in the size of its particles”. We now know that
there are many factors governing the wavelength of light that interacts with these unique
particles, but for centuries, gold colloids were used as pigments in stained glass windows,
potteries, fabrics, and even in medicine, with the observed optical effects believed to arise
from the intrinsic colour of the particles. It was not until Faraday became interested in
light-matter interactions, and delivered this ground-breaking Bakerian lecture, that many
distinguished scientists, such as John Tyndall [6], Lord Rayleigh [7, 8], Sir C.V. Raman [9],
and Gustav Mie [10], saw the potential in these particles, and the study of nanotechnology,
nanoscience and plasmonics was born.
Since then, plasmonic nanoparticles have seen a steady growth in interest over the past
few decades and have found uses in a vast array of disciplines from renewable energy through
to health [11]. Our continued ability to manipulate the many different factors that make
up a plasmonic nanoparticle has seen novel applications appear in unprecedented areas. In
biomedicine alone, nanoparticles are used to deliver drugs and genes to specific areas of the
body [12, 13]; as optical contrast agents in imaging modalities such as magnetic resonance
imaging (MRI) [14]; for the detection of specific disease related biomolecules and proteins
by acting as biosensors [15]; and as diagnostic and therapeutic agents for the detection and
elimination of cancer [16, 17]; among others [18].
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1.1 Scope
Scientific advances in the study of nanotechnology and bioengineering have enabled targeted
therapies - that are designed to specifically target a patients disease - to increasingly be-
come a reality. However, the complex nature of nanoparticles and their interactions with
the human body suggest there is a substantial amount of research that is needed before safe
clinical translation is possible. The work in this thesis aims to investigate and progress some
of the key research areas required to advance the field of nanoparticle-based biomedicines,
by focusing on gold nanoparticles for cancer diagnostics, therapy, and combined multimodal
approaches, often termed ‘theranostics’. Specifically, a subset of gold nanoparticles, known
as gold nanorods, are explored as a means to mediate photoacoustic imaging and plas-
monic photothermal therapy for lung cancer theranostics. Questions such as: what is the
optimal gold nanorod size that provides the highest photoacoustic efficacy? how toxic are
they on their own, and does their size affect this? and can gold nanorods be used in com-
bined theranostic modalities to reduce waiting times and improve patient outcome?, will be
investigated with valid conclusions drawn.
1.2 Motivation
Life-changing discoveries in nanotechnology and biomedicine have the potential to revolu-
tionise the medical world on a global scale. Currently, it is estimated that approximately one
sixth of all deaths worldwide is due to cancer, with the highest mortality rates originating
from patients with lung cancer due to limited diagnostic and treatment options. The results
from continued research into nanotechnology have shown considerable promise, with nano-
particles expected to dramatically improve clinical outcomes through innovative and novel
approaches, in addition to improving upon already existing techniques [19]. In the case of
developing new diagnostic and treatment options, extensive research is required to meet the
strict regulations for safe human use, before a new modality can be routinely used in the
clinic. This is especially true when developing a scheme based on something as complex as
nanoparticles.
Gold nanoparticles have shown to be one of the most promising agents for biomedical
uses, especially in modalities such as photoacoustic imaging and photothermal therapy.
These two techniques are effective on their own, and with the use of gold nanoparticles as
optical-absorbing agents, their efficacy can be greatly improved. Furthermore, since these
techniques are both optical-based, there is the potential for them to be combined into a single
gold nanoparticle-mediated theranostic modality. Techniques with dual-functionalities, such
as this, may provide a means to treat otherwise untreatable diseases, and are the basis of
future medical approaches known as precision medicines. Since gold nanoparticles are at the
core of these procedures, it is clear that continued research into these particles is necessary
to successfully develop new, effective and highly specific treatment options.
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1.3 Objectives of this work and thesis layout
The work in this thesis was centred around the concept of translating gold nanoparticles from
imaging to therapy, for the diagnosis and treatment of lung cancer, while demonstrating their
ability to improve upon current clinical practice. The overall aims were to aid in the creation
of dual-modality biomedical approaches by continuing the research and development of gold
nanorods as optical absorbers in lung cancer theranostics, and to improve upon existing
techniques such as endobronchial ultrasound, a clinical lung cancer staging modality, by
combining it with gold nanorod-mediated photoacoustic imaging.
Starting with chapter 2, the necessary background information required to understand
the rest of the presented work was provided. Important ideas and phenomena were de-
scribed by way of a literature review and critical discussion. Gold nanorods were discussed
in terms of their relevant properties, such as optical interactions and surface plasmon reson-
ance, cytotoxicity and interaction with cells, and synthesis and functionalisation prospects,
framed in context of application in lung cancer treatments. This was followed by introducing
and discussing photoacoustic imaging and plasmonic photothermal therapy, and the role of
gold nanorods in these modalities. The penultimate section considers an existing clinical
technique for diagnosing lung cancer and the potential for improving this technique. Finally,
the current use of gold nanorods as theranostic agents in the literature are discussed.
The aims and objectives of chapter 3 were to investigate the size-dependent effects of
gold nanorods on aspects related to lung cancer photoacoustic imaging. Specifically, the
effects of gold nanorod size was considered in relation to photoacoustic response across a
range of incident laser fluences (taking into consideration other important aspects such as
nanoparticle concentrations defined in terms of both mass and number of nanoparticles), the
toxicity of gold nanorods to a common non-small cell lung cancer cell line, their photostability
and melting thresholds under laser illumination, and an indication of lung cancer cellular
uptake. These objectives will provide a greater understanding of the importance of gold
nanorod since for application in photoacoustic imaging and aid in their future development.
Since multiple sized gold nanorods were used throughout this thesis, a consistent naming
format was followed based on their width and SPR. For example, ‘Au10-811’ had a width
of 10 nm and SPR of 811 nm. The work in this chapter has been published in the following
manuscripts:
• O. B. Knights, S. Ye, N. Ingram, D. M. J. Cowell, A. F. Markham, S. Freear, and
J. R. McLaughlan, “Optimising gold nanorod size for maximum photoacoustic response
while minimising cell toxicity,” Proc. Mtgs. Acoust., vol. 30, no. 1, pp. 020 001–, Jun.
2017
• O. Knights and J. McLaughlan, “Gold nanorods for light-based lung cancer ther-
anostics,” International journal of molecular sciences, vol. 19, no. 11, p. 3318, 2018
• O. B. Knights, D. M. Cowell, T. M. Carpenter, S. Freear, and J. R. McLaughlan,
“Plasmonic gold nanoparticles for combined photoacoustic imaging and plasmonic
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photothermal therapy using a pulsed laser,” in 2018 IEEE International Ultrasonics
Symposium (IUS). IEEE, 2018, pp. 1–4
• O. B. Knights, S. Ye, N. Ingram, S. Freear, and J. R. McLaughlan, “Optimising gold
nanorods for photoacoustic imaging in vitro,” Nanoscale Advances, 2019
Chapter 4 continued with the development of gold nanorods, by moving from their
diagnostic abilities in photoacoustic imaging, to investigating their use as therapeutic agents
in plasmonic photothermal therapy. The optical source used for delivering light to the gold
nanorods was considered, with the aim of determining whether pulsed lasers are able to
replace continuous wave lasers for plasmonic photothermal therapy. The specific objectives
of this chapter were to understand the differences between using continuous wave or pulsed
lasers, in combination with gold nanorods, to reduce cell viability in a lung cancer cell line
with low laser energies, and to understand how targeting gold nanorods to lung cancer cells
can improve therapeutic efficacy under both continuous wave and pulsed laser illumination.
Furthermore, the size of the gold nanorods used as optical absorbers was considered in terms
of their photothermal conversion efficacy under continuous and pulsed wave laser irradiation,
and laser-induced toxicity to a lung cancer cell line. The work in this chapter aims to aid
in the development of optical-based therapeutic modalities that rely on gold nanorods, by
considering the use of pulsed lasers as the optical source in plasmonic photothermal therapy,
leading to future therapeutic techniques with potentially reduced complexities and costs,
and improved patient outcome. Some of the work in this chapter has been published in the
following manuscripts:
• O. Knights and J. McLaughlan, “Gold nanorods for light-based lung cancer ther-
anostics,” International journal of molecular sciences, vol. 19, no. 11, p. 3318, 2018
• O. B. Knights, D. M. Cowell, T. M. Carpenter, S. Freear, and J. R. McLaughlan,
“Plasmonic gold nanoparticles for combined photoacoustic imaging and plasmonic
photothermal therapy using a pulsed laser,” in 2018 IEEE International Ultrasonics
Symposium (IUS). IEEE, 2018, pp. 1–4
In chapter 5, the focus then shifted to the development and enhancement of endobron-
chial ultrasound by demonstrating the capability of combining the existing technique with
gold nanorods and a pulsed laser system for added photoacoustic imaging functionalities.
The objectives of this chapter were to explore the necessary transducer requirements for
both conventional B-mode imaging and photoacoustic imaging with gold nanorods, and to
demonstrate the potential benefits of combining these techniques. This work aims to aid
in the future development of endobronchial ultrasound into an improved lung cancer dia-
gnostic tool, with the potential for a dual-modality approach by enabling a therapeutic
avenue through plasmonic photothermal therapy. Some of the work in this chapter has been
published in the following manuscripts:
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• O. Knights and J. McLaughlan, “Gold nanorods for light-based lung cancer ther-
anostics,” International journal of molecular sciences, vol. 19, no. 11, p. 3318, 2018
• O. B. Knights, D. M. Cowell, T. M. Carpenter, S. Freear, and J. R. McLaughlan,
“Plasmonic gold nanoparticles for combined photoacoustic imaging and plasmonic
photothermal therapy using a pulsed laser,” in 2018 IEEE International Ultrasonics
Symposium (IUS). IEEE, 2018, pp. 1–4
Finally, chapter 6 provided a summary of the thesis along with major conclusions and
the discussion of future work.
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Chapter 2
Gold nanorods in medicine
The aim of this chapter is to provide the necessary background and context for understanding
this thesis by way of a literature review and discussion.
2.1 Cancer
Cancer is the name given to a large group of diseases that share a variety of similar char-
acteristics, such as the growth of tumours and ability to spread to other parts of the body,
known as metastasis [20]. It is one of the leading causes of death worldwide, with a predicted
70 % increase in new cases by 2034 [21]. The most prevalent forms of cancer are lung and
breast, however the highest mortality rates occur in patients with lung cancer (1.76 million
deaths compared with 862 000 deaths for colorectal cancer, the second most common cause
of death by cancer) [21]. This exceedingly high mortality rate can be attributed to the lack
of early diagnosis - an important aspect for successful treatment of any cancer type - and
the limited available treatment options.
Due to the large variety of cancer types and the complex nature of the condition, the
prescribed diagnosis and treatment options must be tailored to the specific case at hand,
often with the aid of large multidisciplinary teams. The idea that there may exist a ‘silver
bullet’ for treating all forms of cancer is a steadily diminishing one, as our understanding
grows. In 1976, Peter Nowell suggested that cancerous tumours were a collection of diverse
cells that were highly individual to the patient and may require a specific, personalised
treatment [22]. This sparked an interest into studying the tumours more closely with regards
to their cellular makeup, but it was not until scientists sequenced the genetic code of single
cells, 35 years later, that we realised just how diverse cancerous tissue was. The considerable
variety of cell types within a single tumour can cause major problems when it comes to
targeted therapies (particularly with treatments involving drugs that target specific cells)
and has been suggested as a leading contributor to the failure of a lot of treatments [23].
One of the biggest problems with many of the current cancer therapies is the unwanted
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destruction of healthy, non-cancerous tissues during treatment. For example, chemotherapy
is the second most common cancer treatment and it relies on the use of highly toxic chemicals
to disrupt cell mitosis and damage rapidly proliferating cells [24]. This passive treatment
option helps to suppress the spread of cancer by preventing certain cells from reproducing,
however it does not selectively target cancerous cells. This indiscriminate elimination of
cells can result in negative sides effects, such as immunosuppression [25], gastrointestinal
distress [26], anaemia [27], hair loss [28], and others [29, 30, 31, 32, 33].
Radiotherapy is another common treatment option that destroys cancerous tissue by
utilising ionising radiation to damage the structure of dividing cells. This can be to either
completely destroy the tumour, known as curative radiotherapy, or to make other treatments
more effective, such as chemotherapy or surgery. Similar to chemotherapy, the beam of
radiation (usually x-rays) does not selectively destroy cancer cells but instead causes damage
to the DNA of any cells in the path of the beam [34]. While this treatment is more localised
than chemotherapy (the radiation is directed at the tumour location, rather than the entire
body), there is still collateral damage as a result of the radiation passing through healthy
tissue to reach the tumour site.
The surgical removal of tumours remains the most common treatment method prescribed
in the clinic [35]. The tumour, and a section of surrounding healthy tissue, is removed
surgically to ensure the complete resection of the tumour volume. This treatment option
is particularly useful in the early stages of cancer since the tumour volume will likely be
small and the boundaries easier to locate. Surgical resection can be an effective method for
eliminating cancer from the body, although it is not always a possibility (or it can result
in major operations) due to factors such as tumour location and size [36]. For example, a
tumour located in breast tissue that is larger than 5 cm is likely to result in a mastectomy.
Patients diagnosed with lung cancer can receive one or all of the discussed treatments,
depending on the stage of the cancer, however their efficacy still remains low. While these
treatment protocols are routinely used in the clinic to treat patients with many different
forms of cancer, they all cause unwanted collateral damage to normal, healthy tissues, and
the resulting side effects can be serious and long-lasting. There is a clear need for highly
targeted, minimally invasive treatment options that facilitate the complete clearance of
cancer from a patients body without causing unwanted damage to non-cancerous tissues.
Laser therapy is a clinically used, minimally invasive treatment option that aims to
reduce or completely destroy a tumour volume by way of laser ablation [37]. The laser
light is delivered via a laser fibre to a cancerous region where the high intensity focused
light heats the tissue to temperatures typically in excess of 48 − 50 ◦C, resulting in tissue
necrosis [38]. It is predominantly used for the treatment of superficial cancers, however
it can also be used to treat lung cancer. This would involve inserting a bronchoscope,
with a laser fibre attached, through the mouth and into the lung, where ablation of the
tumour tissue would be performed from close proximity [39]. Generally, for lung cancer
treatment, this procedure is only used when a patient is having difficulty breathing due to
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the tumour blocking airways and restricting airflow [37], or in some cases, it may be used for
treating early-stage lung cancers (stage 1). It is also often used in combination with other
treatments, such as radiation therapy, chemotherapy, and surgery, to enhance the efficacy
of these treatments and improve patient outcome [40]. However, it is rarely used as a sole
therapeutic procedure for treating lung cancer. Hyperthermia-based therapies, such as these,
are generally low risk treatments with few negative side effects due to their targeted nature.
In addition, hyperthermia has been shown to enhance the efficacy of many anticancer drugs
by increasing the cancer cell sensitivity to the drugs [41]. These therapies have the potential
to be further enhanced through the use of gold nanoparticles as optical-absorbing agents,
and may facilitate their use as a primary treatment option.
It is widely established that early diagnosis of cancer is an essential aspect that governs
survival rates and patient outcome following treatment [42]. In the case of lung cancer,
symptoms do not typically appear in the early stages of the tumour development and this
often leads to detection occurring during the later stages when treatments are less effective.
If indicative symptoms do arise, then the process for diagnosing lung cancer would first
involve a physical examination by a doctor, followed by an imaging technique, such as X-
ray, magnetic resonance imaging (MRI), computed tomography (CT) and positron emission
tomography (PET) scans [43]. If these methods provided an indication that cancer was
present in the lung, then further examination would be carried out to determine whether
the tumour was either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC),
malignant or benign, and the present stage of the cancer. This information would then be
used to form a prognosis and guide treatment. Endobronchial ultrasound transbronchial
needle aspiration (EBUS-TBNA) is one such method for mediastinal staging of lung cancer
(discussed further in section 2.5), and is preferred over other techniques such as mediastino-
scopy [44]. It is capable of reaching the interlobar, mediastinal, and hilar lymph nodes, with
the exception of lymph node stations 5 (subaortic) and 6 (para-aortic) [45], and combined
with its high detection sensitivity, minimal invasiveness, ease of restaging, and in some cases,
its lack of a need for general anaesthesia [43]; this procedure is routinely administered to
diagnose and stage lung cancer. While this technique is already highly effective, there are
potential ways to enhance its efficacy further and extend its capabilities, by combining it
with additional imaging techniques (discussed further in section 2.5 and chapter 5).
2.2 Gold nanoparticles and their properties
Nanoparticles have long been seen as a valuable resource for applications in a wide range of
disciplines [11, 46, 47, 48, 49, 50]. They can be synthesised to be any shape (e.g. sphere,
rod, star, tube, disc) or size, and almost any composition, be that organic (e.g. liposomes,
vesicles, micelles, dendrimers), or inorganic (e.g. copper, silver, gold, carbon, quantum dots,
iron oxide). For application in biomedicine, the choice between using organic or inorganic
nanoparticles relies on the specific needs and desired outcomes of the modality in which it
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is to be used.
Organic nanoparticles have typically been shown to be less toxic than inorganic nan-
oparticles, making them inherently more biocompatible [51]. Furthermore, organic nano-
particles have the benefit of being biodegradable, which reduces many of the concerns sur-
rounding their biodistribution when injected into a patient and their post-treatment clear-
ance from the body [51]. These advantages over inorganic nanoparticles may mean fewer
obstacles preventing them from clinical translation. However, there are still many issues
in the development of organic nanoparticles that are limiting their efficacy as therapeutic
agents [52], such as difficulties achieving uniform sizes, morphologies, and structures with
large-scale synthesis [53]. Furthermore, for optical absorption-based biomedical modalities
that rely on the efficient conversion of light to heat, organic nanoparticles pose significant
challenges, such as a lack of intrinsic near-infrared (NIR) optical absorption, difficulties in
controlling their optical properties, concerns with treatment efficacy due to low photostabil-
ity, and the risk of photobleaching [54, 55, 56, 57, 58]. Nevertheless, organic nanoparticles
that overcome these barriers are starting to emerge [59, 60].
Inorganic nanoparticles are capable of solving many of the issues with organic nano-
particles (a reason why interest has been so high), however they exhibit problems of their
own. For example, the intrinsic biodegradability that organic nanoparticles possess does
not apply to their inorganic counterparts, and there are concerns over long-term toxicity.
However, there are many benefits of using inorganic nanoparticles, especially with regards
to optical absorption-based approaches [61], since inorganic nanoparticles, such as metal-
lic nanoparticles, show excellent photothermal conversion efficacies, high optical absorption
cross-sections, easily tuneable optical properties, and no risk of photobleaching [62, 63]. Of
the many inorganic nanoparticles currently in development, gold has shown to be one of the
most promising compositions.
Bulk gold is widely-established as being one of the least reactive elements in the periodic
table [64]. It is non-reactive with air or water (and so will not oxidise), is extremely resistant
to corrosion, and does not react with chemicals inside or outside the body (a reason why
jewellery is often made from gold) [65]. It has even been used to treat various illnesses, such
as rheumatoid arthritis [66], by medical practitioners for thousands of years [67], suggesting
its potential medicinal benefits and low toxicity in biological systems. Gold nanoparticles
also share these favourable attributes for biological use, however when bulk gold is reduced to
the nanoscale, biological interactions become significantly more complex (see section 2.2.1)
[68].
Gold nanoparticles can be synthesised to be a large range of shapes, with nanorods,
nanoshells, nanocages, and nanostars being studied extensively due to their strong absorp-
tion in the NIR [69]. While these have all shown promise for biomedical uses, this thesis
will focus solely on the gold nanorod (AuNR), due to a combination of desirable charac-
teristics, such as, comparatively easy synthesis for large-scale production, the possibility
for fine-tuning its optical-absorption by dimensional control (and therefore a large range of
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possible sizes), a generally higher cellular uptake and lower toxicity compared with other
shapes, and a large absorption cross section for its size - all of which are important aspects
for clinical translation.
AuNRs have the potential to improve patient care by improving current clinical prac-
tice in both diagnostic and therapeutic areas. As discussed in section 2.1, lung cancer is
particularly difficult to diagnose and treat, and treatments such as laser therapy have lim-
ited use. AuNRs may broaden the versatility of these treatments by facilitating increased
penetration depths and therapeutic access to tumours that would otherwise be inaccessible.
The important properties and development aspects of AuNRs that make them interesting
for biomedical use and support their continued progression into clinical translation will be
discussed in the following sections.
2.2.1 Cytotoxicity and synthesis
The mechanisms with which AuNRs interact with biological systems as they are distributed,
metabolised and eliminated, are key aspects in understanding where cytotoxicity arises from
and how to prevent it. While it has been shown that AuNRs are not toxic under certain con-
ditions [70, 71], there are many factors that must be considered when determining toxicity,
such as the chemicals left behind during the synthesising process. One of the most common
methods for fabricating AuNRs is by seed-mediated growth, and the simplest form of this
process requires the use of a cationic surfactant known as cetyltrimethylammonium bromide
(CTAB) [72, 73]. CTAB is a capping agent that helps to form more accurately shaped
AuNRs and prevent them from aggregating [74], though it has been shown to be toxic to
biological cells [75], especially if there is free-floating CTAB in the AuNR solution [76].
Careful removal of the free-floating CTAB in the supernatant is needed before the AuNRs
can be safely used in a clinical setting [75, 77]. However, on the surface of the AuNR, the
CTAB forms a bilayer that is usually left behind after removal of the supernatant from the
AuNR solution [78]. This CTAB bilayer is not static and can dynamically desorb from the
surface of an AuNR, leading to cellular toxicity. However, the CTAB bilayer is responsible
for preventing aggregation, and removing this coating can result in other problems, such as
a reduction in tumour uptake and a shift in SPR. This can be mitigated by replacing the
CTAB with other, less-toxic coatings (as discussed in section 2.2.3).
Another common capping agent for gold nanoparticles is a citrate layer [79]. While it
is possible to synthesise spherical gold nanoparticles by way of a citrate-based chemical
process (originally developed by Turkevich et. al. [80] and improved by Frens et. al. [81]),
citrate-capped AuNRs can only be synthesised by either displacing or adsorbing onto the
existing CTAB layer of a AuNR that has been synthesised using CTAB [82]. Citrate-capped
AuNRs that have been synthesised in this way have shown to be less toxic to a variety
of cell lines, compared with CTAB-capped AuNRs, due to the reduced toxicity of citrate
itself and the complete removal of CTAB during the synthesising process [83, 84, 85]. The
loosely-bound citrate layer on the AuNRs can also be easily exchanged with a multitude of
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thiolated molecules, such as peptides, proteins, and DNA [86], which is an important aspect
for biomedical applications (discussed further in section 2.2.3). Furthermore, there have
been reports that citrate-stabilised gold nanoparticles do not induce platelet aggregation
or a change in plasma coagulation time in human blood [87], indicating their potential
biocompatibility.
In addition to CTAB and citrate mentioned previously, many other surface coatings for
AuNRs have been tested in the literature, such as mercaptohexadecanoic acid (MHDA),
polyethylene glycol (PEG), poly(acrylic acid) (PAA), poly(allyamine hydrochloride) (PAH),
poly(2-methacryloyloxyethyl phosohorylcholine)-b-poly(lipoic methacrylate) (pMPC-b-pLA),
(16-mercaptohexadecyl)trimethylammonium bromide (MTAB), 3-[(2-aminoethyl)dithio] pro-
pionic acid (AEDP), transferrin, plasmid, rhodamine, and many more [88]. The multitude
of possible surface coatings makes the process for testing toxicity difficult since each new
chemical must go through the same rigorous testing required to ensure safety.
Further to ensuring the chemicals and coatings on the surface of AuNRs are not toxic,
it is also important to understand the other potential routes for AuNRs to induce toxicity
[89], including cellular stresses and biological responses that may not necessarily result in the
death of cells [90]. Their interactions with biological tissues and cells as they flow through
the circulatory system may lead to unwanted cytotoxicity or cell disruption, such as oxidative
stress, inflammation, mutagenesis, DNA damage, and protein up/down regulation, among
others [91, 92, 93], as they interfere with some of the vital cellular components, such as the
cell membrane, mitochondria, or nucleus. For example, citrate-capped gold nanoparticles
were shown to alter the expressions of genes related to detoxification, lipid metabolism, cell
cycle, defence response, and circadian rhythm, in the spleen and liver of rats [94]. There have
been many reports on the properties of AuNRs that can disrupt normal cellular behaviour,
such as their dimensions, overall size, coatings, and surface charge, and results vary between
both in vivo and in vitro testing, with additional differences occurring between different cell
lines [76]. Some of the literature that considers these different routes for in vitro toxicity
have been summarised in table 2.1.
Another crucial feature in the development of AuNRs for biomedical uses is the ability
to scale-up production. Improving the methods of synthesising AuNRs to produce large
volumes of AuNRs, that exhibit highly controllable dimensions and properties, will make
clinical uses of AuNRs more feasible due to reduction in costs and increase in reliability [95].
Furthermore, the clinical translation of AuNRs will require the production to meet specific
regulatory criteria, known as ‘good manufacturing practice’ (GMB) [96], that ensures the
quality and reproducibility of new medical drugs and devices. Citrate-mediated synthesis has
shown to meet the need for large-scale production [97], however there are improvements to
be made with regards to monodispersity. There are many methods for synthesising AuNRs,
such as chemical reduction, polymer-mediated, biological, and electrochemical methods [98,
99, 100, 101, 102], and the continued development and refinement of these techniques will
assist in delivering AuNRs that are ready for clinical use.
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Table 2.1: Cytotoxicity of gold nanorods in the literature.
Dimensions Surface Coating AuNR Concen-
tration
Cell Line Exposure Cell Viability Author
(Year)
100× 200 nm AEDP, plasmid, rhod-
amine, transferrin
750 µg mL−1 HEK293 4 h 750 µg mL−1 ≈ 50 % Salem
(2003) [103]
11× 65 nm PEG, CTAB 0.01− 0.5 nmol HeLa 24 h 0.05 nmol: CTAB ≈ 20 %,
PEG ≈ 90 %
Niidome
(2006) [104]
AR = 4.1 CTAB, PAA, PAH 0.4 nmol HT-29 96 h CTAB ≈ 30 %,
PAA ≈ 90 %,
PAH ≈ 80 %
Alkilany
(2009) [105]
8× 26 nm
10× 36 nm
9× 32 nm
CTAB,
MHDA,
PEG
5− 100 µg mL−1 HaCaT 24 h 50 µg mL−1: CTAB ≈
10 %, MHDA ≈ 110 %,
PEG ≈ 100 %
Grabinski
(2011) [90]
10× 42 nm CTAB,
MTAB
100 µg mL−1 MCF7 24 h CTAB ≈ 5 %, MTAB ≈
95 %
Vigderman
(2011) [106]
25× 52 nm No coating 2.5−15 µg mL−1 A549 4 h 5 µg mL−1 ≈ 75 %,
15 µg mL−1 ≈ 10 %
Tang
(2015) [107]
65× 534 nm Residual oxygen spe-
cies from synthesis
200 µg mL−1,
400 µg mL−1
Human dermal
fibroblast
96 h 200 µg mL−1 ≈ 80 %,
400 µg mL−1 ≈ 75 %
Favi
(2015) [108]
10× 90 nm No coating 0.01 −
5 mg mL−1
ARPE-19 72 h 0.01 mg mL−1 ≈ 90 %,
0.1 mg mL−1 ≈ 35 %
Karakoc¸ak
(2016) [109]
15× 50 nm CTAB, pMPC-b-pLA 30µg mL−1 MCF-7 72 h CTAB ≈ 20 %,
pMPC-b-pLA ≈ 100 %
Jiang
(2017) [110]
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Figure 2.1: The conduction band electrons of a plasmonic nanoparticle begin to coherently
oscillate in the presence of an electromagnetic field, when the frequency of incident light is
in resonance with the oscillation.
2.2.2 Optical properties
Gold nanoparticles exhibit interesting optical properties when compared with bulk gold.
When a plasmonic nanoparticle, such as a AuNR, is under the influence of an electromagnetic
(EM) field, the surface conduction electrons are excited, and begin to coherently oscillate
with the EM field (see figure 2.1) [111]. The negatively charged ‘electron cloud’ is displaced
by the EM field and the positively charged lattice pulls back on the coherent collection of
electrons via a Coulomb restoring force. It occurs only when the wavelength of the incident
EM wave corresponds to the resonant frequency of the electron cloud [112]. This phenomena
is known as a localised surface plasmon resonance (SPR) [113], and the underlying physical
mechanisms can be likened to a dampened spring [114].
As a result of this extraordinary ability to interact with light, and enhance the sur-
rounding EM-field, AuNRs are able to strongly absorb and scatter EM radiation. The
incoming light absorbed by the nanoparticle is converted into heat via electron-electron and
electron-phonon relaxations [115], and enables the possibility for medical techniques, such
as photoacoustic imaging (PAI) and plasmonic photothermal therapy (PPTT), to emerge
(discussed further in sections 2.3 and 2.4). This heightened interaction with light is unique
to plasmonic nanoparticles and the optical absorption is approximately 5 or 6 orders of
magnitude larger than that of other conventional contrast agents used in medicine [116].
The SPR of plasmonic nanoparticles only occurs at a particular wavelength of incident
light, and this is influenced by the composition of the nanoparticle, as well geometrical
properties such as size and shape [117]. For example, nanoparticles of various compositions
and sizes have been used for thousands of years (possibly without knowledge) for visual
14
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Figure 2.2: Absorption coefficient of the five main tissue components: deoxygenated haemo-
globin (blue), fat (orange), melanin (yellow), oxygenated haemoglobin (purple), and water
(green), contributing to overall optical absorption as a function of wavelength. Data is based
on work by Jacques et. al. (2013).
effects in objects such as stained glass windows or the renowned Lycurgus Cup [118]. In the
case of spherical gold nanoparticles (gold nanospheres), the SPR can only be shifted (from
approximately 520 - 550 nm) by altering its size [119], since the composition and shape is
fixed, and they exhibit only one absorption band. AuNRs, however, possess two SPR bands
- a transverse and longitudinal band - due to their specific shape, and the ratio between the
width and length, i.e. aspect ratio, of the AuNR is the most significant contributor to the
absorption bands. An increase in aspect ratio leads to a blue-shift in the transverse SPR and
a red-shift in the longitudinal SPR [120], with the longitudinal SPR, λSPR, scaling linearly
with aspect ratio, R, according to [121],
λSPR = 95R+ 420 (2.1)
This relationship provides a method of fine-tuning their SPRs to absorb at a desired
wavelength, approximately within the range 750− 1400 nm, by synthesising the AuNRs
with a particular aspect ratio. This is particularly useful for medical applications since
biological tissues exhibit a reduced optical attenuation in two distinct near-infrared (NIR)
wavelength regions [122, 123]. The first ranges from approximately 650− 900 nm and is a
region where the optical absorption of water and haemoglobin (the two main absorbers of
light) are minimal (figure 2.2) [116, 124], and the second ranges between 1000− 1350 nm
[125]. Light penetration is much deeper in these regions (commonly referred to as the first
and second ‘biological windows’) and has been shown, in extreme cases, to travel as deep
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Figure 2.3: A schematic showing a functionalised gold nanorod.
as 10 cm into tissue [126]. The ability to tune the longitudinal SPR peak into the NIR
allows for the use of infrared lasers in biomedical applications, and facilitates access to deep
regions of tissue. The majority of AuNRs have been developed to absorb light in the first
NIR window, with the number of second NIR window-absorbing AuNRs remaining limited.
This is largely to due the difficulty in synthesising high aspect ratio AuNRs that absorb
above 1000 nm but remain smaller than 100 nm [127]. The second NIR window has added
benefits such as the further increase in optical penetration due to the large reduction in
absorption of haemoglobin and blood.
2.2.3 Functionalisation and targeting
One of the many potential benefits of using AuNRs for biomedical applications is their
ability to be functionalised with a wide range of organic and inorganic molecules [128]. Gold
has the ability to form strong gold-thiolate bonds that facilitate surface modification [129].
The surface of a AuNR can be modified to achieve one or many different outcomes that
support the AuNRs reaching their desired location. When attempting to deliver a dose
of gold nanorods to a tumour site the injected bolus must overcome a series of complex
barriers, both physiological and chemical, such as particle diffusion, aggregation, protein
adsorption, flow and shear forces, renal clearance, and phagocytic sequestration [130]. For
example, when nanoparticles enter the blood stream of a patient they undergo opsonisation,
and resident macrophages of the mononuclear phagocyte system (MPS) subsequently begin
to uptake the AuNRs, which leads to a build up of AuNRs in the reticuloendothelial system
(RES) (i.e. the liver and spleen) [131]. This non-specific, high accumulation of AuNRs
in healthy organs is undesirable as it reduces the numbers that reach the target region,
limiting treatment efficacy. Furthermore, the complex nature of tumour growth - interrupted
vasculature, aggressive cellular growth, dense extracellular matrix, and impaired lymphatics
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- can be a significant barrier for AuNRs to overcome since it produces a high intratumoral
pressure gradient that can prevent AuNRs from crossing the tumour boundaries [132]. If
these barriers are not addressed, then significantly reduced treatment efficacy could be
observed as an insufficient number of AuNRs reach the tumour location. Alternatively, a
highly concentrated dose of AuNRs would need to be administered to a patient to achieve
sufficient uptake in the tumour, which could increase overall treatment costs and potentially
elevate the required dose above the safe human limit.
The bloodstream of living organisms are diverse mixtures of many different molecules,
such as proteins, nutrients, and electrolytes, and these have been shown to interact with
nanoparticles in previously unexpected ways [133]. Proteins and molecules will adsorb onto
the surface of AuNRs almost immediately after introduction into blood and form what is
known as a ‘corona’ around the AuNRs. Its composition is governed by the nanoparticle
material, size, and surface chemistry, as well as the temperature and length of exposure to
the surrounding physiological fluid [134]. The corona has been shown, not only to affect
the properties of the AuNRs themselves, but also induce structural rearrangements of the
proteins that are bound to it [135, 136], while also facilitating the rapid clearance of AuNRs
via the RES [137]. Furthermore, the toxicity, uptake, pharmacokinetics, and immunogenicity
of the AuNRs are also affected since the corona is what the cells ‘see’ when the AuNRs
come into contact with them [133]. In this case, the AuNRs can essentially be treated as
entirely new particles, since the proteins and molecules that non-specifically bind to the
AuNRs surface alter the physical size of the AuNRs in a dynamic manner. This creates
an inhomogeneous distribution of sizes that differ from the original population, while also
affecting their shape, surface charge, and colloidal stability [138, 139, 140]. A study by
Chithrani et. al. (2007) demonstrated that citrate-capped nanoparticles enhanced cellular
uptake, when compared with transferrin-coated nanoparticles, since proteins were able to
easily adsorb to the citrate layer which facilitated improved cell-surface interactions and
cellular recognition [141]. These AuNR-biological interactions also translate into in vitro
testing, since the many components that make up cell growth media have been shown to
affect the physiochemical properties of AuNRs by altering their colloidal stability, surface
charge, surface chemistry, size, and toxicity, in much the same way [142, 143]. However, it
is possible to overcome some, if not all, of these biological barriers by ‘functionalising’ the
AuNRs. When attempting to deliver AuNRs to a region of interest (ROI), there are two
main approaches:
Passive targeting: The passive approach to targeting cancerous tissues exploits the nat-
ural processes that occur when a tumour is present inside the body. To facilitate the
rapid growth of a tumour, and its need for large amounts of nutrients and other growth
factors, vessels grow abnormally to enable sufficient blood flow to the tumour site [144].
These atypical, leaky vasculatures - that can be up to 2 mm in size [145] - can facilitate
the method of delivery for AuNRs. Furthermore, tumours exhibit an impaired lymph-
atic drainage that can hinder the AuNRs ability to leave the tumour and result in
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the gradual collection of AuNRs within the tumour volume. These unique structural
features give rise to the well-characterised enhanced permeability and retention (EPR)
effect [146, 147, 148]. To successfully take advantage of EPR, the AuNRs must be of
a particular size. In order to enter the tumour via blood perfusion, the AuNRs must
to be small enough to allow them to extravasate into the tumour tissues, but large
enough so that they remain within the tumour site for sufficient time for diagnosis or
treatment to be administered. It has been suggested that AuNRs smaller than 100 nm
are able to achieve this in mice [149], and human studies are now starting to emerge
[150]. However, little is known about the efficacy of this effect in humans due to the
limited number studies [151]. Furthermore, relying solely on this approach may result
in the inability for AuNRs to reach all of the tumour sites since the abnormal growth
of vasculature creates irregularities in the blood supply to the entire tumour volume,
and the heterogeneous distribution of cells within the tumour tissue will affect how
the AuNRs are taken-up [152].
Active targeting: In addition to relying solely on natural processes, it is possible to ‘func-
tionalise’ or ‘target’ the AuNRs with specific tumour targeting ligands, such as pep-
tides, monoclonal antibodies or small molecules [153, 154]. The molecularly targeted
AuNRs (figure 2.3) travelling through the bloodstream will bind to specific tumour re-
ceptors as they come into contact with them, resulting in the accumulation of AuNRs
in and around the tumour site [155]. This in turn can initiate, and in many cases
improve endocytosis [154, 156, 157], leading to the internalisation of the AuNRs [158].
One of the most common methods of molecularly targeting AuNRs is the conjugation
with anti-epidermal growth factor receptor (EGFR) antibodies [159]. A large num-
ber of solid tumours have been shown to overexpress EGFR on the cell cytoplasm
membrane [160], including approximately 80 % of non-small cell lung cancer (NSCLC)
[161], leading to a large amount of research being conducted around this idea [162].
Other benefits of altering the surface chemistry of AuNRs with various ligands are pro-
longed circulation times in the bloodstream [154], increased colloidal stability [163], enhanced
thermal stability [164], and improved photothermal conversion efficacy [165], among others
[166, 167, 168, 169]. Ligands such poly(ethylene glycol) (PEG) have been shown to not only
significantly reduce cytotoxicity and prevent aggregation [137], but also ‘mask’ the AuNRs
from the immune system as they circulate through the bloodstream, leading to longer cir-
culation times [104], a less adverse immune response, and an increase in tumour uptake
[76]. These added benefits in combination with an increased blood half-life - a measure of
how long it takes for the RES organs to deplete the number of circulating nanoparticles by
half [155] - can enhance diagnostic and therapeutic efficacy by ensuring the deliverability
of AuNRs to a desired target region, while negating the possible side-effects of introducing
AuNRs into the circulatory system [170].
Silica-coating is another surface modification that has shown to be beneficial in many
ways [171]. Gold nanoparticles can be synthesised with a surrounding layer of silica on the
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surface of the gold that has either a dense or porous structure [172]. This silica shell has
shown to improve the photostability of the surface-modified gold nanoparticles, and therefore
reduce the risks associated with losing its peak optical absorption due to reshaping. The
silica shell can also enhance the photothermal conversion efficacy under laser irradiation and
heighten effects, such as photoacoustic emission amplitudes and nanoparticle heating [173,
174]. Moreover, silica-coated AuNRs have shown to exhibit enhanced colloidal stability and
biocompatibility compared with AuNRs without this coating, as well as excellent potential
as drug carriers [175]. While these added benefits are important for biomedical efficacy,
large-scale synthesis and surface functionalisation of silica-coated AuNRs still remains one
of the biggest challenges, and ultimately limits their potential for future clinical translation
[176], although new methods are beginning to appear [177]. Furthermore, the addition of the
silica-shell around the core gold nanoparticle increases the overall size of the nanoparticle
which potentially leads to other issues around cellular uptake and deliverability to a tumour
site, since nanoparticle size is important for delivery.
If the AuNRs can indeed be delivered to a tumour, then the AuNRs must remain there
long enough to allow for therapy to be administered [178]. The natural tendency for AuNRs
to remain inside a tumour, governed by the EPR effect, in conjunction with functionalising
and molecularly-targeting AuNRs to cell surface-receptors, can facilitate the large up-take
and retention of AuNRs. Current research into the therapeutic efficiency of targeted AuNRs
has shown promise [179], however there is a need to develop more effective methods for
analysing targeting efficiency and tumour uptake if successful clinical translation of AuNRs
is to occur [130].
2.3 Photoacoustics with gold nanorods
Photoacoustic imaging (PAI) is a non-invasive, non-ionising imaging modality that utilises
the photoacoustic (PA) effect to image targeted areas of biological tissues [180]. It combines
the high-contrast and spectral specificity of optical-based imaging methods with the high
spatial resolution of ultrasound [181]. The photoacoustic phenomenon occurs when short
laser pulses (generally nano- or femto-second) are absorbed by a material and the near-
instantaneous deposition of energy causes rapid heating (< 0.1 K [182]) of the area under
laser-illumination. The thermal expansion of the target results in the emission of broadband
acoustic waves in the 1-50 MHz range [183]. Any material can exhibit this effect, as long
as the laser pulse width, τp, is shorter than the required time for the mechanical stress
to propagate through the heated region and return to equilibrium, τth, simply given by
τp < τth [184]. This is known as the stress confinement condition, and if satisfied, a high
thermoelastic pressure increase will be observed [183].
The maximum initial pressure increase, P0, experienced by the material undergoing
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Table 2.2: Tissue components for characterising absorption.
Tissue components Description
S HGb oxygen saturation of vasculature
B Average blood volume fraction
W Water content
CBilli Bilirubin concentration
CβC β-carotene concentration
Fa Fat content
M Melanosome volume fraction
thermal expansion is related to the incident laser fluence, F , given by,
P0 =
βγ2
cp
µaF, (2.2)
where β is the thermal expansion coefficient (or isobaric volume expansion coefficient), γ is
the speed of sound through the medium, cp is the specific heat capacity at constant pres-
sure, and µa is the absorption coefficient of the absorbing material. This can be simplified
by grouping the first term into a dimensionless, thermodynamic parameter known as the
Gru¨neisen Parameter (or coefficient), given by βγ2/cp. Equation 2.2 then becomes,
P0 = ΓµaF, (2.3)
When attempting to generate a photoacoustic signal in a medical setting, the light from
a laser pulse incident on the skin, for example, will travel through the various tissues,
experiencing absorption and scattering events as it travels, until the light energy diminishes
to zero. The tissue components that have absorbed the light will thermally expand to create
a pressure increase, governed by equation 2.3, and subsequently contract to result in the
generation of an ultrasonic wave that propagates radially through the surrounding tissue. If
this signal is detected by an ultrasonic transducer (e.g. at the surface of the skin) then the
recorded information can be spatially and temporally resolved to create an image of the tissue
components that absorb at that specific wavelength of light [182]. If the laser wavelength is
scanned through a known, specified range, then a more complex spectrally-resolved image
can be reconstructed from the recorded signals based on the optical absorption spectra of
the many different tissue types [185]. This technique is known as multispectral optoacoustic
tomography (MSOT) (or functional photoacoustic microscopy (fPAM)) and is an imaging
modality that is widely used [186, 187, 188, 189].
If the ROI within a biological environment is weakly absorbing, or too deep for sufficient
light to reach it, then exogenous contrast agents can be used to enhance the optical absorp-
tion contrast between the tissue of interest and the background tissues [190]. The variety
of different tissue types that the light must pass through to reach the destination site, such
as skin, fat, blood, muscle, mucous tissue, dermis etc., often results in significant optical
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attenuation and the generation of a weak acoustic signal [123]. The optical intensity, I(z),
decays exponentially with distance, z, according to,
I(z) = I0e
−αz, (2.4)
where I0 is the initial light intensity and α is the optical attenuation coefficient. In tissue,
α is large due to the optical scattering and absorption caused by all the distinctive tissue
types, resulting in the rapid attenuation of light as it passes through. Furthermore, the
large scattering contributions of the tissues cause the once omnidirectional light to quickly
become diffuse and lose all directionality. The absorption and reduced scattering coefficients,
µa (cm
−1) and µ′s (cm
−1), have been described by Jacques et al. (2013) as a function the
various absorbing chromophores (see table 2.2), and the size of the scatterers in tissue,
respectively [123]. These components, which all depend on the wavelength of light, λ, can
then be used to calculate µa and µ
′
s of a tissue, given by,
µa = BSµa.oxy +B(1− S)µa.deoxy +Wµa.water + Faµa.fat +Mµa.melanosome
+ 2.3Cbillibilli + 2.3CβCβC ,
(2.5)
µ′s(λ) = a
′
[
fRay
(
λ
500 (nm)
)−4
+ fMie
(
λ
500 (nm)
)−bMie]
, (2.6)
where µa.oxy, µa.deoxy, µa.water, µa.fat and µa.melanosome are the absorption coefficients of
oxygenated blood, deoxygenated blood, water, fat and melanosome respectively. billi and
βC are the extinction coefficients of bilirubin and β-carotene respectively. a
′ = µ′s(λ =
500 nm), bMie is known as the ‘scattering power’, and fRay and fMie are the contributions
from Rayleigh and Mie scattering, respectively. This general empirical model for evaluating
tissue optical properties was based on measured characteristics, that allow the estimation
of such properties and subsequent modelling of light propagation in tissue by specifying the
absorption and reduced scattering coefficients in equations 2.5 and 2.6.
Exogenous contrast agents - such as AuNRs, small-molecule dyes, quantum dots, and
organic or inorganic nanoparticles [191, 192] - located in a ROI are able to negate the
effects of minimal optical penetration by facilitating the absorption and enhancement of the
remaining light. AuNRs have shown to be effective contrast agents for PAI [174, 193, 194]
by providing an enhanced optical absorption contrast against background tissue, leading
to larger PA emission amplitudes being generated from highly localised and targeted areas
[195]. PA images are reconstructed by acquiring ‘A-lines’, via the scanning of a single-
element transducer or the use of a phased array beamforming technique (see chapter 5 for
further discussion), and either used directly to form images - by determining time-of-flight
and speed of sound measurements - or in more complex reconstruction algorithms such
as back-projection [182, 196]. Multispectral optoacoustic tomography (MSOT) is another
PA imaging modality that utilises the multiple spectral components of different tissues,
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where image contrast is achieved by exciting the tissues according to their unique absorption
spectra [197]. PA imaging is rapidly emerging as an effective alternative imaging modality
for clinical use [198, 199], however further research into AuNRs is required. As discussed in
section 2.2.3, AuNRs that are targeted to a specific site in the body will build up over time
until there is a sufficient number to generate a detectable PA signal [200]. The amplitude of a
PA signal emitted by AuNRs must be large enough to travel back through the multiple tissue
types, where higher frequencies will experience a greater degree of attenuation compared with
lower frequencies [201], and be detectable by a transducer probe. Generally, the probe will
be located at the surface of the skin, however in some cases it may be possible to position
the transducer in a closer proximity to the ROI (see section 2.5).
Another solution to increasing the PA signal amplitude generated by the absorbed laser-
light is to increase the energy of the laser pulse. This increase in light intensity, incident
on the surface of the skin, would subsequently result in more light reaching the target area
and a larger PA emission. However, this can be problematic since high-intensity laser pulses
can be damaging to tissues. A safe exposure limit for laser irradiation on skin, set out by
the American National Standards Institute (ANSI) [202], provides a guide threshold for the
typical laser energies and exposure durations that will cause skin or ocular damage. This
is known as the Maximum Permissible Exposure (MPE), and is discussed in more detail in
section 2.4.1. Nevertheless, if a therapeutic modality is developed that requires laser energies
that are above this guideline exposure limit, then the MPE may be overlooked as a restrictive
measure since the benefits of the therapy would negate the potential superficial damage
caused by the laser. This is seen, in a more extreme case, with chemotherapy, whereby
the benefits of administering the highly toxic, non-specific anticancer drugs outweighs the
negative side effects.
2.4 Photothermal therapy with gold nanorods
Plasmonic photothermal therapy (PPTT) is a therapeutic modality that can utilise the
unique properties of AuNRs [203]. Instead of exploiting the AuNRs ability to generate
acoustic waves for non-invasive imaging, the AuNRs are used to locally destroy regions
of tissue [204]. Photothermal ablation of tissue is possible without the use of AuNRs or
other exogenous optical absorbers (as discussed in section 2.1), however its efficaciousness
can be dramatically increased by utilising AuNRs [205]. Unlike PA imaging, where pulsed-
wave (PW) lasers are essential to achieve the desired outcome, PPTT is conventionally
administered with continuous wave (CW) lasers (PW and CW lasers are discussed in greater
detail in section 2.4.1). While CW lasers are the most common optical source for PPTT, it
has been suggested that PPTT is possible with PW lasers [206]. However, the laser pulse
fluence is often high (> 420 mJ cm−2) and significantly above the MPE guidelines.
Similarly to PAI, the AuNRs are used to enhance the optical absorption contrast between
the target tissue and the surrounding healthy tissues [207]. A tumour containing sufficient
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numbers of AuNRs is irradiated with a NIR laser that is tuned to the SPR of the AuNRs,
where the incident light is absorbed and converted to heat [121]. If a CW laser is used
to excite the AuNRs, then the target region will experience bulk-heating due to the long
exposure times (generally on the order of minutes). Hyperthermia is achieved when the
cells reach temperatures above 41− 48 ◦C and several processes begin to activate on the
cellular level, such as protein denaturation, cell inactivation, and cell aggregation, causing
irreversible damage and the eventual death of cells [208]. The pathways for cell death, via
cellular apoptosis or necrosis, is largely governed by laser exposure parameters and AuNR
concentration in the target tissue [209, 210]. A parameter known as the thermal isoeffective
dose (TID) was developed [211] as a clinically relevant way to measure and compare ‘slow’
thermal treatments based on a given biological endpoint, such as cell death. It is most
commonly described as the cumulative equivalent minutes held at a temperature of 43 ◦C
(CEM43) and is given by,
TID =
∫ τend
0
[RCEM]
(43−T (t))dt (2.7)
where TID is the thermal dose in CEM43, RCEM is an approximated parameter equal to
0.25 for temperatures < 43 ◦C and 0.5 for temperatures > 43 ◦C, T (t) is the temperature
at time t, and dt is the time interval. τend represents the final time point of the thermal
treatment. This relationship has been found to provide a reasonable prediction of cell death
in vitro between 40− 47 ◦C [208, 212].
As a stand-alone therapeutic technique, PPTT has many advantages over other con-
ventional cancer therapies, as tissue destruction is highly localised to the areas containing
AuNRs. Compared with treatments such as chemotherapy - where the relatively high doses
of toxic drugs cause major damage to a wide range of healthy cells (see section 2.1) - PPTT
allows for the selective destruction of cancerous tissues without causing collateral damage to
the surrounding healthy tissues [213]. Additionally, PPTT is a potentially minimally invas-
ive therapeutic approach, since surgery is not required to administer AuNRs systemically,
nor to deliver light to a tumour region. However, where a tumour is located too deep for
light to penetrate from the skin surface, it may be necessary to situate the laser fibre closer
to the target tissue via an endoscope (see section 2.5), or in some cases, a small incision.
Nevertheless, overall patient outcome is likely to be significantly better than that of many
alternative medical procedures [214].
Secondary treatments can also benefit from PPTT, since the laser-induced heat can dis-
rupt processes on the cellular level and enhance therapeutic efficacy. It has been shown that
combined therapies are generally more effective than the ‘sum-of-their-parts’, since the heat
damage can increase sensitivity to therapeutic drugs, enhance vascular and cell membrane
permeability, and inhibit DNA repair mechanisms, among others [215]. Furthermore, it
could be used to reduce tumour volume to improve the outcome of secondary treatments,
such as surgery, or to treat tumour recurrences.
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2.4.1 Lasers: continuous wave vs pulsed
There are two categories of lasers: pulsed (PW) and continuous wave (CW). CW lasers emit
a continuous beam of light that generally lasts seconds or longer. The laser medium is con-
tinuously pumped by another light-source (usually another laser) resulting in the continual
excitation of atoms within the lasing medium and the emission of photons [216]. CW lasers
are also relatively inexpensive compared with most pulsed laser systems, while also having
the advantage of compactness and portability.
High power pulsed lasers (PW), in contrast, are usually complex, bulky systems with
multiple components such as gas tanks, movable crystals, and liquid cooling units, requiring
longer, more sophisticated calibration and installation times. Unlike CW lasers that have a
steady, constant power output, PW lasers frequently have intra-cavity delays that are built
into the laser system to enable the build-up and ‘storage’ of energy in the lasing medium
until it is released as a high-intensity burst of light [217]. Since there is a delay between
exciting the lasing medium and a light pulse being emitted from the shutter, PW lasers
can usually only achieve pulse repetition frequencies (PRFs) of around 10 − 20 Hz. The
process of rapid accumulation and release of energy in very short, nano- or femto-second
pulses is termed “Q-switching” and facilitates the lasers ability to generate extremely high
peak powers in the order of 106 to 109 Watts. This is because the peak power, Ppeak, is the
energy transfer of a single laser pulse, given by,
Ppeak(W ) =
Epulse
τp
(2.8)
where Epulse is the energy of a single pulse, and τp is the duration of the pulse. The average
power, Pave, of a pulsed laser takes into account the time between each pulse by the following
equation,
Pave(W ) =
Epulse
τT
= Epulse × PRF(Hz) (2.9)
where τT = 1/PRF is the time-period of the pulses. This means for a single, 7 ns pulse with
an energy of 1 J and PRF = 10 Hz, the peak power is 143× 106 W and the average power is
only 10 W.
The fundamental differences between CW and PW lasers lead to significant differences
in the way they interact with materials. When a laser interacts with a material, and is ab-
sorbed, the energy first excites the conduction electrons and sets them oscillating [218]. This
energy is then transferred to the surrounding electrons via femtosecond electron-electron re-
laxations, before being further transferred to the lattice, via electron-phonon collisions on a
picosecond time-scale. When a material absorbs light from a CW laser, the heat is spread
out over a much larger volume since the continuous nature of the incoming light allows for
the heat to diffuse radially [219]. If the absorbing material is a solution of AuNRs, then this
effect will be significantly enhanced as the AuNRs efficiently convert the laser energy into
heat (see figure 2.4) [220]. Conversely, under pulsed laser illumination, the short (< 10 ns)
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BULK
HEATING
ULTRASOUND
EMISSION
PULSED LASER CONTINUOUS LASER
Figure 2.4: Under pulsed laser illumination, the AuNRs located in a tumour will experience
a rapid increase in temperature that likely causes an expansion of both the AuNR and the
localised surroundings, resulting in the emission of an ultrasonic wave. Conversely, under
continuous wave laser illumination, the same AuNRs will continuously radiate heat to the
surroundings, causing bulk heating of the environment.
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high intensity laser pulses induce a higher initial peak temperature in the absorbers, com-
pared with that of CW lasers. However, due to the time period between laser pulses, the
absorbing region has time to cool sufficiently before each consecutive pulse. If AuNRs are
the absorbing medium, then they will experience extremely high peak temperatures (and
the emission of PA signals if the stress confinement condition is met), before rapidly cooling
ahead of the next pulse (see figure 2.4). Thus, two distinct mechanisms exist depending on
the type of laser employed: highly localised heating when PW lasers are used, and bulk,
volumetric heating when CW lasers are used. There are also differences in the guidelines
for the maximum exposure limit for skin (as mentioned in section 2.3). The maximum per-
missible exposure (MPE) is governed by the optical wavelength, λ, and duration of the laser
exposure, t(s) [202]. Within the wavelength range 700 nm ≤ λ ≤ 1400 nm, the MPE for skin
is determined by the following,
MPEskin =

2× 1011 C4 (W m−2), if t(s) < 10−9
200C4 (J m
−2), if 10−9 ≤ t(s) ≤ 10−7
1.1× 104 C4 t(s)0.25 (J m−2), if 10−7 ≤ t(s) ≤ 10
2000C4 (W m
−2), if 10 ≤ t(s) ≤ 30000
(2.10)
where C4 is a wavelength-dependent constant given by,
C4 =
100.002(λ−700), for 700 nm ≤ λ ≤ 1050 nm5, for 1050 nm ≤ λ ≤ 1400 nm (2.11)
This relationship between laser wavelength and exposure duration gives rise to a different
MPE depending on the laser employed. As the length of laser exposure is increased from a
nanosecond pulse (10−9) to a duration of 10 s, the MPE for skin increases from approximately
400 to 38 000 J m−2 (using equations 2.10 and 2.11 with a laser wavelength = 850 nm). This
suggests that short pulses of light are more damaging to skin than a prolonged energy
deposition. For exposures longer than 10 s, the defining limit changes from the total energy
per unit area delivered to the skin (J m−2) to the total power per unit area (W m−2), and
becomes a function of wavelength only. As the wavelength is increased from 700 to 1400 nm,
the MPE for skin increases from approximately 2010 to 10 000 W m−2, for exposures lasting
more than 10 s, indicating that the longer NIR optical wavelengths are less damaging to
skin. Since CW lasers are predominately used on the order of minutes (for example in
photothermal therapy), their MPE limits are measured in terms of the total power per unit
area, with a limit of MPEskin = 4000 W m
−2 (λ = 850 nm). However, a PW laser employed
for photoacoustics will operate with a pulse length on the order of a few nanoseconds and
therefore its MPE is measured in terms of the total energy per unit area. For a 7 ns pulse
at 850 nm, its MPEskin = 400 J m
−2. While these guidelines provide a potential upper limit
on the safe exposure for skin, they do not cover other biological tissues (other than ocular
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exposure) that may be exposed during therapy, such as lung tissue, and therefore they should
be taken as a reference guideline only for future therapeutic development.
PPTT is conventionally administered with CW lasers to induce hyperthermia via bulk
heating of a target region. This volumetric elevation in temperature can lead to the death
of cells via two basic pathways: apoptosis and necrosis. Necrosis is the death of cells
related to injury, disease, or low blood supply, and typically results in the loss of membrane
integrity and the uncontrolled release of intracellular material into the surroundings [221].
Apoptosis differs from necrosis in that it is a form of controlled cell death, where a series
of specific cellular biochemical and morphological events occur that ultimately lead to the
‘programmed’ elimination of ageing, superfluous, or damaged cells [222]. This method for
cell death is a natural way for the body to eliminate unwanted or unneeded cells that are no
longer operating as normal. If cells experience an apoptotic death, then no immunogenic or
inflammatory response will be observed [210]. Conversely, if cells are destroyed via a necrotic
pathway, then the release of cellular contents will initiate an inflammatory response. The
cellular mechanisms and processes that govern necrosis and apoptosis have been discussed
in great detail in the literature and so will not be discussed here [223, 224].
With regards to laser-based therapies, the conditions that influence whether cells un-
dergo either necrosis or apoptosis vary based on the laser exposure parameters and whether
absorbing agents, such as AuNRs, are used. It has been shown that the threshold for
apoptosis and necrosis of human prostate cancer cells is between 44 ◦C or 45 ◦C when main-
tained at this temperature for 120 min [225]. However, this study was not performed using
a laser as the heating source and instead was conducted by placing a 96-well plate onto a
pre-heated hotplate for heating. This method for applying heat may result in a different
temperature profile compared with that of a laser, and so comparisons must be made with
caution. Another more recent study investigated CW laser-induced cell-death of a murine
melanoma cell line that was incubated with AuNRs and exposed to 15 min laser irradiation
[226]. It was found that, when heated to a maximum of 43 ◦C after 15 min laser exposure,
the majority of the cells survived. However, when temperatures between 43 − 49 ◦C were
reached, significant cell death was observed (approximately 80 %) and the primary mech-
anism was apoptosis. Above 49 ◦C, necrosis became the leading cause of cell death. This
study was consistent with previous reports on temperature thresholds, where temperatures
above 50 ◦C were shown to induce necrosis, and temperatures below this threshold primarily
induced apoptosis [227, 228]. The strong temperature dependence on the mechanisms for
cell-death give rise to the ability for CW lasers to selectively destroy tissues via either the
necrotic or apoptotic pathways, by simply controlling laser exposure parameters.
Unlike CW lasers, PW lasers do not induce bulk temperature changes in an absorbing
region, and therefore the mechanisms for destroying tissue are different. The absorption of
high-intensity light pulses likely result in the destruction of tissue via mechanical stresses
and bubble cavitation [205, 229]. As a result of this, pulsed-wave plasmonic photothermal
therapy (PW-PPTT) (a.k.a. photoacoustic therapy) can only induce necrotic cell-death,
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since the mechanical stresses destroy the cells likely by disrupting the cell membrane and
releasing the intracellular contents into the surroundings.
Although apoptosis is generally preferred over necrosis, due to the lack of immunogenic
or inflammatory response, cell-death via necrosis has its potential benefits, such as the
immediacy of the killing effect, no risks associated with cancer cells developing resistance to
the therapy [209], increased selectivity as a result of no heat conducting from the target site
and damaging surrounding healthy tissues, potentially lower laser powers compared with
CW lasers, and the ability for the generated PA signals to provide simultaneous imaging
during treatment [230]. Furthermore, PW-PPTT may enable the ability to combine PAI
with PPTT through the use of PW lasers, and incorporate a single laser system into already
existing medical technologies (see section 2.5), ultimately improving patient outcome and
treatment efficiency.
2.5 Endobronchial Ultrasound (EBUS)
As discussed in section 2.1, endobronchial ultrasound (EBUS) is an existing, routine, clinical
imaging technique that enables the visualisation and staging of lung cancer via needle-biopsy
[232]. A bronchoscope with a curvi-linear transducer located at one end (see figure 2.5) is
passed through the trachea or oesophagus and into the lung, where conventional ultrasound
imaging is performed to locate possible tumour sites and access lymph node stations [233].
The bronchoscope contains a channel that runs the entire length of the bronchoscope and
enables a route for a variety of tools, such as a needle, to access the tumour tissue or lymph
node [234]. A curvi-linear probe is utilised to increase the imaging field of view (FOV), and
the centre frequency of the probe is between 5−12 MHz. This range of available frequencies
enables flexibility in terms of the imaging resolution and depth. High frequencies allow for
high spatial resolution imaging of fine shallow structures, while lower frequencies penetrate
tissue more easily at the cost of resolution [235].
EBUS lends itself to other biomedical modalities that rely on acoustic signals, such as
PAI, since the existing transducer probe could be utilised to receive PA signals with minimal
alterations. It is possible that a laser fibre could be incorporated into a bronchoscope to
illuminate the lung tissues from within the lung. The resulting PA signals could be detected
by the transducer and combined with conventional B-mode ultrasound signals to provide
a contrast-enhanced image with a greater amount of information than a standard B-mode
image [236]. Additionally, it would provide a possible means for treating the tumour tissue
with PPTT, using the same AuNRs.
However, the bronchoscope used to house the EBUS device is small (width < 7 mm) and
the space available to incorporate additional features into the device is limited. Generally,
there is only one working channel in the device, meaning only a single tool can be used at
any one time. However, in some cases it is possible to remove the tool from the working
channel and replace it with another, while the bronchoscope remains in situ [237]. Laser
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Curvi-linear probe
Working channel
Aspiration needle
Figure 2.5: An annotated image of an endobronchial ultrasound device taken from work by
Herth, et al., (2006) [231]
fibres are generally small in diameter, meaning it should be possible to develop a modified
EBUS device that incorporates a laser fibre relatively easily. However, if the aim is to add
both PAI and PPTT capabilities to the device then, as discussed in the previous section, it
would be beneficial if the therapeutic aspect could be administered with a PW laser, as this
would negate the need for potentially two laser fibres since both PAI and PW-PPTT could
be achieve with the same bronchoscope-laser system.
This potential new multi-modal theranostic approach could enable the locating, staging,
imaging, and treating of patients with lung cancer. However, its success would rely on the
development of the multiple factors it relies on, such as the efficacy of PW-PPTT, feasibility
of PAI with a typical EBUS probe, and availability of AuNRs that exhibit a high reshaping
threshold (ie. photostability). The photostability of AuNRs is a particularly important
aspect for theranostic applications since an AuNR that melts during the first stages of
procedure (ie. imaging/staging) would no longer be effective for the therapeutic aspect,
since the photothermal conversion efficacy would be significantly diminished or non-existent
[238, 239]. Therefore, it is important that these issues are addressed to ensure the success
of this potentially revolutionary approach to lung cancer treatment.
2.6 Gold nanorods for theranostics
As discussed in the previous sections, AuNRs have shown to be promising agents for ap-
plication in optical absorption-based biomedical modalities to develop and enhance, new
and existing clinical procedures. However, before AuNRs can be safely and effectively used
clinically, there still remains extensive research into developing the AuNRs themselves and
understanding their behaviour. This thesis aims to investigate some of the important areas
surrounding the use of AuNRs for diagnostic, therapeutic, and theranostic applications.
One such area of AuNR development, that requires further investigation and optim-
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isation, is their size. There have been many published reports that consider AuNRs for
photoacoustic and photothermal applications, in addition to cellular interactions and tox-
icity, however there is very little consistency between the reports in terms of experimental
setup, nanoparticle structure and modifications, nanoparticle concentration, and reported
details, with often no consideration for their size on the observed outcomes. For example,
Adnan et. al. (2016) synthesised gold nanoparticles of various shapes (spheres, rods, and
stars) and investigated their abilities for photothermal therapy and drug delivery, however
the AuNR dimensions were not reported, limiting its scope [69]. Other reports provide
more detail with regards to the AuNR sizes, such as Cavigli et. al. (2014), who also syn-
thesised their own AuNRs (CTAB-capped) with different sizes, and measured their melting
thresholds as a function of size and PW laser fluence [240]. They determined a negative
relationship between the melting threshold and size of the CTAB-capped AuNRs in terms
of their ‘effective radii’ (5− 22 nm), however no ‘real’ dimensions were reported. Chithrani
et. al. (2006) explored the intracellular uptake of two different sized AuNRs (modified
by chemically replacing the CTAB capping with citric acid) by humancervical carcinoma
(HeLa) cells [241]. The AuNRs of interest were equivalent in width (14 nm) but different
in length (40 and 74 nm), and therefore their aspect ratio (2.86 and 5.29) and SPR peak
(not reported) were different. It was found that the AuNRs with a smaller aspect ratio were
more preferentially taken up by HeLa cells. A well-designed study by Gratton et. al. (2008)
also examined the cellular internalisation of AuNRs (among other shapes) by HeLa cells,
and found that high levels of uptake was observed for all AuNR sizes and aspect ratios, with
larger sized AuNRs (diameter = 150 nm) being taken up to a greater extent than smaller
volume AuNRs (diameter = 100 nm), with equivalent aspect ratios (≈ 3) [242]. The AuNRs
used in this study were comparatively large in size (diameters ranging from 100 − 500 nm,
aspect ratios from 1 − 3) with the largest AuNR possessing a length of 1 µm. Large nano-
particles such as these are unlikely to be useful for optical absorption-based therapies since
cells will not be able to internalise the AuNRs.
The vast number of available reports, such as those described previously, contain large
variations in nanomaterials and experiment designs (e.g. capping agents, cell lines, surface
chemistry, reported dimensions and characteristics) which makes drawing general conclu-
sions and direct comparisons difficult. Moreover, many of the reported studies synthesised
a small batch of AuNRs with specific characteristics that are relevant to that investigation,
and there is no accounting for the large-scale reproducibility required for successful clinical
translation. Therefore, further controlled studies into the size-dependent effects of AuNRs
for optical-based biomedical modalities, that can be synthesised on a large scale with repro-
ducible characteristics, are required to enable accurate conclusions based on AuNR size to
be drawn, and the optimisation of AuNR design for eventual clinical use.
Another area in need of further investigation, is in light-based therapeutic applications
of AuNRs, such as AuNR-assisted photothermal therapy. Continuous-wave (CW) lasers
have generally been the research focus in the literature due to CW lasers generating bulk
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heating in a target region and destroying tissue through heat damage (as discussed in section
2.4.1) [243]. There have been reports that utilise pulsed-wave (PW) lasers as the optical
source for laser ablation of biological tissue, however these are few and far between, and
often the experimental parameters are impractical for clinical translation. Furthermore,
there is very little consideration for gold-based nanoparticles as the absorbing agent for
PW-PPTT in the literature (perhaps due to the risk of AuNRs reshaping under pulsed laser
illumination). The majority of nanoparticles studied for PW-PPTT are single-walled carbon
nanotubes [244, 245, 246], or indocyanine green-containing nanoparticles [247, 248], among
others [249, 250, 251, 252]. However, AuNRs can produce significantly stronger shock waves
under pulsed laser illumination, compared with many of the other nanoparticles currently
considered in the literature, and therefore can potentially be more efficient at destroying cells,
while also making possible the ability to perform image-guided therapy via the monitoring
of photoacoustic emissions [230].
One study that considered gold nanoparticles for PW-PPTT was conducted by Huang
et. al. (2010), who compared the photothermal efficacy of CW and PW lasers for nucleus-
or cytoplasm-targeted gold nanospheres (AuNS) to a human oral squamous cell carcinoma
(HSC-3) cell line [206]. In this study, they found that the CW lasers were more effective at
destroying cells when the AuNSs were targeted to the cytoplasm, while those targeted to
the nucleus were more effective under PW laser irradiation. However, this study was limited
by the optical absorbance of the nanospheres being in the visible spectrum (SPR = 526 nm)
and the laser energies were exceedingly high (PW laser fluence = 101 mJ cm−2, CW laser
power= 25 W cm−2, spot size = 1 mm).
A more recent study that considered rod-shaped gold nanoparticles was by Patino et.
al. (2015) [253]. They investigated the use of ultra-short (100 fs) pulsed lasers to destroy
pancreatic cancer cells that had been incubated with peptide-functionalised AuNRs, and
found that cell-death could be achieved with a relatively low laser fluence (11.3 mJ cm−2).
Although the fluence was low, the short femtosecond laser pulses resulted in peak powers
in excess of 28 MW, and caused cell destruction via cavitation and local vapour/plasma
expansion around the AuNRs (that were situated within the cells).
While the two studies mentioned previously have shown the potential for using PW lasers
for the treatment of cancer cells, the experimental parameters (laser energies, nanoparticles,
treatment times, etc.) need further refinement towards the eventual clinical use. Further-
more, the use of AuNRs in PW-PPTT has likely considerable benefits in the development of
the technique, both in terms of treatment efficacy and additional possible modalities, such as
image-guidance. Therefore, continued research into these areas is clearly needed, especially
with consideration for lower laser energies/powers that are closer to the safe exposure limit
laid out by the American National Standards Institute [202].
The final aspect to be investigated in this thesis, is the development and improvement
of an existing biomedical approach, endobronchial ultrasound (EBUS), by utilising AuNRs.
As discussed in section 2.5, there is the possibility for using AuNRs to improve upon EBUS
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- an effective lung cancer diagnostic tool - by enhancing the ultrasound images with pho-
toacoustic signals, and to help locate cancerous regions and lymph nodes in the lung, with
further improvements made by enabling AuNR-assisted photothermal therapy. The existing
literature in this particular area of research is limited, with very few articles considering
this combination of EBUS and photoacoustics. Other techniques, such as optical coherence
tomography (OCT) [254], have been discussed with regards to improving EBUS, however it
appears that nothing has been implemented so far. Nevertheless, the potential for combined
photoacoustic and conventional ultrasound imaging for other biomedical applications has
been demonstrated [255, 256, 257], and this existing research will translate to improving
EBUS. While this multimodal approach will likely require minimal adaptation to the ex-
isting technologies behind EBUS systems, further development is required before it can be
realised as a clinical approach.
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Chapter 3
Influence of Gold Nanorod Size
in Photoacoustics
As discussed in section 2.2.2, gold nanorods (AuNRs) absorb light based primarily on their
aspect ratio. Due to this fact, they can be synthesised to have many different sizes, but
similar aspect ratios and therefore similar absorption peaks. It is possible that AuNR size
can affect many different aspects relating to a particular biomedical modality, and in the
case of photoacoustic imaging (PAI), aspects such as, photoacoustic conversion efficacy,
melting thresholds, and cytotoxicity, are important to the success of the technique. There
may exist an optimal sized AuNR that achieves the best outcome across these various
important aspects, and currently, this optimal size is not known. Further research into
the size-dependent effects of AuNRs is required before this conclusion can be drawn. In
this chapter, AuNRs with four different size distributions (widths of 10, 25, 40 and 50 nm)
and SPRs of 815 ± 26 nm are investigated with regards to their potential as photoacoustic
contrast agents. Their size-dependent effects on photoacoustic response and photostability
are observed, in addition to their toxicity and cellular uptake of a non-small cell lung cancer
(NSCLC) cell line.
3.1 Introduction
Gold nanorods (AuNRs) possess characteristics such as tuneable surface plasmon resonances
(SPRs) [258, 259], relative biocompatibility [70, 71], high colloidal stability [260, 261, 262],
comparatively easy synthesis [113, 263, 264], and functionalisation [75, 265], that make them
desirable for use in biomedical disciplines including diagnostics, therapeutics, or theranostics
(as discussed in chapter 2) [266, 267, 268, 269]. Furthermore, their potential utilisation
in nanomedicine as drug carriers, nano-probes, cellular labels, and biosensors is evident
[116, 270, 271]. However, they are still some way off from being utilised in the clinic, as
there are a number of key areas that must be addressed to ensure safety and efficacy.
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In AuNR-assisted photoacoustic imaging (PAI), the amplitude of the generated pho-
toacoustic (PA) signals is an important aspect that must be considered for two main reasons:
Firstly, on the optical side, a heightened PA amplitude, as a result of employing AuNRs,
facilitates the use of significantly lower laser fluences to generate an equivalent PA response.
In other words, lower-powered lasers could be used to achieve the same PA response while
reducing the damaging effects that high energy laser exposures can cause. A safe exposure
limit, known as the maximum permissible exposure (MPE) for skin [202], provides a po-
tential upper-limit on the laser fluences that can be employed for diagnostic applications.
Furthermore, it is difficult for light to penetrate deep into biological tissues, since significant
optical attenuation is observed [122, 123, 272, 273]. Secondly, on the acoustic side, PA waves
are generally weak in amplitude (≤ 10 kPa) compared with other modalities that utilise ul-
trasound. For example, the typical focal peak pressures generated by clinical ultrasound
scanners are in excess of 1 MPa. These low amplitude PA signals will consequently be re-
duced further (related to the acoustic amplitude attenuation coefficient αa) as they travel
through the various different tissues, caused by a combination of acoustic scattering, absorp-
tion, and mode conversions of the waves. This ultimately results in the rapid reduction in
signal amplitude (αa = 0.3− 0.5 dB cm−1 MHz−1 for an approximate soft tissue [274]), and
the already weak PA signals may become undetectable. Thus, there is a distinct problem
with both generating and detecting PA signals in biological tissue, especially with several
centimetres of tissue between the light source and region of interest, and the optimisation
of AuNR PA emissions could help to mitigate these issues.
Plasmonic nanoparticles absorb light differently based on their size and shape [275, 276,
277], and the peak absorption wavelength of AuNRs is linearly proportional to their aspect
ratio (see section 2.2) when the relative permittivity of the surrounding medium is constant
[121, 278, 279]. Consequently, if the shape is fixed (i.e. rod-shaped for AuNRs) and the
aspect ratio is restricted to a small range of values to enable maximum absorption in the
near-infrared [280], then there may be an optimal sized AuNR at an equivalent concentration
(NP mL−1) that maximises the PA emission amplitude. Currently this optimal size is not
known, and further research into how the size of AuNRs can enhance a PA signal is required.
It is also important to consider the concentration of the AuNR solutions in terms of the
relative total mass (µg mL−1) since a population of smaller AuNRs will have a smaller
total mass at an equivalent concentration to that of larger AuNRs. Confusion must not
be made between the effects observed as a result of the change in volume over a change in
concentration.
The size (or volume) of AuNRs may also have an effect on a large range of other aspects
related to PAI, such as photothermal conversion efficiency [178, 281], cellular interactions and
uptake [282], cytotoxicity [283], and the thermal stability of AuNRs [240, 284, 285]. These
are all crucial areas in need of further investigation if AuNRs are to be used successfully as
PA absorbers in a clinical environment. For example, if AuNRs, that are situated inside a
tumour, begin to melt under laser irradiation then their ability to absorb the incident laser-
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light will significantly diminish as the peak SPR band begins to blue-shift. This is especially
problematic for ‘theranostic’ applications that rely on their ability to absorb light, since
a reduction in optical absorption will result in reduced clinical efficacy. There have been
many reports on the reshaping, melting and fragmentation of AuNRs [285, 286], but the
quoted fluence reshaping threshold is often very different between sources and the size of the
AuNRs is often not considered. Likewise, the cellular uptake and toxicity of AuNRs has also
been investigated in the literature, however the multitude of different possible AuNR surface
chemistries, and the inconsistencies between the nanoparticle shapes, sizes, incubation times,
and laser parameters in these reports makes forming direct size-based conclusions difficult.
Therefore, further controlled research that considers the size-dependent effects of AuNRs
for PAI is warranted.
In this chapter, we investigated four different sized AuNRs that have similar aspect
ratios but different sizes, in an effort to inform on their future use as contrast agents for
PA imaging, or optical-based theranostics. PA emissions were recorded for each AuNR
size at equivalent concentrations to determine their size-dependent effects on PA emission
amplitudes, in addition to the fluence thresholds for melting, and inherent cytotoxicity to a
lung cancer cell line.
3.2 Materials and methods
3.2.1 Transducer selection for detecting photoacoustic signals
Selecting the correct transducer for the detection of photoacoustic signals is important.
A photoacoustic signal generated from a material will contain a wide range of frequency
components, ranging from approximately 1 − 50 MHz. However, this broadband signal is
only produced when the size distribution of the optical-absorbing particles in the absorbing
region is large and varied [287]. If there is a uniform size distribution of absorbing particles
then the frequency spectrum emitted will be much narrower.
A spherical, focussed, broadband (10 kHz - 15 MHz) hydrophone was first used to detect
the photoacoustic signals from the different sized AuNRs. This particular transducer was
chosen due the potentially broadband photoacoustic signals and to maximise the detection of
all the generated frequencies. However, a PA signal was not detected above the background
noise. This was attributed to the fact that hydrophones sacrifice sensitivity for a wide
frequency detection bandwidth, and it has been suggested that a transducer with a large
bandwidth is more sensitive to the background thermal noise [288]. As a result, a 7.5 MHz,
single-element, focussed transducer was chosen to replace the hydrophone. This probe was
successful in detecting a photoacoustic signal from the AuNRs and the shape of the recorded
signals were approximately as expected (N-shaped) - although there appeared to be other
contributing factors that affected the shape of the signal (figure 3.1a). To check the frequency
components of the signals, a Fast Fourier Transform (FFT) was applied. The results from
this (figure 3.1b) showed a strong frequency component at 1.3 MHz and a reduction in signal
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7.5 MHz
1.3 MHz
(a)
(b)
Figure 3.1: (a) Examples of the photoacoustic signals generated by four different sized
AuNRs, recorded with a 7.5 MHz, single-element, focussed transducer. Coloured line rep-
resents signal from each AuNR and black line is the baseline (water), and (b) an example
of an FFT applied to the photoacoustic signal generated by the Au10-811s compared with
the baseline.
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Figure 3.2: The laser energy output was calibrated for each desired wavelength as a function
of the maximum output energy by altering the timing between the flash lamp and q-switch.
amplitude of approximately −28 dB at 7.5 MHz. This lead to the decision to use a focussed
1 MHz probe for the following experimental work.
3.2.2 Controlling laser energy
To facilitate the experimental work in this study, it was necessary to measure and control
the energy output of the laser accurately. The laser energy was controlled via adjusting the
timing between the laser flash lamp firing and the q-switch opening. The starting q-switch
timing was set to 180 µs (the shortest timing permitted by the laser system and therefore
the highest energy output possible). This was calibrated so that the user could specify the
laser energy output as a percentage of the maximum energy achievable (figure 3.2) which
provided a linear relationship. To ensure that equivalent laser fluences were used to generate
a PA response from each AuNR size, the output energy of the laser was measured across 100
pulses and calibrated for each wavelength used in the study (the exact SPR of each AuNR
size).
3.2.3 Characterisation of gold nanorods
Commercially bought, citrate capped AuNRs (A12, Nanopartz, USA) with certified latit-
udinal widths of 10 nm, 25 nm, 40 nm and 50 nm were chosen (see inset of figure 3.4) as the
source of the generated PA signals so that a relationship could be made between the PA
response of AuNRs with different sizes, but similar aspect ratios. AuNRs with a citrate
capping were selected due to the increased biocompatibility, compared with other capping
37
3. INFLUENCE OF GOLD NANOROD SIZE IN PHOTOACOUSTICS
Figure 3.3: Transmission electron microscope images of the four different sized AuNRs used
in this study.
Table 3.1: Dimensions and SPRs of the AuNRs used in the study, determined by TEM ana-
lysis (n = 546) and absorbance measurements respectively. The uncertainty of measurement
is the standard deviation of the sample.
Name Width Length Aspect Ratio Peak SPR
Au10-811 9.9 ± 1.1 nm 39.7 ± 5.4 nm 3.98 ± 0.51 811 ± 2 nm
Au25-803 23.2 ± 2.6 nm 85.6 ± 9.8 nm 3.73 ± 0.63 803 ± 2 nm
Au40-790 39.8 ± 4.1 nm 122.5 ± 13.8 nm 3.10 ± 0.35 790 ± 2 nm
Au50-841 42.2 ± 4.6 nm 142.0 ± 17.0 nm 3.38 ± 0.41 841 ± 2 nm
agents, and the enhanced colloidal stability in cell media. Absorbance spectra of the AuNRs
were measured and normalised to the peak absorbance (figure 3.4) to determine the longit-
udinal SPR of each different sized AuNR. This enabled the laser wavelength to be tuned to
the maximum SPR of each AuNR to ensure maximum optical absorption. A transmission
electron microscope (Tecnai™TF20, FEI, USA) was used (figure 3.5) to take images of the
purchased AuNRs (figure 3.3) with an accelerating voltage of 200 kV and varying magnifica-
tion. These images were subsequently analysed to confirm the size distributions and aspect
ratios of the different AuNRs. The manufacturer of the AuNRs characterise them before
shipping, and have stated that a minimum of 93 % of the population of AuNRs across the
four different sizes were rod shaped.
The TEM determined size distributions (table 3.1 and figure 3.6) for the Au10-811s,
Au25-803s, and Au40-790s were in agreement with their corresponding peak SPRs [121],
however there was a discrepancy with the Au50-841s. The Au50-841s were not measured to
be 50 nm in width, as the certification suggested, and were instead found to be 42.2±4.6 nm.
While the Au50-841s were of a similar width to the Au40-790s, they were still larger in length
and aspect ratio on average and so were still considered relevant for this study. Confirming
and ensuring AuNRs are consistent between each batch is an important aspect for clinical
translation, since there are minimum regulatory criteria, known as good manufacturing
practice (GMP) [96], that any new medical drugs must meet to ensure consistency and
quality.
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Figure 3.4: Normalised measured absorbance spectra displaying SPR peaks at 811, 803, 790,
and 841 ± 2 nm, respectively. The SPR of the Au50-841s showed a 50 nm shift compared
with that of the Au40-790s, which can be ascribed to a combined effect of the AuNR width
and aspect ratio on the SPR position of AuNRs. Inset shows a photo of the four AuNRs.
Figure 3.5: A photograph showing the transmission electron microscope used in this study,
situated in the Leeds Electron Microscopy and Spectroscopy Centre (LEMAS).
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(a)
(b)
Figure 3.6: TEM measured size distributions of the four different sized AuNRs used in this
chapter (n = 546).
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Figure 3.7: A schematic of the experimental setup used to detect the photoacoustic signals
generated from Au10-811s, Au25-803s, Au40-790s, and Au50-841s.
3.2.4 Measuring the photoacoustic signal amplitude
As a result of the preliminary testing (section 3.2.1), an experimental setup was designed
to accurately detect the photoacoustic response of a solution of different sized AuNRs (ex-
perimental schematic shown in figure 3.7). A pulsed tuneable laser system (Surelite™ OPO
Plus, Continuum®, USA) operating at a pulse repetition frequency of 10 Hz with a pulse
duration of 7 ns and spot size of 5 mm (at the focus of the transducer, 15.6 mm from tip of
the fibre) was used to induce a PA response from a region of AuNRs. These parameters were
chosen to ensure the stress-confinement conditions for generating a photoacoustic response
were met, and a large volume of AuNRs were illuminated. The distance between the tip of
the fibre and the absorbing region of AuNRs is governed by the specifications of the laser
fibre (i.e. numerical aperture and core diameter) for a given spot size and should therefore
be calculated for the specific fibre being used. A single-element focussed transducer (V303,
Olympus, UK) with a centre frequency of 1MHz and certified −6 dB bandwidth of 76 % was
mounted on a micrometre translation stage and aligned so that the transducer focus (focal
length = 20.5 mm) was in the centre of the AuNR solution and at the point where the laser
beam spot size was 5 mm. This transducer was chosen and based on the preliminary testing
(section 3.2.1) and accurately aligned with the absorbing region to ensure that the majority
of generated photoacoustic signals were recorded. Similarly to the laser fibre, the distance
from the transducer element to the focus is defined by the specifications of the transducer.
The laser wavelength was tuned to the exact SPR of the AuNRs being illuminated to max-
imise optical absorption, and the detected photoacoustic signals were subsequently passed
through a 40 dB pre-amplifier (SPA.1411, Spectrum, Germany) and recorded with a data
acquisition (DAQ) card (M4i.4420x8, Spectrum, Germany).
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Experimental parameters and data acquisition
A solution of each AuNR size was made to the desired concentration (discussed below) by
calculating the volume of DI-water required to dilute the stock solution of AuNRs (with a
certified stock concentration). To measure the size-dependence of the AuNRs on calculated
PA amplitude, the AuNRs were made to a concentration of 1× 1011 NP mL−1 to ensure a
detectable photoacoustic signal across all AuNR sizes. The incident laser fluence was then
increased sequentially across a wide fluence range (approximately 1− 40 mJ cm−2) in steps
equal to 4 % of the highest laser output energy considered. This fluence range was chosen
to enable a relationship between fluence and PA amplitude to be determined, in addition
to melting thresholds. The AuNRs received 20 laser pulses per fluence step (the data was
averaged to obtain a single photoacoustic amplitude), and this process was repeated 3 times
on fresh samples of AuNRs. The data was averaged to account for small fluctuations in
the laser output energy and to increase the signal-to-noise ratio of the waveforms. A larger
number of laser pulses (and therefore averages) was tested, however it only provided a
minimal increase in signal-to-noise ratio of the signal and therefore the number of repeats
was kept at 20 to reduce the total laser energy incident on the AuNRs. Before laser exposure,
the AuNRs were agitated in an ultrasound bath for 15 min to ensure a uniform colloidal
suspension, prior to being placed inside an Eppendorf for PA emission measurements, with
the laser fibre situated inside the Eppendorf (i.e. with the lid open) to reduce optical
attenuation and maximise the delivered light.
To determine the concentration dependence on PA amplitude, the laser fluence was
fixed at 7 ± 1.9 mJ cm−2, to minimise the chance of AuNR reshaping, and fresh samples
of AuNRs with concentrations ranging from 1× 109−1× 1011 NP mL−1 were illuminated.
The experimental setup was identical otherwise.
Data processing
To calculate the PA signal amplitude, a technique similar to that used in PA image recon-
struction was used [289, 290, 291]. Firstly, each averaged waveform was windowed to a 7 µs
region of interest (ROI) that relates to the width of the absorbing volume (i.e. the spot size
of the laser). A Hilbert transform was applied to obtain the envelope of each signal and
the amplitude was calculated by integrating across the ROI. Photoacoustic signals were also
obtained from the Eppendorf container filled with water, and were recorded and processed
under the exact same conditions as the AuNR target. This data was subtracted from the
AuNR PA amplitude to remove the effects from the container. The subsequent calculated
PA amplitudes (across the entire laser fluence range) was determined from the three sep-
arate samples of AuNRs, and the average was plotted along with the standard error of the
mean. Finally, to provide a baseline measurement, a noise signal was resolved by recording
under the exact same conditions as discussed previously, however the shutter on the laser
was closed while the laser continued to fire (i.e. no light was incident on the target). To
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Figure 3.8: Experimental schematic showing a straw containing 1× 1011 NP mL−1 of
AuNRs, and a second straw containing a water baseline, being placed into a typical turbid,
agar phantom before a multispectral scan is performed at 6 positions using the pre-clinical
MSOT system.
determine statistical significance between the calculated PA amplitude of the AuNR and the
baseline signal amplitude, a two-way analysis of variance (ANOVA) technique was used to
calculate a p-value at each laser fluence studied.
3.2.5 Validation of measurements with a pre-clinical system
To compare the lab results with a commercial PAI system, PA signals were measured at the
SPR of the four AuNRs using a multispectral optoacoustic tomographic (MSOT) system
(MSOT inVision 128, iThera Medical, Germany). Four small thin plastic tubes containing
equivalent concentrations of AuNRs (1× 1011 NP mL−1) and another four with equivalent
mass concentrations (100µg mL−1) were made and inserted into a typical MSOT phantom
(turbid agar phantom), along with a straw containing the supernatant of the AuNRs to
act as a background signal (see figure 3.8). The phantom containing the straws was placed
inside the MSOT system and a multispectral scan (680 nm to 980 nm in steps of 5 nm)
was performed at 6 unique points along the straws. The maximum PA amplitude at the
peak SPR of the AuNRs was recorded and averaged across the 6 data points to give a final
amplitude. Images were processed using open-source software package imageJ [292].
3.2.6 An indication of gold nanorod toxicity
A cytotoxicity study was devised to provide an indication of the relationship between gold
nanorod size and cellular toxicity. To establish the cytotoxicity of the four different AuNR
sizes over the potential length of time AuNRs may reside inside the body, a 72 h MTT
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Figure 3.9: A bright-field microscope image of the human non-small cell lung epithelial
carcinoma (NSCLC) cell line (A549) used in the study.
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) colorimetric assay protocol
was followed [293]. This metabolic assay is a reliable and widely used method for evaluating
cell viability, and it provides a quantitative indication of cell viability by measuring the en-
zymatic activity of cellular mitochondria [76]. There are suggestions that newer tetrazolium
analogues, that are stabilised by intermediate electron acceptors, are a better option for
toxicity evaluation, however these assays exhibit a net negative charge which could inhibit
intracellular uptake and affect observed toxicity [294]. Conversely, MTT has an overall
positive charge that facilitates easy uptake and mitochondrial reduction. Moreover, nano-
particles that interact with cellular membranes may further affect toxicity results from the
newer generation of tetrazolium assays by interfering with the uptake and extracellular re-
duction of the tetrazolium dye [295]. Therefore, an MTT assay was considered to be the
best approach for this particular study.
A human non-small cell lung epithelial carcinoma (NSCLC) cell line (A549, ATCC,
UK) was selected for toxicity evaluation because NSCLCs account for the majority of lung
cancer cases in the UK (approximately 80%) [296], they can be easily used in xenograft
lung cancer models [297], and they have been shown to express EGFR (for future targeting
studies) [298]. Furthermore, A549 cells have been considered widely in the literature in
terms of cancer therapies and nanoparticle interactions [299, 300, 301], making comparisons
straightforward. The intention of this study was to provide insights into the potential
AuNR size-dependence on cell viability, and not to be a comprehensive investigation into
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the cytotoxicity of lung cancer, and so a single cell line was deemed sufficient to demonstrate
this.
A549 cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium) media sup-
plemented with 10 % FBS (Fetal Bovine Serum). A bright-field image of the cell line is
shown in figure 3.9. When the cells reached 80 % confluency, a 96-well plate was seeded
with 1× 103 cells per well and incubated for 24 h. The four different sized AuNRs were
introduced to the cells mixed with culture medium at a concentration ranging between
1.5× 106 NP mL−1 to 3× 1010 NP mL−1 in a 1:3 series dilution. One of the columns was
reserved for a control group containing the supernatant of the AuNRs (DPBS) to ensure
this was not the cause of toxicity. After 72 h incubation the AuNRs mixed with media was
removed from each well and replaced with media containing MTT at a concentration of
500 µg mL−1. After a further 3 h incubation the media containing MTT was removed from
each well and the 96-well plate was wrapped in foil and stored at approximately 4 ◦C, ready
for absorbance measurements.
Before the plates were measured with a plate reader (Mithras LB 940, Berthold Tech-
nologies, Germany), 100µL of dimethyl sulfoxide (DMSO) was added to the wells. The
absorbance was measured at a reference wavelength of 630 nm to minimise the absorbance
contribution from the AuNRs. The data from each column was averaged to obtain a single
absorbance value for each AuNR concentration, and the background absorbance level was
then subtracted from each of the other values. The cell viability was finally calculated by
the ratio of mean absorbance of the sample with respect to mean absorbance of the control
group (DPBS). This methodology was repeated three times on fresh samples to obtain a
mean cell viability.
3.2.7 Visualisation of cellular uptake
To visualise the potential cellular uptake of different sized AuNRs, a dark-field study was
conducted. A549 cells were plated onto 22 × 22 mm glass cover-slips in a 6-well plate at a
density of 1× 105 well−1 and allowed to grow for two days. The DMEM medium was then
replaced with 2 mL of the same medium containing each AuNR type at a concentration
of 1× 1011 NP mL−1. After 4 h incubation, the AuNR-media was removed and the cell
monolayer on the cover-slip was twice-rinsed with DPBS (14190-094, Life Technologies,
UK), fixed in 4 % paraformaldehyde/DPBS for 10 min at room temperature and rinsed with
DPBS twice. The fixed coverslips were mounted and sealed onto glass slides. Bright and
dark-field microscopy imaging was performed with an inverted microscope (Nikon Eclipse
Ti-E, Nikon UK Ltd, UK) and an oil coupled 100x objective (CFI Plan Fluor, Nikon UK
Ltd, UK). Images were recorded with a 5 Megapixel colour camera (DS-Fi1, Nikon UK Ltd,
UK) and saved using the NIS-Elements D software (Nikon UK Ltd, UK). ImageJ was used
to crop and enhance the contrast of saved images.
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3.3 Results and discussion
3.3.1 Photoacoustic response of gold nanorods
Examples of the averaged recorded pre-processed photoacoustic signals are shown in figure
3.10a. The shape of the recorded photoacoustic signals can be explained by the density
of absorbers in the target region [302]. The ROI was assumed to be cylindrical, with a
radius of 1.3 mm (−6 dB radius of the transducer’s focus) and height equal to 5 mm (spot
size of the laser). The total ROI volume was approximately 26.5 µL, yielding an order of
1× 1010 AuNRs converting the absorbed light into ultrasound. The large number of AuNRs
collectively producing a photoacoustic response resulted in a pressure rise only at the outer
edges of the absorbing region since the acoustic waves emitted from the centre interfered
destructively [302]. This is responsible for the signal peaks at 14 µs and 18µs.
Figure 3.10b shows the PA amplitude of each AuNR type as a function of the incident
laser fluence. The PA signals from all four AuNRs were detectable above the noise at the
concentration studied, however the Au10-811s produced a very weak signal in comparison.
Statistical significance was established for the majority of fluence levels (p < 0.05), however
there were a few instances where this was not the case. Firstly, at the lowest laser fluence
studied, 1± 0.7 mJ cm−2, the amplitude of emissions from all AuNR sizes were not signific-
antly greater (p > 0.05) than the baseline measurements. This can be attributed to the laser
fluence being too low to generate a sufficient PA signal from the AuNRs. For the Au25-803s
measurements (figure 3.10b), when the fluence reached and exceeded 29± 3.2 mJ cm−2, the
detected emissions were not significantly above the baseline. Similarly, for the Au10-811s,
this occurred at a laser fluence of 33± 3.3 mJ cm−2. The reduction in the significance of the
data can be ascribed to the reduction in PA amplitude due to potential melting or reshaping
of the AuNRs (investigated in section 3.3.2).
All AuNR types displayed a linear relationship between incident laser fluence and PA
amplitude at low fluences (< 12 mJ cm−2 for the Au10-811s, Au40-790s, and Au50-841s,
and < 8 mJ cm−2 for the Au25s). The Au25s were the first to show a decline in signal
amplitude, occurring when the fluence rose above 7 ± 1.9 mJ cm−2. The PA amplitude of
the Au10-811s, Au40-790s, and Au50-841s continued to increase past 7 mJ cm−2 and lose
linearity at approximately equivalent fluences (12-16 ± 2 mJ cm−2). The thermal stability
of AuNRs is governed by a balance between the rate of heat dissipation to the surroundings
and the atomic surface diffusion of AuNRs. It has been suggested that thermal stability
significantly decreases with increasing aspect ratio [286], and this agrees with the observed
results, where the Au25-803s (aspect ratio = 3.73±0.63) displayed a lower thermal stability
to the Au40-790s (aspect ratio = 3.10±0.35). The Au10-811s may show an enhanced thermal
stability despite having a larger aspect ratio (3.98±0.51) as they are much smaller than the
other AuNRs and are able to dissipate the generated heat more rapidly to the surrounding
environment [240]. Furthermore, it has been suggested that small AuNRs (8 ± 2 nm by
49 ± 8 nm) reach lower peak temperatures under pulsed illumination compared with larger
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Figure 3.10: (a) Typical examples of averaged photoacoustic signals (laser fluence =
8 mJ cm−2) generated by four AuNR sizes, and (b) the photoacoustic signal amplitude gen-
erated from the same four AuNRs (concentration = 1× 1011 NP mL−1), detected with a
1 MHz focussed transducer. Au10-811s (blue), Au25-803s (red), Au40-790s (green) and
Au50-841s (yellow). The black line represents the water baseline signal.
47
3. INFLUENCE OF GOLD NANOROD SIZE IN PHOTOACOUSTICS
Figure 3.11: The photoacoustic amplitude of four different sized AuNRs as a function of
concentration ranging from 1× 109 to 1× 1011 NP mL−1.
AuNRs, and therefore may not reach a high enough temperature to exhibit melting [303]. It
is worth noting that the quoted fluence levels here are all below 31 mJ cm−2 - the approximate
maximum permissible exposure of skin for a single pulse (wavelength between 700-1400 nm)
[202].
The two larger AuNRs (Au40-790s and Au50-841s) both displayed a similar PA rela-
tionship with increasing laser fluence, but it was the Au50-841s that ultimately produced
the largest peak signal. The similarity between the two larger AuNRs is most likely due to
the similarities in AuNR size distributions as confirmed by TEM analysis (see table 3.1).
Furthermore, these AuNRs continued to produce an increasing PA amplitude past the point
where linearity is lost (12-16 ± 2.2 mJ cm−2) and began to decline in amplitude at approx-
imately 25± 2.7 mJ cm−2. This was due to the significant number of large AuNRs that had
not fully reshaped and still able to absorb light.
The PA response of the four different sized AuNRs was measured across a range of AuNR
concentrations from 1× 109 to 1× 1011 NP mL−1 and the maximum amplitude calculated
(figure 3.11). A logarithmic relationship between AuNR concentration and PA amplitude
was observed, indicating the importance of maximising the number of AuNRs delivered to a
region in vivo, which could be facilitated by the functionalisation and molecular targeting of
AuNRs [230]. At equivalent concentrations (NP mL−1), the PA signal amplitude scales with
AuNRs size, where the larger AuNRs produced the strongest PA signal. Across the entire
concentration range, the Au40-790s and Au50-841s exhibited similar PA amplitudes. This
was due to the Au50-841s being only slightly larger than the Au40-790s (see table 3.1) and
therefore exhibiting a similar total mass (0.3 mg mL−1 for the Au40-790s, compared with
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Figure 3.12: The photoacoustic response of the Au10-811s, Au25-803s, Au40-790s, and
Au50-841s were measured with a multispectral optoacoustic tomographic (MSOT) system
at equivalent mass (100 µg mL−1) and number of particles (1× 1011 NP mL−1). The figure
shows an example of MSOT images of the four AuNRs, reconstructed from the raw signal
data captured with the MSOT system with a logarithmic colorbar.
0.5 mg mL−1 for the Au50-841s).
The maximum PA amplitude of the same four AuNRs was also measured using a MSOT
system [197] at a fixed number of particles (1× 1011 NP mL−1) and fixed total mass (100 µg mL−1).
The reconstructed PA images (linear regression) are shown in figure 3.12 and the PA amp-
litude data is shown in figure 3.13. At equivalent particle numbers, the data is in agreement
with the results in figure 3.10b, where an increase in AuNR size produced an increase in
PA emission amplitude, and the Au40-790s and Au50-841s showed similar PA amplitudes.
However, when the total mass was fixed between samples, the Au10-811s produced a signi-
ficantly larger PA signal when compared with the other three. The smallest of the AuNRs
exhibited an amplitude more than 2.5 times that of the Au40-790s, the next largest amp-
litude. The Au50-841s and Au25-803s produced a similar PA response, but the Au25-803s
displayed the lowest photoacoustic conversion overall. A recent study by Chen et al. (2019)
showed that small AuNRs (8×49 nm) produced an enhanced photoacoustic signal compared
to larger AuNRs due to the increased heat transfer exhibited by the AuNR, facilitated by
an increased surface-to-volume ratio. This may explain the large PA signal generated by
the Au10-811s.
At an equivalent total mass of 100µg mL−1 the number of particles within each sample
varied significantly. The Au10-811s contained more than an order of magnitude more
particles (1.57× 1012 NP mL−1), the Au25-803s were approximately the same concentration
(1.46× 1011 NP mL−1), and the Au40-790s and Au50-841s contained 3 and 5 times fewer
49
3. INFLUENCE OF GOLD NANOROD SIZE IN PHOTOACOUSTICS
Figure 3.13: The maximum photoacoustic amplitude of the four different sized AuNRs at
equivalent concentrations (purple = 1× 1011 NP mL−1, orange = 100µg mL−1) averaged
across 6 repeats. Errorbars represent the standard deviation.
particles (3.31× 1010 NP mL−1 and 1.82× 1010 NP mL−1), respectively. These difference in
AuNR concentration agree with the observed differences in MSOT signal.
The results indicate the importance of AuNR size for PA emissions, and how the concen-
tration of AuNRs is defined. There is a clear distinction between the effects generated by a
total number of particles and total mass of gold, and this must be taken into consideration
for tumour targeting, accumulation, and uptake of the AuNRs in a clinical setting [130]. For
instance, if the accumulation of AuNRs in situ is restricted by the total number of AuNRs,
regardless of size, then the data would suggest that the larger AuNRs would be more effective
at achieving the desired effects since they produce the strongest PA signal per particle (see
3.13) [304]. Conversely, if the total mass is the driving factor behind tumour uptake, then
clearly the smallest AuNRs (< 25 nm) would be most suited [141]. The Au25-803s should
be avoided in either situation, however, since they produced a weak PA signal in both cases.
Further studies into the size- or mass-dependent uptake for different sized AuNRs in an in
vivo model are needed to address these concerns.
3.3.2 Photostability of gold nanorods
To confirm if the reduction in amplitude with increasing fluence (and subsequent increase in
calculated error) was a result of the AuNRs beginning to melt and reshape, thus causing a
reduction in optical absorption (at the wavelength used) and photoacoustic emission; TEM
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Figure 3.14: TEM images taken for each sized AuNR at specific points in the study: before
laser irradiation, and after 20 pulses at 11 mJ cm−2, 20 mJ cm−2, and 40 mJ cm−2. Scale
bars = 50 nm
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Figure 3.15: Absorbance measurements normalised to the maximum of the absorbance spec-
tra taken before laser irradiation (figure 3.4) for each AuNR size at a concentration of
1× 1011 NP mL−1 after exposure to 20 laser pulses at a fluence of 11 ± 1.7 mJ cm−2 (left),
20± 2.2 mJ cm−2 (middle), and 40± 2.6 mJ cm−2 (right).
images (figure 3.14) and absorbance measurements (figure 3.15) were taken after the AuNRs
were exposed to specific laser fluences at key points (11 ± 1.7 mJ cm−2, 20 ± 2.2 mJ cm−2,
and 40 ± 2.6 mJ cm−2) across the range studied. Fresh samples of AuNRs were separately
exposed to 20 laser pulses - the same number of pulses used in the PA study - to ensure
the observed effects were not due to cumulative absorption. The absorbance spectra were
normalised to the original spectra to highlight the change in SPR due to melting.
At 11 ± 1.7 mJ cm−2, the Au25-803s showed partial melting and reshaping while the
other three showed no reduction or flattening of the peak absorbance (the minimal reduc-
tion of the Au40-790s is within error). After 20 pulses at 20 ± 2.2 mJ cm−2, there was a
significant ‘hole’ in the peak SPR of the Au25-803s, and the TEM images confirmed that
the majority of the AuNRs had melted and reshaped into spheres. Both the Au40-790s and
Au50-841s also displayed a flattening and minor dip in the peak absorbance at this laser
fluence, whereas the Au10-811s maintained photostability, with only a minimal reduction
in peak absorbance. Finally, at a fluence of 40 ± 2.6 mJ cm−2, the Au25-803s, Au40-790s
and Au50-841s all demonstrated melting and reshaping of almost the entire population of
AuNRs. The Au10-811s exhibited a significant reduction in peak absorbance at this laser
fluence, however a considerable number of Au10-811s appeared to have remained stable,
indicated by a reduction of half the peak absorbance. This would suggest that smaller
AuNRs (widths < 25 nm) are more resistant to reshaping under laser illumination than lar-
ger AuNRs, and would further support the idea that small AuNRs do not reach high enough
peak temperatures to exhibit melting, and are able to dissipate heat to the surroundings at
a faster rate, compared with larger AuNRs [305].
The photostability of AuNRs can be affected by a number of factors, including photo-
thermal conversion efficacy, thermal conductivity, surface diffusion, AuNR defects, thermo-
dynamic stability, and the coating surrounding the AuNRs [306, 307]. Furthermore, the
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optical absorption of the particles can have a significant effect on the reshaping of AuNRs.
As the AuNR size decreases, the optical absorption of the particle will also decrease. This
could suggest why the smaller AuNRs in this study were resistant to higher laser fluences.
However, equivalent particle numbers of the different sized AuNRs results in the total mass
of gold within the absorbing region being different. Thus, a decrease in AuNR size will
result in a decrease in total mass, which could result in a maximum (or minimum) of the
mass-normalised optical absorption for different sized AuNRs, and suggest why the Au25-
803s appear to be significantly less photostable than any of the other AuNRs studied [276].
The melting-point depression phenomenon may also contribute to the reshaping thresholds
of small AuNRs, nevertheless the overall thermal stability is mostly governed by a balance
between the total absorbed light and the thermodynamic stability of the AuNRs [308, 309].
In addition to the large reduction in absorbance at the longitudinal SPR of the AuNRs,
a noticeable increase in the absorbance at the latitudinal SPR is observed (see figure 3.15).
This can be explained by an ever-increasing number of AuNRs reshaping into spheres (see
figure 3.14), as confirmed by TEM. The Au10-811s were the only exception, where the
absorbance around 532 nm does not increase despite the reduction in the 811 nm peak.
TEM analysis confirmed that the majority of Au10-811s had not fully reshaped into spheres
but had instead become φ-shaped or imperfect spheres. Figure 3.15c supports this idea
as the spectra around the peak SPR broadens, indicating a distribution of particle shapes
between a rod and sphere. This may be due to small AuNRs exhibiting a higher thermal
coupling to the surrounding environment and therefore enabling a rapid dissipation of heat
to the surrounding area, solidifying before becoming completely spherical.
Knowledge of the way in which AuNRs melt and reshape under laser illumination is
crucial to the development of the modalities that rely on them. Slight changes in their
size and shape can have a substantial effect on the optical interactions exhibited by the
AuNRs. If melting occurred during PA tomography, or any other optical-based diagnostic
or therapeutic modailty that relies on AuNRs, the quality and efficacy would diminish
as a consequence. The effect that AuNR size has on optically-induced degradation is an
important aspect to consider in the AuNR selection process.
3.3.3 Gold nanorod toxicity and uptake to lung cancer cells
Further to understanding how the size of AuNRs affects the induced PA response, it is also
important to determine the impact that size has on cellular toxicity. Figure 3.16 shows
the percentage viability of a NSCLC cell line (A549) after 72 h exposure to all four AuNRs
across a range of concentrations from 1.5× 106 NP mL−1 to 3× 1010 NP mL−1. Figure 3.17
shows an example bright-field image of A549 cells having metabolised MTT, turning it blue.
As expected, the data suggested that an increase in concentration of AuNRs also resulted in
an increase in cytotoxicity. The concentration at which cell viability drops to 50 %, known
as the IC50, could not be deduced for the Au10-811s or Au25-803s since the concentration
used in this study did not reach a high enough level to cause major detriment to the cells.
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Figure 3.16: Percentage viability of an A549 lung cancer cell line after 72 h incubation with
Au10-811s (blue, top-left), Au25-803s (red, top-right), Au40-790s (green, bottom-left) and
Au50-841s (yellow, bottom-right) at a maximum concentration of 3× 1010 NP mL−1.
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Figure 3.17: A bright-field image showing A549 cells after metabolising the added MTT and
turning it blue, indicating cell viability.
A four parameter logistic regression curve was fitted to the Au40-790 and Au50-841 data
to enable the IC50 to be determined [310]. The Au40-790s displayed noticeable toxicity
to the A549 cells, however an IC50 value (IC50 = 6.6× 1010 NP mL−1) higher than the
maximum concentration studied, was extrapolated from the regression curve. The Au50-
841s demonstrated the highest toxicity of the four AuNR size, where a concentration of
3× 1010 NP mL−1 resulted in necrosis or apoptosis of almost the entire cell population. An
IC50 of 7.3× 109 NP mL−1 was easily deduced for this AuNR size. While conclusive results
cannot be drawn on the size-dependent toxicity of AuNRs to general cell populations, the
data suggests that larger AuNRs exhibited a higher toxicity at equivalent concentrations
compared with that of smaller AuNRs. It is important to note that at equivalent concen-
trations, a solution of large AuNRs contains more mass than a solution of small AuNRs.
To further understand the interactions between cells and the different sized AuNRs,
bright-field and dark-field microscopy images were taken (figure 3.18) of A549 cells after
incubation for 4 h in media containing each-sized AuNR. The bright-field microscopy images
suggested that the cells incubated with AuNRs maintained their attachment to the glass
slides and their normal morphology. It can be seen from the dark field microscopy images
that the cells appear to have taken up AuNRs of each size, as observed by the scattered light.
Careful examination of the dark-field microscopy images showed that the AuNRs enriched
the cytoplasm of the cells instead of being evenly or randomly distributed, as would be the
case for non-specific adhesion [115]. While the uptake of the AuNRs by the lung cancer cell
55
3. INFLUENCE OF GOLD NANOROD SIZE IN PHOTOACOUSTICS
line cannot be determined quantitatively by dark-field microscopy, the results suggest that
the larger AuNRs may have been taken up more readily than the smaller AuNRs, and have
demonstrated the potential of AuNRs with varied size for cell-related applications such as
photoacoustic imaging and photothermal therapy.
As this study was limited to in vitro testing, it was not possible to consider some of
the other important aspects that could affect the choice of AuNR for biomedical use, such
as the ability for AuNRs to reach a tumour site, immune response, and blood circulation
time [311]. Nevertheless, future studies will benefit from the presented work by guiding the
selection process of AuNRs with respect to PA response, cellular toxicity, and photostability.
3.4 Conclusions
AuNRs display highly desirable characteristics for use as molecular-targeted contrast agents
in photoacoustic imaging and other optical-based diagnostics and therapeutics. It is sug-
gested that there may be an optimal size and concentration that achieves maximum PA
emission amplitudes while resisting melting and reshaping, and exhibiting minimal cytotox-
icity. It was demonstrated in this chapter, that it is important to consider the size of the
AuNRs when making a selection for biomedical applications, while also taking into account
the concentration of AuNRs at a desired location. At equivalent NP mL−1, the smaller
AuNRs were shown to exhibit the lowest cytotoxicity to the lung cancer cell line while also
displaying the lowest PA emission amplitude, and the larger AuNRs produced the highest
PA emission but were the most toxic. Conversely, if the total mass of AuNRs was fixed,
then it was the smallest AuNRs that were the most effective PA converters, while the other
three sizes produced similar responses. This highlights the need for further in vivo work sur-
rounding the cellular uptake and deliverability of AuNRs to a desired location to determine
the best metric for defining AuNR concentration (µg mL−1 or NP mL−1). Size-dependent
AuNR influences on the melting and reshaping thresholds were also demonstrated, indicat-
ing that careful consideration must be made with regards to the laser fluence. The smallest
AuNRs (Au10-811s) displayed the most resistance to melting over the fluence range studied,
suggesting the increased photostability of small AuNRs (10 nm width). Dark-field micro-
scopy demonstrated the potential of different sized AuNRs for cell-related applications such
as photoacoustic imaging and photothermal therapy since cellular uptake was observed for
all AuNR sizes. The presented study has shown that the size of AuNRs is an important
aspect to consider when choosing AuNRs for biomedical uses, since it has a strong effect on
many characteristics, such as PA emission amplitude, photostability, cellular uptake, and
cell toxicity.
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Figure 3.18: Bright-field (left) and dark-field (right) microscopy images of an A549 cell line
after 4 h incubation in media containing (a) Au50-841s, (b) Au40-790s, (c) Au25-803s, (d)
Au10-811s, and (e) control. AuNR images at a concentration of 1× 1011 NP mL−1 for each
AuNR type. All dark-field microscopy images are presented using the same brightness and
contrast conditions. Scale bar = 20 µm.
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Chapter 4
Plasmonic photothermal
therapy with gold nanorods
Cancer is a leading cause of death worldwide with approximately 70% of deaths occurring
in low- and middle-income countries [21]. Lung cancer, in particular, is the most prevalent
and deadly form of cancer since there exists very few options for diagnosis or treatment.
Endobronchial ultrasound (EBUS) is a routinely used diagnostic tool for staging lung cancer
via needle-biopsy, and it is generally used when signs of lung cancer have been observed via
X-ray or CT scan. EBUS lends itself to the possibility for combining with photoacoustic
imaging (PAI), and as an extension of this, plasmonic photothermal therapy (PPTT), since
the device houses an ultrasonic probe. As discussed in section 2.4, PPTT is a therapeutic
modality that, when combined with AuNRs, can provide a highly selective, minimally in-
vasive treatment option for cancer. It would be beneficial if PPTT could be administered
with a pulsed-wave (PW) laser since it would reduce the potential damage to surrounding
tissues by eliminating the bulk heating effect caused by continuous wave (CW) lasers. In this
chapter, the use of PW lasers for PPTT is explored using multiple different sizes of AuNRs
as the photoabsorbers, in addition to the impact of targeting AuNRs to lung cancer cells,
and comparisons are made between the photothermal efficacy of PW lasers and continuous
wave (CW) lasers.
4.1 Introduction
The photothermal effect relies heavily on a light source that can deliver a large amount of
energy to a localised region, and thus a laser is often used [312]. Laser ablation (LA), a
common clinical therapeutic technique that relies on lasers, is predominantly used to com-
pliment additional therapies by reducing tumour volume [313]. It is mostly used for treating
superficial and lung cancers where laser access and light delivery is feasible [314]. Continu-
ous wave (CW) lasers with high powers (around 5 W) are employed to induce bulk heating
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and irreversible thermal damage in the target tissue, however pulsed wave (PW) lasers have
also shown potential for photothermal applications [315]. Depending on the type of laser
system employed - either PW or CW - there will be significant differences in the observed
outcomes. CW lasers are capable of inducing either apoptosis or necrosis, depending on
laser intensity and AuNR distribution, whereas PW lasers can only induce necrosis [152].
These two pathways for cell death have their own advantages and disadvantages. For ex-
ample, an apoptotic pathway can lead to cells developing drug and thermal resistance but
does not cause immunogenic or inflammatory responses, while the opposite is true for a nec-
rotic pathway [210]. PW lasers create a highly-localised rapid temperature increase in the
target AuNRs [316], and this almost-instantaneous and high temperature increase causes
large mechanical stresses (peak pressures 10− 100 MPa [247]) that can induce necrotic cell
death depending on particle location and laser energy. As discussed in section 2.6, there
are very few reports on pulsed wave plasmonic photothermal therapy (PW-PPTT) (also
known as photoacoustic plasmonic photothermal therapy (PA-PPTT)), and the majority
predominately use either high energy laser pulses, ultra-short laser pulses (femtosecond),
or alternative photoabsorbers, with little in the way of low-energy, nanosecond pulses that
utilise AuNRs as the absorbing agent. Moreover, there are few reports addressing how the
size of the AuNRs may affect the treatment efficacy of both PW-PPTT and conventional
PPTT at equivalent concentrations. The optimisation of both the optical absorbers and
laser parameters is crucial to the success of this technique. If PW lasers can be used to suc-
cessfully and efficiently destroy target regions of tissue, with similar or superior outcomes
to that of CW lasers, then new and combined diagnostic and therapeutic techniques may
be possible.
The aim of this chapter is to provide an understanding of how CW and PW lasers can be
used for AuNR-assisted PPTT. Firstly, the laser-induced heating of different sized AuNRs in
two different media (water and cell media) across a range of concentrations will be explored,
using both CW and PW lasers, to gain insight into how the AuNR size can affect observed
outcomes. The same AuNRs will then be used to treat a common lung cancer cell line
(A549) via both conventional PPTT and PW-PPTT to determine the treatment efficacy of
PW lasers. Finally, the effects that AuNR targeting to lung cancer cells has on both CW
and PW laser treatment will be investigated.
4.2 Photothermal heating of colloidal AuNR dispersions
A CW laser is capable of inducing a bulk temperature change in a target material due to
the continuous deposition of energy over time. If the target is a colloidal suspension of
AuNRs in a medium, and the laser wavelength is tuned to the exact longitudinal SPR of
the AuNRs, then an enhanced heating effect may be observed. However, this is only true
when the concentration of AuNRs is high enough to cause a measurable influence. It was
therefore important to understand how the concentration of AuNRs influenced the overall
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Table 4.1: Certified dimensions and SPRs of all AuNRs used in section 4.2.
Name Width (nm) Length (nm) Aspect Ratio SPR (nm)
Au10-840 10 44 4.4 840
Au40-850 40 148 3.7 845
heating effect before the study could progress any further.
4.2.1 Water
The photothermal heating of Au10-840s suspended in water was measured at increasing
AuNR concentrations from 1× 109 to 1× 1012 NP mL−1 in addition to water without added
AuNRs. The AuNRs were 10 nm in width with a SPR of 840 nm (see table 4.1). The AuNR
solutions were placed in separate wells of a 96-well plate and irradiated from beneath the
plate with a 1.5 W CW diode laser for 5 min. An infrared (IR) sensor was used to measure
the temperature change of the well under laser irradiation in 1 s intervals across the duration
of the laser exposure, with a 10 s ‘pre-exposure’ and a 20 s ‘cooling off’ period, making a
total recorded time of 5 min 30 s. This process was repeated 6 times per data point to obtain
a mean temperature change, and the results are displayed in figure 4.1.
It is worth noting that there are limitations with using an IR sensor to measure tem-
perature as it can only determine the temperature of a surface (discussed further in section
4.2.3). This means that all measurements recording during these studies are of the bot-
tom of plate (i.e. the plastic), and therefore the actual temperature inside the well may
be slightly higher. However, this difference will likely be small due to the thickness of the
plastic (1.4 mm).
The experiment was conducted at room temperature, with the variation in starting tem-
peratures arising from a varying room temperature, and slight variations in the temperature
of the water. As expected, an increase in AuNR concentration resulted in an increased
laser-induced temperature compared with a target of water only (ie. without the addition
of AuNRs). At low concentrations (≤ 1× 1010 NP mL−1) the difference in temperature is
minimal (maximum 2 ◦C), however at AuNR concentrations beyond this, the difference is
more prominent with a maximum achieved temperature of 73.7± 1.3 ◦C after 5 min.
4.2.2 Cell media
Small AuNRs (Au10-840s)
A more accurate representation of the final experimental study is a suspension of AuNRs in
cell media since the cells will need to be surrounded by cell media to survive. Thus, the pre-
vious study was repeated with the Au10-840s suspended in cell media (DMEM). A few addi-
tional AuNR concentrations (5.5× 1010 NP mL−1, 4× 1011 NP mL−1 and 7× 1011 NP mL−1)
were also recorded to provide greater detail of the temperature curves at high AuNR concen-
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(a)
(b)
Figure 4.1: (a) Temperature profile monitored with an infrared sensor during continuous-
wave (CW) laser-heating of water containing increasing concentrations of Au10-840s, and
(b) the peak temperature increase achieved for each concentration. The laser was turned on
after 10 s and turned off after a 5 min exposure, with a cooling off period of 20 s. Errorbars
represent the standard deviation across 6 averages.
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trations. For the purposes of this chapter, AuNRs with a width ≤ 25 nm will be considered
‘small’ and those larger than this will be termed ‘large’.
A similar trend was observed with the AuNRs in cell media (figure 4.2) compared
with the AuNR-water suspensions (figure 4.1), where an increase in AuNR concentration
saw an increase in temperature rise across the duration of the laser exposure, however
the average temperature was generally higher (+4 ◦C at 1× 1011 NP mL−1 and +8.5 ◦C at
1× 1012 NP mL−1). This could be attributed to the fact that the cell media has a higher
absorbance in the near-infrared, compared with water, and the laser wavelength was tuned
to 840 nm to match the peak absorbance of the AuNRs. To assess this, the absorbance
spectrum of DMEM cell media was measured with a spectrophotometer and referenced to
that of water. As can be seen in figure 4.3, the absorbance around 840 nm is higher than
that of water (approximately 3 %), and as a result the media itself was absorbing some of
the incident laser energy and generating heat.
After the CW laser was turned on, the solution of AuNRs experienced a rapid change
in temperature and slowly began to plateau as the exposure time approached 5 min. The
majority of the heating (93 %) occurred in the first 3 min of laser exposure before the rate of
thermal transfer from the AuNR solution to the surroundings approached the rate at which
the AuNRs could convert the absorbed light into heat. As the concentration of AuNRs was
increased, the larger number of absorbing AuNRs provided a higher photothermal conversion
efficiency, as a larger proportion of light was absorbed and converted to heat. This allowed
the liquid to reach a higher temperature before the rate of heat flow achieved equilibrium.
Figure 4.4 shows the peak temperature change achieved after the full 5 min laser expos-
ure, compared with the starting temperature. The top axis shows the AuNR concentration
represented in terms of mass (µg mL−1) and the bottom axis in terms of number of AuNRs
(NP mL−1). Again, at concentrations below 1× 1010 NP mL−1, the change in temperature
was minimal, and there was no difference between AuNRs suspended in water and AuNRs
suspended in cell media. However, at a AuNR concentration of 1× 1011 NP mL−1, a max-
imum temperature increase of 17.5± 1.5 ◦C was achieved for the AuNRs in cell media, and
at 1× 1012 NP mL−1, the maximum change in temperature was 53.5±2.2 ◦C. A more clinic-
ally useful parameter, that can be determined from these temperature curves, is the thermal
isoeffective dose (TID). It provides a way to compare different thermal treatments by a meas-
ure of the number of equivalent minutes the tissue is maintained at 43 ◦C (CEM43), and can
be calculated using equation 2.7, discussed in chapter 2. Accordingly, the TID for AuNRs in
cell media with a concentration of 5.5× 1010 and 1× 1011 NP mL−1 was 0.2 and 10 CEM43,
respectively. At the higher concentrations of 4× 1011, 7× 1011, and 1× 1012 NP mL−1, the
TID was 8.3 × 105, 3.5 × 109, and 4.9 × 1012 CEM43, respectively. These thermal doses
are significantly higher than the majority of relevant threshold values for determining the
destruction of biological tissue, and would likely result in the total destruction of cells if
conducted in biological tissue. However, this preliminary study was performed with high
concentration, colloidal dispersions of AuNRs that are situated in cellular media and under
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(a)
(b)
Figure 4.2: (a) Temperature profile monitored with an infrared sensor during continuous-
wave (CW) laser-heating of cell media containing increasing concentrations of Au10-840s,and
(b) the peak temperature change after 5 min laser exposure. The laser was turned on after
10 s with a cooling off period of 20 s. Errorbars represent the standard deviation across 6
averages.
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Figure 4.3: Measured absorbance spectrum of DMEM (Dulbecco’s Modified Eagle Medium)
cell media. Inset shows a close-up of the data in the near infrared.
Figure 4.4: Peak temperature change after 5 min continuous-wave (CW) laser exposure for
Au10-840s at increasing concentrations in water (blue) and cell culture media (red).
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Figure 4.5: Temperature profile monitored with an infrared sensor during pulsed-wave (PW)
laser-heating of cell media containing increasing concentrations of Au10-840s. The laser was
turned on after 10 s and turned off after a 5 min exposure with a cooling off period of 20 s.
Errorbars represent the standard deviation across 6 averages. The inset shows the same
data with an expanded temperature scale for clarity.
almost direct exposure to laser irradiation. This scenario is very different compared with
what may be seen in vivo, where inhomogeneous dispersions of AuNRs may receive laser
light that has been attenuated by several millimetres of tissue. Nevertheless, it is important
to understand how the temperature curves and AuNR concentrations affect the calculated
thermal dose in this in vitro scheme, so that comparisons can be made with the future PPTT
studies of lung cancer cells.
In the current literature, there is a large range of TID(CEM43) values that have been
determined to induce cell death. For example, it has been shown that a TID of 240 CEM43
in vivo results in the coagulative necrosis of prostate tissue using high intensity focused
ultrasound (HIFU) [317]. Other reports have shown that 9.9 CEM43 caused thermal tissue
damage in dog liver [318], and 288−1.5×104 CEM43 resulted in complete necrosis of human
skin [319]. The reported values appear to fluctuate depending on tissue type, exposure times,
and method of heat delivery. Aspects such as the rate of heating have also been suggested
to affect overall tissue damage and alter the calculated TID(CEM43) threshold [320].
The previous study was repeated with the CW laser swapped out for a PW laser to enable
a comparison to be made between the two laser types. The PW laser was the same laser
system described in chapter 3 with the wavelength tuned to 854 nm (to match that of the CW
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laser) and a fluence = 35 mJ cm−2 (energy per pulse = 22.3 mJ, spot size = 9 mm). These
laser parameters were chosen due to being within the maximum permissible exposure (MPE)
limitations for skin. As can be seen in figure 4.5, the temperature remained unchanged across
the entire exposure time regardless of AuNR concentration. The temperature variation
between the highest and lowest curves is approximately 6 ◦C, and this was attributed to the
variation in initial water and room temperature. The fluctuation for each individual curve
is within 2 ◦C across all repeats.
The AuNRs used for the CW and PW laser studies were equivalent in all attributes
(width = 10 nm, SPR = 840 nm), yet the observed thermal outcomes using each laser was
different. With a CW laser, the temperature of the AuNR suspension reached in excess of
80 ◦C, while there was no measured change in temperature with the PW laser, even with the
highest concentration of AuNRs (1× 1012 NP mL−1). This confirms the unique differences
between CW and PW lasers, where CW lasers induce bulk heating and PW lasers do not.
Furthermore, for therapeutic purposes, the method for monitoring the efficacy of treatment
using a PW laser will likely need to be different to that of a CW laser, since there will
be no temperature change to monitor to provide an indication of cell-death. Additionally,
the concentration of AuNRs governed the initial rate of temperature rise and the maximum
temperature achievable under CW laser irradiation, suggesting that careful consideration
must be made regarding the concentration of AuNRs for therapy.
Large AuNRs (Au40-850s)
Currently, there does not exist a universally recognised AuNR size for therapeutic purposes
and so it is crucial that the effects of different sized AuNRs are considered. The previous
study was based around small AuNRs (Au10-840s), thus it was repeated with AuNRs that
have a similar aspect ratio (and therefore SPR) to the Au10-840s but with a larger width
(40 nm) and therefore size (see table 4.1). Again, cell media was used as the suspension
fluid.
Figure 4.6a shows the photothermal heating of Au40-850s under CW laser irradiation
(power = 1.5 W) at increasing concentrations from 2 × 107 − 2× 1010 NP mL−1 and the
maximum temperature achieved after 5 min exposure is shown as a function of AuNR con-
centration in figure 4.6b. As expected, an increase in concentration corresponded to an
increase in the rate at which the solution heated, as well as an increase in the maximum
temperature reached after 5 min exposure. At the highest concentration (2× 1010 NP mL−1
or 64 µg mL−1), the maximum temperature reached was approximately 83 ± 5 ◦C, and at
an equivalent mass, the Au10-840s achieved a similar peak temperature of 85± 5 ◦C (figure
4.7), while at equivalent number of particles, the smaller AuNRs produced only a 38± 4 ◦C
temperature rise. This highlights the importance of how the AuNR concentration is defined
between AuNR sizes, since to achieve an equivalent temperature rise between AuNR sizes,
there must be an equivalent total mass in the absorbing region. The delivery of AuNRs to
a tumour site is a complex process, and it may not be possible to deliver an equivalent total
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mass of AuNRs to a tumour for different AuNR sizes. There are many studies that report
on the deliverability of nanoparticles to tumours [130, 321, 322, 323], however none appear
to address the important issue of whether an equivalent dose of small or large nanoparticles,
in total number of particles or total mass, will achieve optimal delivery efficiencies.
For completeness, the photothermal heating of Au40-850s was also measured under PW
laser irradiation with equivalent parameters (fluence = 35 mJ cm−2, energy per pulse =
22.3 mJ, spot size = 9 mm, and wavelength = 854 nm). As was expected, no temperature
rise was observed across the entire laser exposure for any AuNR concentration.
The results presented in this section are important in the context of treating a tumour
with PPTT. If the concentration of AuNRs is high, and a CW laser is used, then the tumour
region may reach exceedingly high temperatures and cause damage to surrounding healthy
tissues as a result of heat conducting to the surroundings. Conversely, if the concentration is
too low then a sufficient temperature rise may never be reached. This signifies the importance
for developing a method for monitoring temperature during therapy to provide an indication
of when therapy should cease. Conversely, if a PW laser is used for treatment, then thermal
monitoring will not provide an indication of treatment efficacy since no temperature rise will
be observed, suggesting that a different indicator will be needed to determine therapeutic
efficacy.
4.2.3 Validation of infrared camera temperature monitoring
The temperature monitoring during PPTT of a cell population presents a challenge. To
ensure the toxicity results are accurate and reliable, it is essential that no contaminants
(such as bacteria) make their way into the vessels containing the cells, as any form of
contamination can affect the overall toxicity. This limitation requires that the cells are not
openly exposed to the air at any point within the experimental procedure, unless the air is
sterile (such as the inside of a bio-cabinet). Thus, it is impracticable to have foreign object,
such as a thermocouple, situated inside the well of a 96-well plate in addition to the cell
population, since the thermocouple would have to be completely sterile and the lid would
have to be removed or partially open to allow access for the thermocouple. For this reason,
it was decided that a thermal imaging camera would be the best approach for monitoring
the temperature changes during therapy. While the thermal camera can only measure the
temperature of a surface (such as the plastic bottom of the 96-well plate - see figure 4.10),
it would enable the experiment to be conducted without the risk of contamination.
The difference between the two temperature monitoring methods were compared under
similar conditions to the experimental procedure, however without the inclusion of cells.
Colloidal AuNRs were added to wells of a 96-well plate and a CW laser operating at 1.5 W
was used to induce heating. The laser was switched on after 10 s and remained on for 5 min
(300 s) before a 20 s ‘cooling off’ period. A K-type thermocouple was placed inside the
well containing colloidal AuNRs to measure the temperature of the liquid directly, while an
infrared thermal camera was used to monitor the temperature from beneath the plate (i.e.
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(a)
(b)
Figure 4.6: (a) Temperature profile monitored with an infrared sensor during continuous-
wave (CW) laser-heating of cell media containing increasing concentrations of Au40-850s,
and (b) the peak temperature change after 5 min continuous-wave (CW) laser exposure.
The laser was turned on after 10 s, with a cooling off period of 20 s. Errorbars represent the
standard deviation across 6 averages.
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Figure 4.7: Peak temperature change after 5 min continuous-wave (CW) laser exposure for
Au10-840s (purple) and Au40-850s (green) at increasing concentrations in cell culture media.
Figure 4.8: Temperature profile monitored with an infrared sensor during pulsed-wave (PW)
laser-heating of cell media containing increasing concentrations of Au40-850s. The laser was
turned on after 10 s and turned off after a 5 min exposure with a cooling off period of 20 s.
Errorbars represent the standard deviation across 6 averages. The inset shows the same
data with an expanded temperature scale.
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Figure 4.9: A comparison between monitoring the temperature change of laser-induced
heating of colloidal gold with a K-type thermocouple (red) and infrared thermal camera
(blue).
Figure 4.10: An image recorded with the thermal imaging camera employed in this chapter.
Bright region shows the elevated temperature of the area under CW laser illumination.
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the bottom of the 96-well plate). Figure 4.9 shows the change in temperature measured with
both the thermocouple and infrared camera. As expected, there is a difference between the
two temperature monitoring methods. The thermocouple recorded a maximum temperature
increase of 26.8± 1.7 ◦C, compared with 21.5± 1.8 ◦C for the thermal camera - a maximum
difference of 5.3 ◦C.
It is safe to assume that the thermal camera will underestimate the temperature of the
liquid since the heat generated in the AuNRs must propagate through the plastic to be
detected by the IR camera. Conversely, it is likely that the thermocouple will overestimate
the temperature as the AuNRs may adhere to the tip of the thermocouple and directly heat
the thermocouple itself. Therefore, the actual temperature experienced by the cells will lie
somewhere in between these values and be no more than 5.3 ◦C higher than the thermal
camera measurement, which is within the error range for this study. It is important to note
that using a thermal camera is the standard method for monitoring temperature changes
during photothermal therapy in the literature.
4.3 Photothermal therapy of lung cancer cells
The AuNRs used in this study were the same as the AuNRs used in the PA study in chapter
3, however table 4.2 has been provided for convenience. The main focus of the presented
research was to determine the capability of a single PW laser system, combined with AuNRs
of varying sizes but similar SPRs, for the treatment of lung cancer.
A human non-small cell lung epithelial carcinoma cell line (A549, ATCC, UK) was cul-
tured in DMEM (Dulbecco’s Modified Eagle Medium) media supplemented with 10 % FBS
(Fetal Bovine Serum). When the cells reached 80 % confluency, a 96-well plate was seeded
with 1× 103 cells per well and incubated for 24 h. The plate was split into five sections
(see figure 4.11b): a reference section containing nothing but cell media, a control section
containing cells with media only, and three sections containing cells incubated with AuNRs.
Two of the sections containing AuNRs were reserved for laser irradiation by two different
lasers (details below), and the final section served as an AuNR toxicity reference. The
AuNRs used in the study were purchased (A12, Nanopartz, USA) and the dimensions and
SPRs confirmed via TEM analysis and spectrophotometry (see table 4.2). A solution of
Table 4.2: Dimensions and SPRs of the AuNRs used in the study, determined by TEM
analysis and absorbance measurements respectively. The uncertainty of measurement is the
standard deviation of the sample.
Name Width Length Aspect Ratio Peak SPR
Au10-811 9.9 ± 1.1 nm 39.7 ± 5.4 nm 3.98 ± 0.51 811 ± 2 nm
Au25-803 23.2 ± 2.6 nm 85.6 ± 9.8 nm 3.73 ± 0.63 803 ± 2 nm
Au40-790 39.8 ± 4.1 nm 122.5 ± 13.8 nm 3.10 ± 0.35 790 ± 2 nm
Au50-841 42.2 ± 4.6 nm 142.0 ± 17.0 nm 3.38 ± 0.41 841 ± 2 nm
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96-well plate
To computer
Thermal imaging
camera
Pulsed
laser fibre
3-axis motorised
translation stage
Continuous-wave
laser fibre
Media only
Cells with AuNRs under
with PW laser irradiation
Cells with media
Cells with AuNRs
No laser irradiation
96-well plate layout for PPTT
Cells with AuNRs under
CW laser irradiation
(a)
(b)
Figure 4.11: (a) A motorised stage enables the two laser fibres to be scanned across the
96-well plate, while a thermal imaging camera records the temperature of the bottom of
the plate. (b) A schematic depicting how the 96-well plate is split for the experimental
procedure. The wells under laser irradiation (CW = blue, PW = brown) were alternated to
reduce the effects from laser treatment of neighbouring wells.
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AuNRs in media was added to the relevant sections of the 96-well plate at a concentration
of 20µg mL−1 and were left to incubate for 24 h before being either: 1) treated with a laser
with the AuNRs still remaining (i.e. with free-floating AuNRs), or 2) treated with a laser
after replacing the media-AuNR solution with fresh media (to remove free-floating AuNRs).
These two strategies were considered to discern the differences between the photothermal
effects from a large number of absorbing AuNRs (that were both surrounding and taken
up by the cells), compared with only AuNRs that have been taken up by cells and were
located in close proximity. This enabled a more detailed evaluation of how the cellular up-
take of AuNRs, in addition to the total number of AuNRs in the absorbing region, affects
laser-induced toxicity.
Two lasers were used to induce cell death at different locations: A pulsed tuneable laser
system (Surelite™OPO Plus, Continuum®, USA) operating at a pulse repetition frequency
of 10 Hz with a pulse duration of 7 ns, spot size of 9 mm (at the bottom of the 96-well plate)
and fluence of 25 mJ cm−2; and a continuous wave diode laser (B4-852-1500-15C, Sheaumann
Laser, USA) operating at 1.5 W across a spot size of 9 mm with a fixed wavelength at 854 nm.
The pulsed laser system was tuned to the same wavelength as the CW laser (854 nm) to
ensure an accurate comparison could be made between the two laser types, by facilitating an
equivalent optical absorption by the AuNRs. The wells that were targeted with the lasers
were alternated (see figure 4.11b) to reduce any effects from the laser heating of neighbouring
wells, and each well was exposed for a total of 5 min. Laser fibres were mounted onto a 3-axis
motorised translation stage (see figure 4.11a) to enable the scanning of the fibre tips across
the 96-well plate. The cells were irradiated for 5 min from above the plate, while an infrared
thermal imaging camera (thermoIMAGER TIM 640, Micro-epsilon-Messtechnik GmbH &
Co KG, Ortenburg, Germany) recorded the temperature change of the wells from below,
by taking a frame every second for the duration of the exposure. The thermal camera was
synchronised with the laser system through the use of an SDK provided by the manufacturer,
and this also enabled the direct acquisition of thermal image data into MATLAB for further
analysis.
4.3.1 Quantification of cell viability
After treatment, a standard MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) colorimetric assay protocol was followed [293] to establish the level of cell death
between the two laser types. This metabolic assay provides an indication of cell viability by
measuring the enzymatic activity of cellular mitochondria [76].
After laser irradiation, the media from each well of the 96-well plate was replaced with
fresh media and the plate was placed in the incubator. 24 h later, the media was removed
from each well and a solution of media containing MTT (500µg mL−1) was added. After
a further 3.5 h incubation the media containing MTT was removed from each well and the
96-well plate was wrapped in foil and stored at approximately 4 ◦C ready for absorbance
measurements.
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Before measuring the plates with a plate reader (Mithras LB 940, Berthold Technolo-
gies, Germany), 100µL DMSO was added to each well. The divided sections of the plate
were averaged to obtain a single absorbance value for each AuNR concentration, and the
background absorbance level was subtracted from each of the other values. The cell viability
was finally calculated by the ratio of mean absorbance of the sample with respect to mean
absorbance of the control group (cells with media and no laser or AuNR exposure).
4.3.2 Continuous wave vs pulsed laser treatment of lung cancer
cells
Figure 4.12a shows the results of the PPTT treatment of lung cancer cells under CW laser.
The cells exposed to CW laser irradiation without the inclusion of AuNRs showed no change
in cell viability compared with the control group, suggesting that a 1.5 W CW laser system
is not capable of therapy on its own. The AuNRs themselves (without laser treatment)
showed a minimal level of toxicity, with a cell viability of approximately 80 %, due to the
relatively high concentration (20µg mL−1) of AuNRs incubated with the cells. When the
cells were treated with both AuNRs and CW laser irradiation, significant cell death (> 50 %)
was observed for all AuNR sizes. The lowest cell viability was exhibited by the CW laser
combined with Au10-811 and the highest cell viability was from the Au25-803s, suggesting
that the smaller AuNRs were either more efficient at inducing cellular necrosis or apoptosis
through thermal damage, or the AuNRs were located in a position relative to the cells that
lead to more proficient damage.
Figure 4.12b shows the temperature of the target regions that correspond to the data in
figure 4.12a, as monitored with the thermal camera. The peak temperature after 5 min CW
laser irradiation lies within the range 48.1 ± 0.9 ◦C − 51.1 ± 1.0 ◦C for all the data points,
suggesting that bulk heating was the cause of cell-death for all experimental parameters,
since an increase in peak temperature showed a reduction in cell viability. To induce hyper-
thermia in cells it has been reported that the temperature must reach between 42− 47 ◦C,
and according to the IR-camera measurements (figure 4.12b), all of the targets reached,
and in some cases exceeded, this temperature range. In terms of the TID delivered to the
cells, an increase in the calculated CEM43 values appeared to correspond to an reduction
in cell viability. For the target regions containing free-floating AuNRs, TID values were
calculated to be 290, 80, 170, and 150 CEM43 for the Au10-811s, Au25-803s, Au40-790s and
Au50-841s, respectively. Likewise, a TID of 120, 40, 60, and 50 CEM43 was calculated for
the Au10-811s, Au25-803s, Au40-790s, and Au50-849s, respectively, when the free-floating
AuNRs were removed. As discussed previously, the reported threshold CEM43 values for
tissue destruction and cell death vary significantly depending on tissue type, method of heat
delivery, and the rate of temperature increase, making direct comparison difficult. Further-
more, the original TID was designed to operate in the 40− 47 ◦C range and so deviations in
the behaviour of the formula outside of this range can be expected. However, the presented
results show a positive correlation between thermal dose and cell death, and therefore the
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(a)
(b)
Figure 4.12: (a) Cell viability of a lung cancer cell line (A549) under different experimental
parameters: a control group representing no incubation with AuNRs or laser exposure (grey),
after exposure to CW laser irradiation without AuNRs (orange), after incubation with dif-
ferent sized AuNRs without laser irradiation (green), after incubation with different sized
AuNRs followed by CW laser exposure after removing free-floating AuNRs (light purple),
after incubation with different sized AuNRs followed by a CW laser exposure without remov-
ing free-floating AuNRs (dark purple (*)). (b) Monitored temperature of the wells under
CW laser irradiation. The total laser exposure time was 5 min. Errorbars represent the
standard deviation.
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TID parameter could potentially be used to determine therapeutic efficacy with CW lasers
and AuNRs.
A PW laser was also used to treat cells under the same conditions. This was done to
enable a comparison to be made between the PPTT efficacy of the different laser types. A
fluence of 25 mJ cm−2 was used to irradiate the cells and keep within the MPE guidelines
for skin - a potentially important limiting factor. Figure 4.13a shows the cell viability of the
PW laser-treated cells, and figure 4.13b shows the monitored temperature distribution of
the wells. The PW laser treatment did not cause any damage to the lung cancer cells on its
own (i.e. without AuNRs), however, under equivalent conditions as the CW laser exposure,
the PW laser induced significant cell-death when AuNRs were introduced. The laser was
not sufficient to cause damage to cells without the introduction of photoabsorbers such as
AuNRs. There was minimal difference between the viability of the cells that had free-floating
AuNRs remaining in the wells and those that had the AuNRs removed, suggesting that the
AuNRs that had been taken up by the cells were the main contributors to cell-damage, and
the remaining AuNRs, that were situated on top or around the cells, had little to no effect.
This is due to the PW laser generating an intense and rapid temperature increase in the
AuNRs that is distributed in extreme proximity to the AuNRs (approximately 70 nm from
the AuNR during an 8 ns pulse [324]), meaning that the AuNR must be positioned such that
the heat can cause damage to the cells or disrupt cellular membranes and cause irreparable
damage to cells by the large mechanical stresses induced from the AuNRs absorbing the high-
intensity laser pulses [230]. Nevertheless, it is clear that bulk heating was not a contributing
factor since figure 4.13b showed no measurable increase in temperature throughout the
duration of the experimental procedure. Consequently, it was not possible to determine a
TID for this treatment.
The smallest AuNRs studied (Au10-811s) were the most effective therapeutic agents,
destroying almost 80 % of the lung cancer cells, whereas the least effective were the Au25-
803s, killing approximately half of the cell population. The two larger AuNRs (Au40-790s
and Au50-841s) were only marginally more effective at inducing cell-death than the Au25-
803s. The differences between the total cellular uptake of the different sized AuNRs will
have a significant effect on overall cellular toxicity under laser illumination. A well-cited
study by Chithrani et al. (2007) suggested that AuNRs display a negative relationship
between AuNR aspect ratio and cellular uptake [141], however the AuNRs used in that
study were different in size and either transferrin-coated (to help uptake via endocytosis),
CTAB-coated, or not coated at all. The many differences between those used in the study
by Chithrani et al. and those considered in this study make a direct comparison difficult.
Other more recent research has shown that there are a large number of factors that govern
the uptake of AuNRs by cells, such as AuNR coating, colloidal stability, volume, and surface
functionalisation, among others [325, 326]. Some studies have suggested that large aspect
ratio AuNRs can increase cellular uptake due to being in contact with the cell membrane for
longer, facilitating the clustering of AuNRs and increasing cell membrane bending energies
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(a)
(b)
Figure 4.13: (a) Cell viability of a lung cancer cell line (A549) under different experimental
parameters: a control group representing no incubation with AuNRs or laser exposure (grey),
after exposure to PW laser irradiation without AuNRs (light green), after incubation with
different sized AuNRs without laser irradiation (dark green), after incubation with different
sized AuNRs followed by PW laser exposure after removing free-floating AuNRs (light yel-
low), after incubation with different sized AuNRs followed by a PW laser exposure without
removing free-floating AuNRs (dark yellow (*)). (b) Monitored temperature of the wells
under PW laser irradiation. The total laser exposure time was 5 min. Errorbars represent
the standard deviation.
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Figure 4.14: Cell viability of a lung cancer cell line (A549) under different experimental
parameters: a control group representing no incubation with AuNRs or laser exposure (grey),
after exposure to PW laser irradiation without AuNRs (light green), after exposure to
CW laser irradiation without AuNRs (orange), after incubation with different sized AuNRs
without laser irradiation (dark green), after incubation with different sized AuNRs followed
by PW laser exposure with free-floating AuNRs removed (yellow), after incubation with
different sized AuNRs followed by a CW laser exposure with free-floating AuNRs removed
(purple (*)). The total laser exposure time was 5 min. Errorbars represent the standard
deviation.
[327]. However, this is not consistent across all studies. For example, Qiu et al. (2010)
reported that smaller aspect ratio AuNRs (< 4) showed higher uptake levels compared
with longer ones and concluded that AuNR size has a significant effect on cellular uptake
in combination with aspect ratio. The current research seems to suggest that there may
be an AuNR with optimal size and aspect ratio that facilitates high uptake levels (and
therefore PPTT efficacy) and may explain the differences in PPTT-induced toxicity for the
four AuNRs in this study.
As discussed, the location of the AuNRs in relation to the different parts of the cell (i.e.
cytoplasm, nucleus etc.) is an important factor governing the efficacy of PPTT and it has
been suggested that a particular laser type (either CW or PW) is more effective at inducing
cell death depending on this location [206]. According to Huang et al. (2010), a CW laser
is more effective (i.e. requires lower laser energies) when the AuNRs are situated in the
cytoplasm, whereas a PW is more effective for nucleus-targeted AuNRs. Figures 4.14 and
4.15 show the PPTT toxicity data from figures 4.12 and 4.13 to enable easy comparison
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Figure 4.15: Cell viability of a lung cancer cell line (A549) under different experimental
parameters: a control group representing no incubation with AuNRs or laser exposure (grey),
after exposure to PW laser irradiation without AuNRs (light green), after exposure to
CW laser irradiation without AuNRs (orange), after incubation with different sized AuNRs
without laser irradiation (dark green), after incubation with different sized AuNRs followed
by PW laser exposure with free-floating AuNRs (yellow), after incubation with different
sized AuNRs followed by a CW laser exposure with free-floating AuNRs (purple (*)). The
total laser exposure time was 5 min. Errorbars represent the standard deviation.
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between the PPTT efficacy of CW and PW lasers. When the free-floating AuNRs were
removed and only AuNRs that had been taken up by the cells remained (figure 4.14), the
difference in cell viability between the CW and PW lasers was minimal for all AuNR sizes
considered. However, in the case where the free-floating AuNRs were left in the media, the
CW laser produced a measurable increase in cell toxicity. As discussed previously, the extra
AuNRs in the solution enabled the CW laser to produce significantly more heat than when
they were removed, and the increased heat resulted in larger, more wide-spread damage to
the cells. As for the PW laser irradiation, the extra free-floating AuNRs did not facilitate
an increase in cell damage since heating was not the primary therapeutic pathway and the
location of the AuNRs was the most important aspect. This data suggests that PW lasers
are capable of destroying lung cancer cells with an almost equivalent efficiency as a CW
laser, however the location of the AuNRs is the most important factor governing the efficacy
of cell death.
4.4 Targeting AuNRs to lung cancer cells
The functionalisation of AuNRs to molecularly target specific binding sites, such as epi-
dermal growth factor receptors (EGFR), is increasingly seen as an essential aspect of using
AuNRs for biomedical purposes. This is largely due to the need for high numbers of AuNRs
to be localised in a tumour region for a sufficient PA or PPTT effect to be observed. Fur-
thermore, relying solely on the EPR effect to accumulate AuNRs in target tissue may not be
sufficient [328]. If the particular target ligand is known, then the AuNRs can be function-
alised with monoclonal antibodies (for example anti-EGFR) that will enable monovalent
affinity. This is a highly desirable characteristic that can result in a much larger accu-
mulation of AuNRs at a particular site. It is known that many forms of cancer express
EGFR-positive ligands and it has therefore become a common method for molecular target-
ing. To determine the EGFR expression of A549 cancer cells, an immunofluorescence (IF)
staining was performed using a standard IF protocol. Briefly, the A549 cells were grown
in a 6-well plate on microscope coverslips. Once 70 % confluence was reached, the media
was removed and the cell monolayer was washed with Dulbecco’s Phosphate-Buffered Saline
(DPBS). 4 % PFA (Paraformaldehyde) was added and left for 15 minute at room temper-
ature to fix the cells to the coverslips. The coverslips were then washed twice with DPBS
before being permeabilised with a solution of DPBS and 0.3 % Triton X-100. The coverslips
were then washed twice in DPBS, followed by sample blocking in 10 % FBS (fetal bovine
serum) for 1 h. The blocking buffer was removed and Alexa Flour 488-conjugated anti-EGFR
antibodies, diluted in 5 % FBS, was added to the coverslips and incubated for 2 h at room
temperature. Finally, the coverslips were washed 3 times in DPBS and mounted on mi-
croscope slides using DAPI (4,6-diamidino-2-phenylindole) reagent (ProLong Gold Antifade
Mountant). The same protocol was repeated to form a control group without adding the
conjugated antibodies. The level of EGFR expression (as determined from the IF images
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Table 4.3: Certified dimensions and SPRs of all AuNRs used in section 4.4.
AuNR Name Width (nm) Length (nm) Aspect Ratio SPR (nm)
S-Au40-849 40 148 3.7 849
in figure 4.16) in A549 cells was not as high as expected. Nevertheless, EGFR expression
was observed during the IF staining and therefore it was decided that the effect of targeting
AuNRs to the EGFR receptors would be investigated.
To begin with, AuNR-targeting was considered using dark-field microscopy. As discussed
previously (section 2.2.1), if AuNRs are to be used clinically then it is crucial that large-
scale synthesis with consistent properties and uniform distributions is possible. Hence,
highly concentrated Streptavidin-conjugated AuNRs were purchased (see table 4.3) from
Nanopartz - a company that are able to synthesis AuNRs on a large scale with repeatable
characteristics - to enable them to be easily functionalised with an anti-EGFR targeting
ligand (figure 4.17). A protocol was designed to enable the comparison of cellular uptake
for targeted versus untargeted S-Au40-849s at three different time-points: 4 h, 8 h, and
24 h. These were chosen to provide an indication of the time-scales required for wide-spread
affinity of the targeted AuNRs to the lung cancer cells. Furthermore, in chapter 3, high
levels of uptake were seen after 4 h incubation. The biotinylated antibody used in this study
was a mouse monoclonal antibody (ab24293, abcam) and the amount required to facilitate
the conjugation with the AuNRs was explored along-side the targeting efficiency. A series
of 21 microscope coverslips were soaked in ethanol overnight before being allowed to dry
completely, and were then placed inside a separate well of six 6-well plates. For each time-
point there was enough cover-slips to allow for: one blank (3), two untargeted (6), two
targeted with 10µL biotinylated antibody (6), and two targeted with 20µL biotinylated
antibody (6). A human non-small cell lung epithelial carcinoma cell line (A549, ATCC,
UK) was cultured in DMEM (Dulbecco’s Modified Eagle Medium) media supplemented
with 10 % FBS (Fetal Bovine Serum). When the cells reached 80 % confluency, the 6-well
plates were seeded with 4× 103 cells per well and incubated for 48 h. Before the AuNRs
were added to the wells, a functionalising protocol was followed (see figure 4.18). The stock
S-Au40-849s (concentration = 4× 1012 NP mL−1 = 13.2 mg mL−1) were first sonicated for
15 min to minimise aggregation and then 45µL of the stock S-Au40-849s was split between
three sterile Eppendorfs (i.e. 15µL per Eppendorf). The first Eppendorf (named ‘UT’)
was reserved for untargeted AuNRs, 10µL of the biotinylated antibody was added to the
second Eppendorf (named ‘T10’), and 20 µL of the biotinylated antibody was added to the
final Eppendorf (named ‘T20’). All of the Eppendorfs were then topped up with Dulbecco’s
phosphate-buffered saline (DPBS, 14190-094, Life Technologies, UK) to a total volume of
40 µL (i.e. 25µL DPBS in Eppendorf UT, 15 µL DPBS in Eppendorf T10, and 5 µL DPBS in
Eppendorf T20). All three Eppendorfs were then sonicated for 10 min before being placed on
a vortex for 30 min to facilitate the conjugation of the AuNRs and antibodies. The AuNRs
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Figure 4.16: A fluorescence image of lung cancer cells (A549) showing the expression of
anti-EGFR receptors. Blue represents the staining of the cell nucleus and green shows the
expression of EGFR.
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Figure 4.17: The biotinylated anti-EGFR antibodies exhibit high affinity to the Streptavidin
proteins that are already conjugated to the AuNR.
were then purified by centrifuging for 10 min at a relative centrifugal force (r.c.f.) of 5.9,
followed by the removal of the supernatant and addition of 40 µL DPBS, and then further
mixing was performed with the vortex for 2 min followed by sonication for 10 min. After
repeating the purification process twice, the supernatant was replaced with 100 µL DMEM
media before being added to separate 15 mL falcon tubes filled with DMEM media to a
total volume of 6 mL. Finally, each falcon tube was vortexed for 2 min and sonicated for
10 min before the media-AuNR solutions were added to the 6-well plates at a total volume
of 2 mL per well, giving a final AuNR concentration of 30 µg mL−1. The plates were then
incubated for different lengths of time (4 h, 8 h, and 24 h) before a standard protocol for
preparing microscope slides for dark-field imaging was followed. A549 cells were plated onto
22 × 22 mm glass cover-slips in a 6-well plate at a density of 1× 105 well−1 and allowed to
grow for two days. The AuNR-media was removed from each well and the cell monolayer
on the cover-slip was twice-rinsed with DPBS, fixed in 4 % paraformaldehyde/DPBS for
10 min at room temperature and rinsed with DPBS five times. The fixed coverslips were
then mounted and sealed onto glass slides. Bright and dark-field microscopy imaging was
performed with an inverted microscope (Nikon Eclipse Ti-E, Nikon UK Ltd, UK) using an
oil coupled 100x objective (CFI Plan Fluor, Nikon UK Ltd, UK). Images were recorded
with a 5 Megapixel colour camera (DS-Fi1, Nikon UK Ltd, UK) and saved using the NIS-
Elements D software (Nikon UK Ltd, UK). Open-source software package ImageJ [292] was
used to crop and enhance the contrast of saved images. To ensure valid comparisons could
be made, all of the images were enhanced in the same way.
A large number of images (N = 248) were acquired by scanning pseudorandomly across
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Figure 4.18: A schematic depicting the functionalisation process for the S-Au40-849s. UT
= untargeted AuNRs, T10 = targeted AuNRs (10 µL antibody), T20 = targeted AuNRs
(20 µL antibody).
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Figure 4.19: Bright- and dark-field images of lung cancer cells (A549) incubated with untar-
geted versus targeted S-Au40-849s for (a) 4 h, (b) 8 h, and (c) 24 h. The S-Au40-849s have
different surface properties to those in the previous studies.
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Figure 4.20: Large AuNR aggregates were apparent when a high volume (20µL) of biot-
inylated anti-EGFR antibodies were used in the conjugation process of the S-Au40-849s.
the entire microscope slide to cover the majority of the sample and ensure an accurate rep-
resentation of the cellular uptake across the entire slide was observed. Figure 4.19 shows
a selection of those images to illustrate the typical distribution observed after analysing all
obtained images. The untargeted S-Au40-849s displayed little-to-no cellular uptake across
all of the time points considered in this study, which was surprising since it might be expec-
ted that after 24 h incubation, much higher levels of uptake would be seen compared to that
which was observed here. In comparison with the dark-field images taken of the citrate-
capped AuNRs in section 3.3, there was considerably less cellular uptake of the untargeted
S-Au40-849s. This was likely due to the streptavidin ligands that were already conjugated
to the surface of the AuNRs, limiting the penetration of the S-Au40-849s into the lung
cancer cells, since streptavidin has a relatively large molecular weight (approximately 60
000 Da) and has been shown to restrict cellular uptake [329]. Furthermore, the potentially
reduced biocompatibility of untargeted S-Au40-849s may negatively affect cellular uptake.
Conversely, the targeted S-Au40-849s significantly enhanced AuNR uptake by the lung can-
cer cells after 8 h and 24 h (potentially via affinity to EGFR receptors) and while minimal
uptake was observed after 4 h incubation with the A549 cells, there was an increase in overall
uptake compared with their untargeted counterparts. The conjugation of the S-Au40-849
AuNRs with the anti-EGFR monoclonal antibodies had a considerable effect on the overall
uptake when incubated with the lung cancer cells for longer than 4 h and the results provide
a compelling argument to use molecularly targeted AuNRs for the selective delivery of high
concentrations of AuNRs to malignant tissues.
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The volume of biotinylated antibodies (10µL or 20 µL) that was used in the conjugation
process appeared to affect the aggregation of AuNRs. As can be seen from figure 4.20, large
aggregates formed when 20µL biotinylated antibodies was used in the conjugation process.
The AuNR aggregates did appear to be bound to the surface of the A549 cells, however
the large number of AuNRs making up the aggregates lead to a decrease in the distribution
of AuNRs across the cell sample. When 10µL was used, a reduction in AuNR aggregates
was seen and the overall distribution of AuNRs throughout the cell population was more
uniform.
4.4.1 Photothermal therapy with targeted AuNRs
The functionalisation and subsequent cellular uptake of the S-Au40-849s in the previous
section showed positive results and therefore justified investigating how the targeting of the
AuNRs to lung cancer cells may affect the toxicity under both CW and PW laser irradiation.
A protocol akin to the previous section (figure 4.18, section 4.4) for conjugating the S-Au40-
849s to anti-EGFR monoclonal antibodies was followed, however the 6-well plates were
replaced with two 96-well plates and were seeded with A549 cells at a concentration of
1× 105 cells per well. The experimental setup was the same as figure 4.11 (section 4.3),
however untargeted (UT) AuNRs were added to one plate and targeted (T10) AuNRs were
added to the other - both at a concentration of 30µg mL−1 - and left to incubate for either
4 h or 24 h. Immediately prior to laser exposure, the media in the wells of the 96-well plate
was removed, the cell monolayer washed once with DPBS, and then 100µL of fresh media
was added. This washing step was performed to minimise the number of AuNRs remaining
in the wells that were not bound to the cell surface receptors or taken up by the cells. Both
of the laser systems were operating under the same parameters as in the previous section to
enable a fair comparison to be made (5 min exposure duration, PW fluence = 25 mJ cm−2,
CW power = 1.5 W).
Figure 4.21 and 4.22 show the cell viability evaluation results of the A549 cells after
incubation with both untargeted and targeted S-Au40-849s for 4 h and 24 h, respectively.
After a 4 h incubation period, there was no discernable reduction in cell viability induced
from the AuNRs, either on their own or following laser irradiation. The lack of photothermal
ablation can be attributed to an insufficient number of AuNRs remaining in the absorbing
region after washing. This is in agreement with the cellular uptake study (figure 4.19) where
a 4 h incubation period resulted in minimal uptake of both untargeted and targeted S-Au40-
849s. Conversely, after 24 h incubation with S-Au40-849s (figure 4.22), reduced cell viability
was observed in some cases. The AuNRs that received no laser exposure did not reduce
the viability of the lung cancer cells, independent of whether they had been functionalised
with the anti-EGFR ligands. This was in contrast to the study in the previous section
where a small but notable reduction in cell viability (approximately 20 %) was observed.
The difference between these data sets can be attributed to the differences in the surface
chemistry of the AuNRs used here, compared with the ones in the previous study. In this
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Figure 4.21: The cell viability of a lung cancer cell line after 4 h incubation with either
untargeted S-Au40-849s or targeted S-Au40-849s.
Figure 4.22: The cell viability of a lung cancer cell line after 24 h incubation with either
untargeted S-Au40-849s or targeted S-Au40-849s.
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case, the AuNRs were either surrounded by streptavidin proteins - which reduce cellular
uptake (as seen in section 4.19) and therefore reduce toxic effects - or were conjugated with
anti-EGFR ligands and were bound to the surface receptors on the cell membrane, limiting
penetration into the cells. The cells that experienced a combination of untargeted S-Au40-
849s and either CW or PW laser irradiation, also did not display a reduction in cell viability
after the 5 min laser exposure. As discussed previously, the untargeted AuNRs had limited
penetration into the cell membranes due to the large streptavidin molecules bound to the
surface of the AuNRs and so were likely almost entirely removed during the washing stage.
Perhaps the most significant result was that the PW laser reduced the viability of 93±
12 % of the population of lung cancer cells when combined with anti-EGFR targeting S-Au40-
849s (after 24 h incubation), in comparison to the CW which destroyed almost half (46 %)
of the cells. There are likely multiple contributing factors to the enhanced PPTT efficacy
of the PW laser. The first reason may be that the efficacy of the CW laser for inducing
cell-death is at its highest when there are a large number of AuNRs in the absorbing region
and the light can be efficiently converted into wide-spread, bulk heating. The washing of the
cell monolayer removed any AuNRs that weren’t bound to the cell surface and the number
remaining in the path of the laser will not have been high enough to induce hyperthermia.
The AuNRs that did persist would still have absorbed the incoming laser-light and converted
it into heat, causing damage to the cells, however the overall heat generated from the
exposure was not enough to provide a broad destruction of cells. The second reason may be
due to an enhanced optical absorption and bubble-formation around the AuNRs under PW
exposure due to AuNR clustering. It has been shown that the accumulation of antibody-
conjugated AuNRs on the surface of a cell membrane can further facilitate the self-assembly
of the AuNRs into nanoclusters [324]. This in turn leads to an enhancement of the bubble
formation around the AuNRs under high intensity laser pulses and subsequently an increase
in damage to the cellular membrane. Zharox et al. (2005) concluded that pulsed lasers
were more effective at inducing cell death when AuNRs formed nanoclusters on the cell
membrane, and this is in agreement with our findings.
4.5 Conclusions
Cancer of the lung is a particularly difficult form of cancer to treat due largely to the inability
to access the tumour site. Gold nanorod assisted photothermal therapy has the potential
to treat lung cancer by targeting AuNRs to the tumour tissue and irradiating the tumour
from a close proximity by inserting a laser fibre through the mouth and into the lung. The
conventional approach to PPTT is to use CW lasers as the light source to induce bulk heating
in a target region and subsequently induce hyperthermia, however this has its drawbacks such
as the potential for damage to healthy tissue due to heat ‘leaking’ into the surrounding tissue
and the need for high concentrations of AuNRs to produce sufficient heating. PW lasers
have been explored as potential alternatives for destroying malignant tissues since there are
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possible advantages over CW lasers, such as a ‘mechanical’ method for cell damage that does
not increase resistance to drugs or heat, a highly localised destruction of cell tissue without
the chance of damage to healthy tissue, and the potential for simultaneous imaging during
therapy by monitoring the photoacoustic signals. Irrespective of the laser system used, the
need for exogenous photo-absorbing agents such as AuNRs is critical to the enhancement
and versatility of these light-based therapies.
The effect of AuNR size (or volume) on the photothermal efficacy was explored using two
laser systems - continuous wave and pulsed wave - operating below the maximum permissible
exposure guidelines. CW lasers induce bulk temperature changes in an absorbing medium
whereas localised heating occurs when PW lasers are used. This suggests that PW lasers
are only able to destroy cancer cells via a necrotic pathway, which reduces the risk of
the cells developing drug or heat resistance but can cause immunogenic or inflammatory
responses due to the immediate expulsion of the cells internals. Conversely, depending on
the laser exposure parameters, CW lasers have been shown in the literature to induce cell
death via either apoptosis or necrosis (although this particular aspect was not addressed
in this study). Understanding these important distinctions between the two laser types is
imperative for guiding therapy design. The relevant temperatures required to initiate the
destruction of cells and the inducement of hyperthermia is in excess of 42 ◦C, which is only
approximately 5 ◦C above internal body temperature. The length of time the cells remain
at elevated temperatures has an effect on the therapeutic efficiency and a clinically relevant
parameter known as the thermal issoeffective dose (TID) is often used to compare thermal
treatments. There is a large range of TID threshold values in the literature for determining
when complete destruction of tissue is achieved and this is due to the differences between the
cellular compositions of different tissues. If TID values are to be used as a clinical measure
of therapy, it is necessary to determine a TID threshold for the specific tissue that is being
treated, otherwise it may be difficult to ensure maximum therapeutic effect.
Following on from the initial findings, a more detailed and relevant study was conducted
to determine the toxicity of 4 different sized AuNRs with similar aspect ratios on a lung
cancer cell line under a range of experimental parameters. It was shown that the AuNR
size is a governing factoring in overall photothermal efficacy at equivalent AuNR particle
concentrations and laser exposure parameters. The smallest AuNRs used in the study (Au10-
811s) were the most effective at inducing cell death in all cases, killing almost the entire
population of cells when combined with a CW laser and free-floating AuNRs. The least
effective overall were the Au25-803s, and this may be due to a number of reasons such as
limited uptake, and reduced photothermal conversion efficacy. The PW laser, while not as
effective at damaging the lung cancer cells as the CW laser, still displayed significant toxicity
when combined with AuNRs. There was also minimal difference between the toxicity of the
PW laser when combined with either an excess of AuNRs surrounding the cells or when the
excess AuNRs were removed, suggesting that the location of the AuNRs was an important
part governing toxicity. The AuNRs that had been taken up by the cells and situated in the
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cytoplasm were causing the majority of the damage, due to the mechanical stresses induced
by the high-intensity laser pulses, whereas with the CW laser, the availability of the excess
AuNRs to generate heat resulted in a significant difference in overall toxicity. These results
are important for clinical application because they suggest that the location of AuNRs in
relation to the cells is important for the efficiency of plasmonic photothermal therapy.
Further to the consideration of AuNR size on photothermal efficacy, the effect of targeting
AuNRs to the lung cancer cells was explored. AuNRs with a similar size and aspect ratio to
those used previously were purchased with streptavidin proteins conjugated to the surface,
enabling the AuNRs to be easily functionalised with anti-EGFR targeting ligands. Lung
cancer cells (along with many other malignant tissues) have been shown to overexpress anti-
EGFR receptors and provide a potential method for increasing AuNR delivery efficiency to
the cells - a critical aspect to the success of this therapy. The cellular uptake of untargeted
S-Au40-849s was compared with that of targeted ones, and the results demonstrated the
importance of molecularly targeting AuNRs for increased uptake. The untargeted AuNRs
showed minimal uptake across the cell samples after the longest incubation time studied
(24 h), however the accumulation and uptake of targeted AuNRs was evident. Under laser
irradiation, targeting also provided a significant advantage over untargeted AuNRs, when
the incubation time was long enough (24 h). After 4 h there was no observed reduction in cell
viability for any of the parameters studied, which agreed with the uptake study. However,
a 24 h incubation resulted in an observable reduction in cell viability in some cases. The
untargeted AuNRs were not able to reduce cell viability under any laser exposure parameters.
In the case for targeted AuNRs, the PW laser was the most efficient laser system, destroying
almost 93 % of the total population of lung cancer cells, compared with almost half for the
CW laser. This reversal in photothermal efficacy between the laser types may be due to the
AuNRs forming nanoclusters, facilitated by the anti-EGFR targeting ligands, and increasing
the mechanical stresses induced by the PW laser.
The results presented in this chapter highlight the subtleties in how the design of AuNRs
and choice of laser system can influence the outcomes for photothermal therapy. In terms
of the therapeutic efficacy of different sized un-targeted AuNRs, it appears that smaller
AuNRs (width = 10 nm) are most suited as photoabsorbers under both CW and PW laser
illumination, whereas AuNRs with a width of 25 nm were the least suited. The location of
AuNRs was a critical aspect for therapeutic efficacy, and targeting them to bind specific-
ally to cell-receptors, such as EGFR, can improve cellular uptake and overall therapeutic
outcome. Furthermore, if the eventual goal is to use AuNRs as clinical therapeutic agents
then it is crucial that the production of AuNRs with consistent and uniform dimensions,
properties and coatings, can be scaled-up to a level that ensures the practicality and safety
of wide-spread clinical use.
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Chapter 5
Contrast-enhanced
photoacoustic imaging with gold
nanorods
Photoacoustic imaging (PAI) is capable of providing functional anatomical and molecular
information through the use of endogenous and exogenous contrast agents. It combines the
high spectral selectivity of optical-based approaches with the high resolution of ultrasound
imaging. The inherent nature of PAI lends itself to be combined with conventional ultra-
sound B-mode imaging due to similarities in the signal detection and image processing. Ul-
trasound imaging is used to clinically evaluate and stage non-small cell lung cancer (NSCLC)
via a technique known as endobronchial ultrasound-guided transbronchial needle aspiration.
There is the potential to increase the usefulness of this modality by combining it with other
techniques such as PAI with gold nanorods. The aim of this chapter is to demonstrate the
potential for incorporating PAI into an endobronchial ultrasound device for the enhance-
ment of this routine diagnostic technique, and provide the groundwork for progression in
this area.
5.1 Introduction
As a stand-alone modality, PAI shows greater tissue specificity and differentiation than con-
ventional ultrasound imaging as the technique is ‘absorption-based’ and distinct biological
regions (such as oxygenated and deoxygenated blood, fat, melanin, etc.) absorb different
wavelengths of light. This facilitates the ability to scan through various known wavelengths
of light, record the corresponding photoacoustic (PA) signals generated, and then build up a
composite image of the various tissue-types [182]. The specificity of the technique can be fur-
ther enhanced through the use of exogenous contrast agents. Plasmonic nanoparticles, such
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as gold nanorods (AuNRs), can provide an additional optical absorption contrast against
the background tissues. If, for example, the AuNRs have accumulated in tumour tissue
(which may be difficult to see with other imaging modalities) by exploiting the enhanced
permeability and retention (EPR) effect, and the peak absorption wavelength (or surface
plasmon resonance (SPR)) of the AuNRs is known, then the tissue can be easily identified
against the background tissue. This is especially true if the AuNRs have been molecularly
targeted to specifically target the tumour tissue of interest.
One of the most difficult forms of cancer to diagnose and treat is lung cancer and as a
result it is one of the most common causes of cancer-related deaths worldwide [330]. The
prognosis and course of treatment is guided by the important process of clinically staging the
cancer. Currently this can be a lengthy process involving multiple invasive and non-invasive
procedures, such as CT scans, bronchoscopy, radiology-guided biopsy sampling, and medi-
astinoscopy [237]. The diagnosis and prognosis from these complex and expensive procedures
can take a long time to complete (often several weeks) and can allow the disease to continue
to develop into a less treatable, more complex disease with the final treatment decision be-
ing invalid by the time it has been made. A technique known as endobronchial ultrasound
(EBUS) can facilitate the mediastinal staging of lung cancer via needle biopsy [331]. Known
as EBUS-guided transbronchial needle aspiration (EBUS-TBNA), it is often only used after
a CT-scan or other aforementioned examination when there are already signs of a tumour.
However, it has the potential to be used as a primary investigation tool to diagnose and stage
patients with suspected lung cancer since it shows a high sensitivity (90 %) for the detection
of mediastinal nodal metastases - higher than other currently used investigatory procedures
[237] - and the technology could be combined with AuNR-assisted imaging and therapeutic
techniques, such as PAI and plasmonic photothermal therapy (PPTT). AuNRs targeted to
the tumour site could be illuminated with a laser incorporated into the EBUS device and
provide another level of contrast to the ultrasound images through PAI. Furthermore, there
is a potential treatment avenue via plasmonic photothermal therapy using the same AuNRs
and laser system. The underlying technology required to combine these modalities together
already exists, and doing-so could enable the ability to locate, diagnose, stage, and treat
a lung tumour within a single modality, all while reducing the time and costs commonly
required.
There is very little literature that considers this new approach to EBUS and the follow-
ing chapter aims to provide the groundwork for future research into this important area.
To begin with, the methods for generating and receiving ultrasonic waves using transducer
arrays were discussed in context of relevant beamforming techniques. This was to provide
an introduction into how ultrasound signals can be transmitted and received, and insight
into the reasons for using steered focussed beams for mimicking EBUS later in the chapter,
since any beamformer can be applied to almost any type of transducer. This was followed
by an investigation and discussion into the suitability of three different transducer arrays for
imitating EBUS, using one of the previously discussed beamformers, and its potential for en-
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hancement with photoacoustics. Finally, the concept of combining conventional ultrasound
imaging with PAI, in the context of future integration with EBUS, was considered.
5.2 Beamforming
Beamforming is a signal processing technique that is used in a broad range of applications
and relies on the propagation of waves [332]. It is used to provide spatial and directional
selectivity of signals that have been sent and/or received by an array of sensors, and results
in the enhancement of signals that might otherwise be lost [333]. Beamforming is an essential
aspect of medical ultrasound and there are a considerable number of beamforming techniques
employed depending on the desired application and outcomes [334]. Beamforming is used in
both the transmission and receiving of ultrasound signals. In transmission, it can be used
to electronically steer a beam without changing the physical angle of an array by applying
delays to each element in the array. In receive, it is used to determine where the signals
originated from by calculating the time-of-flight of received signals from a specific point
in space. Furthermore, some beamforming techniques allow for dynamically focusing the
received beams by applying delays to each element to compensate for the propagation delay
differences between the point of interest and the array of receiving elements. This generally
works better for signals in the near-field because the (assumed) spherical wavefronts emitted
or reflected from a specific point in the near-field will be more curved than those at greater
distances and the time-delays will therefore be larger.
In medical ultrasound, the majority of beamforming techniques are based on the standard
delay-and-sum (DAS) method [335]. In DAS, each point of the beamformed image is created
by applying a delay to the radio-frequency (RF) data received on each element of the array
- based on the time required for the signal to travel from the transmitter to the field point
and then return to the receiving element - before being summed together. This technique
is the foundation for a large number of variations, such as delay multiply and sum (DMAS)
and filter delay multiply and sum (FDMAS), however the ultimate aim of improving the
image quality is the same. All of the work in this chapter is based on the DAS beamformer.
5.2.1 Transmission beamforming
There a multiple ways to electronically influence a transmitted wavefront, generated by an
ultrasound array, without physically moving the transducer. A few of these techniques are
discussed in this section.
Plane wave
Plane wave imaging (PWI) is the simplest method described in this chapter for generating an
ultrasound wave - other than using a single element transducer - and is achieved by exciting
all of the elements in a transducer array at the same time, producing a flat wavefront that
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Figure 5.1: A simple diagram showing how the wavefront of a transmitted beam can be
altered by applying different delays to each channel in the array.
propagates perpendicular to the surface of the transducer (see figure 5.1). This method of
beamforming is the fastest transmission scheme available and can achieve very high frame
rates, on the order of 10 kHz [336]. This is because the frame rate is limited by the time it
takes to record one image, timage, which is given by,
timage =
Nlines × 2× z
γ
(5.1)
where Nlines is the number of lines required to create the image, z is the image depth, and
γ is the speed of sound in the medium. In the case of PWI, the number of lines is equal
to 1 since only a single transmission is used to create the image, meaning the frame rate is
only limited by the time it takes for the ultrasound wave to propagate from the transducer
surface to the deepest desired location and return. While this technique allows for ultrafast
imaging, it does so at the expense of image contrast and resolution.
Steered plane wave
Transmitting steered plane waves is a slight alteration to the basic PWI format. A delay is
applied to each successive element in the array by a linearly increasing amount, resulting in
a wavefront that is angled (see figure 5.1). The pulse repetition frequency (PRF) using this
method is lower than standard PWI due to the added delay between the first and last element
for each transmitted wavefront. However, this technique for wave generation can improve
image resolution and contrast, compared with standard PWI, if multiple transmissions at
different angles are used (see section 5.2.2 below). This technique was developed to improve
upon the image quality of PWI while still maintaining very high frame rates (> 1 kHz [337]),
and depending on the desired outcomes, the image quality can be increased or decreased at
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the expense of frame rate.
Focused beam
Focused beams are generated by increasing the delays from the outer to inner elements of
the array (mirrored along the central axis), leading to a spherical wavefront that converges
to a point at the centre of that concentric ring (see figure 5.1). This beamforming method
enhances the pressure and signal amplitude at the focal region and can help to improve
image contrast. The array is usually split into a subgroup (or sub-aperture) of elements,
for example 32 elements in a 128-element array, and the sub-aperture is used to transmit
and record a focused beam along the central axis. The sub-aperture is translated along the
transducer surface by adding one element to one side of the group and removing one element
from the other. In this way, a series of focused beams centralised along the longitudinal axis
of each sub-aperture is generated and an image can be formed line-by-line with a focal
region perpendicular to the imaging plane. This technique is generally used with linear and
curvi-linear arrays to enhance lateral resolution and is the most common method for clinical
ultrasound imaging.
Steered focused beam
Generating a steered beam that focuses to a specific point (or region) is the most complex
transmission beamforming technique described in this section, and is essentially a combin-
ation of the steered plane wave and focused beam methods above. Delays are applied to
the elements asymmetrically about the central axis of the transducer so that the generated
beam has a spherical wavefront that converges to a focal point situated off the central axis
(see figure 5.1). This scheme enables an image to be formed with a greater contrast ratio
and resolution along the focal region and can provide an increased field of view (FOV) as the
beam is swept in an arc. Generally this technique is reserved for phased array transducers
as they are able to steer the beam with large angles without deteriorating image quality by
introducing side lobes, while possessing a small footprint that is useful for imaging between
the ribs in applications such as echocardiography.
5.2.2 Receive beamforming
Applying delays to beamform the acoustic signal during transmission is one method for
altering and enhancing the received signals, however it is also possible (and often more be-
neficial) to beamform the received signals with post-processing. If the reflected signals are
recorded on the entire array of elements then receive beamforming can enhance the resolu-
tion, contrast, and dynamic range of the resultant image [338]. With receive beamforming
it is possible to create the final image on a pixel-by-pixel basis using a technique called
‘dynamic’ or ‘adaptive’ beamforming. This works in much the same way as transmission
focusing since the behaviour of acoustic waves is reciprocated in both directions. The ‘focus’
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is dynamically altered based on the time-of-flight to that specific point in space, and the
received signals on the entire array are delayed and summed based on this calculation. If
we consider a point in space (xf , zf ), the complete time-of-flight of an ultrasound wave,
ti(xf , zf ), is a sum of the time it takes for a transmitted ultrasound wave to propagate to
that point, tTX(xf , zf ), and the time it takes to return to the transducer array, tRX(xf , zf ),
given by,
ti(xf , zf ) = tTX(xf , zf ) + tRX(xf , zf ) (5.2)
=
zf
γ
+
√
z2f + (xi, xf )
2
γ
(5.3)
where xi is lateral position of element i, xf is the lateral position of the point, zf is the
depth of the point, and γ is the speed of sound in the medium. Using this equation, the
total time-of-flight to a specific point in space can be calculated for each element, ti, in the
array, and the original radio frequency (RF) data can then be delayed and summed to form
a single B-mode imaging point. This process is repeated for every point (or pixel) in the
imaging space until the full B-mode image is formed.
Compound plane wave imaging
In PWI, the full array of elements of a linear transducer is used to insonify the imaging region
with a single, parallel plane wave (see section 5.2.1) and the entire array is subsequently used
to record the backscattered echoes [339]. Compound plane wave imaging (CPWI) introduces
the emission of a series of plane waves that are steered at different angles, θn (where n is the
number of angles). Each transmission is recorded on the full array and, similarly to equation
5.2, the necessary delays are applied to each element according to the transmit and receive
time delays, given by,
ti(xf , zf ) = tTX(xf , zf ) + tRX(xf , zf ) (5.4)
=
zf cos θn + xf sin θn +
L
2 sin θn
γ
+
√
z2f + (xi, xf )
2
γ
(5.5)
where L is the length of the aperture. Using these delays, an image is formed for each
transmitted/received signal and the multiple coherently aligned images are finally summed
together to produce a single rectangular image with increased contrast and resolution com-
pared with single transmissions, due to the suppression of speckle. The more angles (and
therefore transmissions) that are used to generate the final image, the more information
that is gathered for a specific point in space and the more accurately the time delays can
be calculated, however this is at detriment to overall frame rate. Generally this technique is
used when ultrafast frame rates are required, such as when attempting to monitor moving
objects like tissue motion, blood motion and the movement of contrast agents through the
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vascular system [340], as it can typically achieve frame rates that are 100-fold compared to
‘line-by-line’ imaging [341].
Phased B-mode imaging
Phased B-mode imaging is a technique that produces a series of ‘A-lines’ that originate from
the centre of the array. Steered focused beams (discussed in the previous section 5.2.1) are
generated using all the elements of the array, with each line focused to a specified depth
and steered through a series of angles calculated depending on the required FOV. The entire
array is again used to record the scattered signals for post-processing where delays are
applied (calculated by the time-of-flight to the intended focal point) and summed together.
The resultant image is a circular sector with a large FOV that can span as much as 90°. A
phased array is the most appropriate transducer for this type of application because they
are designed with small pitch sizes (the distance between each element on the array), and
often lower centre frequencies, that enable the beams to be steered at large angles without
introducing side-lobes.
Photoacoustic imaging
Unlike the two imaging modes discussed previously, capturing PA data does not require
the transmission of an ultrasound pulse. Instead, the transducer is solely used to record
the signals generated from a laser pulse interacting with a material or a contrast agent. In
this case, the entire array of elements is used to record the PA signals and the image is
reconstructed based only on the receive time delays, tRX(xf , zf ), since the signal originates
from the imaging space and propagates back towards the transducer. To ensure the signals
are accurately located within the imaging space, the imaging system must be synced with the
laser system that is generating the photoacoustic signal. The travel time for a pulse of light is
considered to be instantaneous and the photoacoustic waves emitted by the absorbers in the
imaging space are assumed to be generated at the exact moment the laser fires. Therefore,
recording begins when the laser pulse is emitted and the location of the photoacoustic signals
are accurately positioned relative to a B-mode image by doubling the time-of-flight of the
received signals to account for the halved propagation time compared with a transmitted
ultrasound wave.
5.3 Transducers for EBUS mimicking
Due to the prohibitive cost of purchasing an EBUS system (upwards of £60k) the work
presented in this chapter was not performed using an EBUS probe. Instead, the following
work was implemented with a custom-built ultrasound array research platform (UARP) (see
figure 5.2), which allowed for a greater flexibility with regards to the imaging parameters
and excitation schemes, in addition to the ability to easily integrate it with a laser system.
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Linear (L11-4) Phased (P4-2) Phased (P9-1)
CIRS phantomUARP II
Figure 5.2: Images of the UARP II system, CIRS tissue-mimicking test phantom, and the
three transducer probes used in this study: linear (L11-4), phased (P4-2), and waterproof-
phased (P9-1).
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Table 5.1: Specifications of the three transducers available for imitating an EBUS system.
Transducer Centre frequency −6 dB Bandwidth Elements Pitch
Linear L11-4 7.55 MHz 4− 11 MHz 128 0.3 mm
Phased L4-2 2.78 MHz 2− 4 MHz 64 0.3 mm
Phased L9-1 5 MHz 1− 9 MHz 64 0.15 mm
Ultimately this provided a platform to imitate the EBUS technique and the combination
with PAI.
Three different transducers (see table 5.1 for specifications and figure 5.2 for images)
were available as imaging probes for the study and all three were investigated for suitability
as EBUS-mimicking devices. Due to the commercial nature of currently-available EBUS
systems, many of the specific details of the system are not publicly available, making it
difficult to imitate the technique exactly. However, reasonable assumptions were made with
regards to these unknown aspects. The transducer employed in a commercial EBUS system
is a curvi-linear array and the probe is likely to be made up of 64 elements. Thus, the
number of elements was fixed to 64 when transmitting and recording signals from each of
the different transducers. Furthermore, the typical centre frequencies of EBUS probes are
5, 7.5, 10, and 12 MHz, with 7.5 MHz being the most common, and so this was also closely
replicated. This range of possible frequencies enables the clinician to select a probe based
on the desired imaging parameters. Due to the centre frequency remaining fixed for each
specific transducer, the resolution also remains fixed. For example, a lower frequency probe
(5 MHz) facilitates the imaging of deeper locations within the lung, at the cost of image
resolution. Conversely, a higher frequency probe (12 MHz) provides high resolution images
of shallow regions. The range of available EBUS probes enables the detection and imaging
of a large number of lymph nodes within the lung, since both shallow and deep lymph nodes
can be resolved depending on the probe chosen. Another important parameter is the signal-
to-noise ratio (SNR) of an ultrasound image. However, unlike resolution (which is usually
a fixed parameter due to the excitation frequency), the SNR is governed by factors that
can change on a case-by-case basis, such as transmit energy and the strength of acoustic
reflections in tissue. Generally, the parameters chosen for optimal imaging in EBUS will
be a balance between sufficient image resolution needed to accurately determine and locate
lymph nodes, and the SNR.
A CIRS test phantom was used as a basis for testing the transducers and a series of im-
ages were recorded with various excitation parameters (outlined below). The CIRS phantom
is a multi-purpose ultrasound phantom that is the standard for quality assurance and per-
formance testing in ultrasound. In all cases, focussed beams were transmitted to a specific
depth to enhance the signal in that region and the beams were steered and beamformed to
varying degrees to mimic the typical images received using a clinical EBUS system. The
raw data was captured from the transducer probe to enable a higher level of flexibility when
post-processing at a later date. The raw data was frequency filtered between varying band-
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widths depending on the specifics of the study, such as the type of transducer used, imaging
depth, and excitation frequency. This was followed by line-by-line beamforming in polar
coordinates using a delay-and-sum (DAS) beamformer. Figure 5.3a shows an example of a
single line of raw data (recorded with the centre channel) and figure 5.3b shows a 3D mesh
of a beamformed image in decibels (dB), referenced to the maximum signal intensity of the
image.
5.3.1 Linear (L11-4)
The linear array transducer has a total of 128-elements and a high centre frequency (7.55 MHz)
that is designed for high resolution imaging of shallow tissue regions such as peripheral vas-
culature. The pitch size of 0.3 mm and high centre frequency imply that it is not suitable
for generating ultrasound waves with large beam steering angles due to the introduction
of side-lobes. Generally, a maximum steering angle of 5° is used for CPWI. However, aim
was to mimic the typical images and large FOVs obtained with EBUS systems, and so the
transducer was tested on a CIRS tissue-mimicking phantom with a 60° FOV using steered
focused beams (figure 5.4). The lateral resolution and signal-to-noise ratio (SNR) of the
central wire at the focal depth of 10, 20, 30, and 50 mm is given in table 5.2. The real
diameter of the wire is 0.1 mm. The high centre frequency facilitates the high resolution
of the images, despite only using the centre 64 elements of the array. At deep locations
(> 50 mm), the image became noisy, and the wires were harder to resolve. This is true even
when the focal depth was increased beyond 50 mm, since the natural elevation focus (or
intrinsic focus) of this transducer is 18 mm, and increasing the electronic focus significantly
beyond this natural limit will begin to have diminishing effects. Despite the large steering
angles (maximum 30°), the appearance of grating lobes in the beamformed images was not
obvious. This was likely due to the homogenous nature of the test phantom used for imaging.
The signal from the scatters was large enough to mask the grating lobes.
5.3.2 Phased (P4-2)
The P4-2 phased array was approximately 3 cm wide (half the size of the linear array) and
contained only 64 elements. This is because they are generally used for imaging in small
spaces where a large array would not be effective, such as between the ribs in the chest
area. The pitch size is equivalent to the linear array (L11-4), but the low centre frequency
(2.78 MHz) enables this probe to easily steer transmitted beams with large steering angles.
The low centre frequency and narrow bandwidth also enable the transducer to easily image
deep locations within the body (elevation focus = 50−70 mm), making it perfect for cardiac
imaging, however image resolution is reduced as a result. Figure 5.5 shows the beamformed
images of the same CIRS test phantom used for the linear probe, and in approximately
the same location, but with the P4-2 array. The transducer was excited with a 4 MHz sine
wave and the images were filtered between 2 − 5 MHz. The resolution and SNR values are
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Transmission pulse
Signal from wire
Signal from wire Hyperechoic region
(a)
(b)
Figure 5.3: An example of (a) a single recorded line of raw data from the centre channel of
a phased array (P9-1), and (b) a 3D mesh of the beamformed image in decibels.
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Figure 5.4: Ultrasound B-mode images of a CIRS test phantom using the linear array
transducer (L11-4) with an excitation frequency of 7.55 MHz, 60° FOV, and focal depth of
10 mm (top-left), 20 mm (top-right), 30 mm (bottom-left), and 50 mm (bottom-right).
Table 5.2: Calculated parameters for the linear array (L11-4) at different focal depths,
corresponding to figure 5.4.
Focus Lateral Resolution Signal-to-Noise (dB)
10 mm 0.97± 1 mm 9.3
20 mm 0.60± 1 mm 9.6
30 mm 0.58± 1 mm 10.9
50 mm 0.92± 1 mm 17.8
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Figure 5.5: Ultrasound B-mode images of a CIRS test phantom using the phased array
transducer (P4-2) with an excitation frequency of 4 MHz, 60° FOV, and focal depth of
10 mm (top-left), 20 mm (top-right), 30 mm (bottom-left), and 50 mm (bottom-right).
Table 5.3: Calculated parameters for the phased array (P4-2) at different focal depths,
corresponding to figure 5.5.
Focus Lateral Resolution Signal-to-Noise (dB)
10 mm 3.13± 1 mm 18.4
20 mm 1.50± 1 mm 16.1
30 mm 1.50± 1 mm 18.4
50 mm 2.31± 1 mm 19.3
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given in table 5.3, and the wire in the shallow focal region (10 mm) of the phantom was
poorly resolved (3.13 ± 0.1 mm) compared to those at 20 and 30 mm (resolution = 1.5 and
1.5±0.1 mm, respectively). The resolution and speckle pattern was overall poorer than that
of the linear array and, as mentioned previously, was due to the low centre frequency and
narrow bandwidth of the probe. In general, this probe is not suited for mimicking EBUS
systems as the centre frequency is below that of clinical systems (minimum 5 MHz) and the
narrow bandwidth will limit its ability to detect any photoacoustic signals when attempting
to combine it with PAI.
5.3.3 Phased (P9-1)
The P9-1 phased array has the widest bandwidth (90 % −6 dB) of any of the transducers
used in this study, and the slightly higher centre frequency of 5 MHz facilitates its ability
to create higher resolution images compared to the P4-2. To compensate for the higher
centre frequency and to enable large transmission steering angles, the distance between the
elements is smaller (pitch size = 0.15 mm) than the other two probes. The transducer was
excited at its centre frequency with a 60° FOV, and the recorded signals were filtered across
the −6 dB bandwidth of the transducer (figure 5.6). This probe was easily able to resolve
both the shallow and deeper located wires in the CIRS phantom and the resolution at the
focal depths of 10, 20, 30, and 50 mm was 1.03, 1.19, 1.43, and 2.31 ± 0.1 mm (table 5.4)
- overall higher than that of the P4-2 due to the higher transmission frequency and wide
bandwidth. As a probe for combined B-mode EBUS imaging and PAI, this transducer is
a suitable choice since it is able to detect frequencies as low as 1 MHz through to 9 MHz -
lending itself to identifying photoacoustic signals - and can be excited at higher frequencies
that match those of typical EBUS systems. As discussed in section 2.3, photoacoustic
signals are potentially broadband (depending largely on the size of the absorbers) and so a
transducer that is sensitive across a broad frequency range will capture a greater proportion
of the signal.
5.3.4 Wider FOVs
Clinical EBUS systems have a minimum FOV of 60°, however some can achieve up to 80°
[342]. This is accomplished with a curvi-linear, convex probe that additionally facilitates
the high-frequency range (5−12 MHz). Therefore, the three transducers were used to image
the CIRS phantom with a half steering angle of 40° (i.e 80° FOV) and the focus was kept
consistent at a depth of 30 mm below the phantom surface. The beamformed images for all
three probes are shown in figure 5.7. The wire nearest to the focal region in all three images
was easily resolved, with a resolution of 0.85, 1.43, and 1.5 ± 0.1 mm for the L11-4, P9-1,
and P4-2, respectively. Comparing the three images, it appeared that the P9-1 provided the
best image quality for all of the features. For example, the P4-2 had difficulty with resolving
the shallower wires when the focal depth was fixed to 30 mm, where the resolution of the
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Figure 5.6: Ultrasound B-mode images of a CIRS test phantom using the phased array
transducer (P9-1) with an excitation frequency of 5 MHz, 60° FOV, and focal depth of
10 mm (top-left), 20 mm (top-right), 30 mm (bottom-left), and 50 mm (bottom-right).
Table 5.4: Calculated parameters for the phased array (P9-1) at different focal depths,
corresponding to figure 5.6.
Focus Lateral Resolution Signal-to-Noise (dB)
10 mm 1.03± 1 mm 16.1
20 mm 1.19± 1 mm 19.3
30 mm 1.43± 1 mm 20.6
50 mm 2.31± 1 mm 21.5
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wires at 10 and 20 mm was 5.47 and 4.63±0.1 mm. Furthermore, the full set of 5 horizontal
wires located at approximately 42 mm can be seen in the P9-1 image, while the right-most
wire is not visible for the L11-4 and the 2 outer wires in the P4-2 image are beginning to be
lost to the background speckle.
The benefit of the wide FOV in EBUS is the ability to ‘see’ an increased area of tissue
and to enable the clinician to easily locate the lymph nodes for biopsy. With both of the
phased arrays, the features nearer the edges of the image (the circular hyperechoic region on
the right-hand side, and the first two wires 30 mm deep) are more prominent than with the
linear. Furthermore, it is possible to determine the next hyperechoic region (see figure 5.2
for the CIRS phantom layout) with the phased arrays. The ability for the phased probes to
steer the ultrasound beams without degrading image quality is evident with these images,
and the P9-1 is able to produce the clearest and most well-defined images compared with the
other two, owed largely to its wide bandwidth. Overall, these results suggest that the P9-1
array is most suited for application in EBUS-mimicking, with the L11-4 also performing
adequately. The P4-2 was deemed unsuitable for further use due to its poor general image
quality across the parameters studied.
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(a)
(b)
(c)
Figure 5.7: Ultrasound B-mode images of a CIRS test phantom using three different probes:
(a) Linear L11-4 (7.55 MHz centre frequency), (b) Phased L1-9 (7 MHz centre frequency),
(c) Phased L2-4 (4 MHz centre frequency), all with a 30 mm focus and 80° FOV.
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5.4 Imaging tissue-mimicking phantoms with gold nanorod
inclusions
To investigate combining conventional B-mode ultrasound with AuNR-mediated photoacous-
tic imaging, a tissue model was required. A section of ex vivo tissue could be used for this
part of the study, however it was important that the region of tissue that contained AuNRs
was a known and defined volume to enable the accuracy of photoacoustic imaging to be de-
termined. Therefore, it was necessary to conceive a replacement tissue model that reasonably
approximated real tissue and its scattering/absorption properties. Thus, a tissue-mimicking
phantom based on agar and gelatin was created as a suitable replacement.
5.4.1 Fabricating an agar tissue-mimicking phantom
The recipe was devised and adapted from original work by Ricky et al. (1995) [343] and
Madsen et al. (2005) [344] (table 5.5). 5.76 g (3.6% by mass) of agar powder (Acros Organics,
Geel, Belgium) was mixed with 132.64 mL filtered, degassed water (82.9% by volume) and
0.8 g of gelatine powder (0.5% by mass). The mixture was heated to 96 ◦C and maintained at
this temperature for approximately 30 min while being continuously degassed. The mixture
was left to cool to approximately 70 ◦C before 1.6 g (1% by mass) of Germall plus (Gracefruit,
Stirlingshire, U.K.) and 16 g Glycerin (10% by mass) was added and mixed. A small amount
of the mixture was poured into a separate container where Au50-849s were added to a final
concentration of 20µg mL−1 and mixed together. This AuNR-agar mixture was poured into
three wells of a 96-well plate and left to set into a cylindrical shape. Once set, the three
AuNR-agar cylinders were removed and placed into a larger rectangular plastic container at
increasing distances of 3 mm, 10 mm, and 20 mm away from the edge of the container. The
rest of the mixture was then carefully poured around the inclusions and left to set.
5.4.2 Plane wave imaging with a linear array
To validate the combined ultrasound and PAI technique, the phantom was imaged using the
CPWI beamforming method with the 128-element linear array transducer (L11-4, Verasonics
Inc., WA, USA) with a central frequency fc = 7.55 MHz and a certified −6 dB bandwidth
of 91 %, together with the Ultrasound Array Research Platform (UARP) II, to image the
Table 5.5: Recipe components for fabricating an agar tissue-mimicking phantom.
Component Quantity Proportion
Agar powder 5.76 g 3.6 % (w/v)
Filtered, degassed water 132.64 mL 82.9 % (v/v)
Gelatine powder 0.8 g 0.5 % (w/v)
Germall plus 1.6 g 1 % (w/v)
Glycerin 16 g 10 % (w/v)
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Figure 5.8: An agar tissue-mimicking phantom was created with 3 inclusions of AuNRs at
increasing depths (5 mm, 10 mm, and 20 mm). An ultrasound probe (Linear L11-4) was
used to insonify the phantom using plane waves and capture the reflected sound waves, in
addition to capturing the photoacoustic signals generated by the AuNR inclusions under
pulsed laser irradiation. Schematic shows both the front- and side-view of the experimental
setup.
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phantom both actively (plane wave, 9 compounding angles) and passively (photoacoustic
signal, 100 averages). The phantom containing the AuNR inclusions was placed inside a
tank of degassed, filtered, and de-ionised water (see figure 5.8)
The same PW laser system used in all the previous studies was used to generate PA
signals from the AuNR inclusions with a laser fluence = 19 ± 2 mJ cm−2 at the surface of
the phantom. The laser Q-switch was synced with the trigger of the UARP II to enable the
passive recording of PA signals generated by the laser. A background signal was also recorded
under the same conditions as the photoacoustic signals but with the laser shutter closed.
This enabled the background noise to be removed from the raw averaged PA data before
the images were reconstructed using a delay-and-sum (DAS) beamformer [196]. Finally, the
reconstructed PA image was overlaid onto the plane wave B-mode image.
Figure 5.9 shows the beamformed images at the various stages of the post-processing. The
9 compounding angles produced an image of the agar phantom with a well defined surface.
Axial filtering in the frequency domain between the −6 dB bandwidth of the transducer, and
lateral filtering of γ/2fc was applied to enhance the contrast and resolution of the image.
There was no clear evidence of the AuNR inclusion in the B-mode image, suggesting that
the phantom was well-made with perfectly matched boundaries between the inclusion and
the rest of the phantom, and no trapped pockets of air. The photoacoustic signal that was
averaged across 100 laser pulses resulted in the removal of almost all the background noise,
and the inclusion can be clearly seen. However, the image was not completely void of noise
(as can been seen by the horizontal signal located at a depth of approximately 24 mm in
figure 5.9d). Thus, a background signal was recorded (figure 5.9d) and subtracted from the
averaged PA image. The horizontal ‘strip’ of noise can be clearly seen in the background
signal and was caused by inherent noise from the electronics of the imaging system itself.
Once subtracted from the averaged PA image, the noise was successfully removed. Similarly
to the B-mode image, the PA signals were axially and laterally filtered to help improve the
image quality. The clearest PA images were recreated by axially filtering between 2−6 MHz
(figure 5.9), suggesting that the PA signals emitted by the AuNRs were predominately within
this frequency range. Subsequently, the separate B-mode image and processed PA image
were overlaid to create the final combined image (figure 5.10). In the final overlaid image,
the PA signal intensity was referenced to the peak signal in the B-mode image.
The inclusion of AuNRs was clearly visible above the background ultrasound image, and
was only discernable under pulsed laser illumination. The circular cross-sectional shape was
well defined except at the lower left side of the inclusion. This is a result of a combination
between the angle of incidence of the laser pulse, high concentration (and therefore high
optical absorption) of the inclusion, and the inhomogeneity of the distribution of AuNRs.
The laser light was incident from the rear of the phantom and just below the surface, and
the signal generated by the pulse hitting the back of the phantom can been seen in the
photoacoustic overlay (a small, bright signal originating from a location just above the
AuNR inclusion and approximately 1 mm below the surface). This meant the laser pulse
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(a) (b)
(d)
(e) (f)
(c)
Figure 5.9: (a) Plane-wave B-mode image of an agar phantom containing an inclusion of
Au50-841s with 9 compounding angles, a photoacoustic image with (b) a single laser pulse
and (c) 100 laser pulses (bandwidth filtered), (d) 100 laser pulses (filtered 2− 6 MHz), (e) a
background signal recorded during laser firing but shutter closed (i.e. no laser light emitted),
and (f) the final 128 frame photoacoustic image with the background signal removed.
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Figure 5.10: A combined photoacoustic image of an agar tissue-mimicking phantom with an
inclusion of AuNRs 3 mm below the surface. Both decibel scales are referenced to the peak
signal.
was passing through the phantom directed from right to left, and as the light was absorbed
by the AuNRs, the amount of light available to be absorbed by the AuNRs in the lower left
of the inclusion was reduced, leading to a reduction in PA signal intensity.
After confirming that the PA signals could indeed be detected from the shallow regions,
the ability for PAI of deeper locations was tested. A AuNR inclusion at approximately
10 mm and 20 mm was illuminated with an equivalent laser energy and number of pulses
as used previously, and the same technique (described in figure 5.9) was used to generate
the combined images. The PA signal intensity originating from 10 mm below the surface
is high (figure 5.11a) and comparable to the shallow region imaged previously, despite the
reduced optical intensity due to attenuation caused by the increased penetration depth and
turbid phantom. The circular cross section of the inclusion is discernable, however akin to
the shallow inclusion, the signal in the upper-left is stronger than the lower-right due to
the angle of the laser pulse. Increasing the depth further to 20 mm (figure 5.11b) results
in a significantly reduced PA signal intensity. Only the upper portion of the inclusion is
visible under laser irradiation with little-to-no signal originating from the lower half. In real
biological tissues, laser light incident on the skin surface begins to lose directionality after
several millimetres [273] due to the large number of optical scatters and strong scattering
coefficients of skin and epidermis (> 60 cm−1 at 500 nm [123]). In an agar phantom, the size
of the scatterers (< 1 µm) are not as large as those in tissue (10 − 100 µm) and therefore
the scattering events are not as strong. However, as the light penetrates deeper into the
phantom, scattering (and absorption) events do take place and the light begins to diffuse.
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Figure 5.11: Combined photoacoustic images of an agar tissue-mimicking phantom with an
inclusion of AuNRs (a) 10 mm and (b) 20 mm below the surface. Both decibel scales are
referenced to the peak signal.
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Figure 5.12: A combined ultrasound B-mode and photoacoustic image of an agar phantom
with an inclusion of AuNRs approximately 5 mm below the surface using a linear array
(L11-4) in the style of EBUS (i.e. 80° FOV). Strong reflections are visible from both the
ultrasound pulses and photoacoustic signals due to large trapped bubbles.
After 20 mm, the light has lost a significant amount of its energy at the surface and this is
shown by the reduced PA signal from the deep inclusion.
5.4.3 Steered focused beam imaging
To mimic EBUS, a series of B-mode and PA images were recorded and beamformed with
a wide FOV. A new phantom was created following a similar recipe and procedure to the
previous one (section 5.4.1), with the exception of slightly larger inclusions (approximately
11 mm) to imitate a larger tumour volume. Steered focussed beams were used to obtain an
80° FOV and the focal region was fixed at 30 mm. Figure 5.12 shows the combined image
recorded using the linear array (L11-4). Unfortunately, the fabrication of the phantom
was not homogeneous and large bubbles had formed inside the phantom during the mixing
process, leading to strong reflections from both the transmitted ultrasound pulses and the
PA signals. These are visible by the high intensity white horizontal lines in the B-mode
image (except for the uppermost line at approximately 17 mm which represents the top
surface of the phantom). As a result of this, the inclusion was clearly distinguishable from
the background speckle pattern in the B-mode image. The reduced and incomplete PA signal
was also affected by the large bubbles surrounding the inclusion and led to the signal only
originating from the upper portion of the inclusion where the laser intensity was highest.
Consequently, a new phantom was created in an attempt to reduce the trapped bubbles
and create a more homogenous phantom. Figure 5.13a shows the combined beamformed
B-mode and PA image of the new phantom, recorded using the linear array (L11-4). While
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(b)
(a)
Figure 5.13: A combined ultrasound B-mode and photoacoustic image of a new agar
phantom with an inclusion of AuNRs approximately 5 mm below the surface using (a) a
linear array (L11-4) and (b) a phased array (P9-1), in the style of EBUS (i.e. 80° FOV).
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there were still bubbles present in this phantom the diameters were significantly smaller and
were not obtrusive to the desired aim. The B-mode signals were axially filtered between
4 − 11 MHz (−6 dB bandwidth of the probe) and the PA signals were filtered between
4 − 8 MHz. The AuNR inclusion is mostly visible with the exception of a portion of the
lower region. The bottom edge of the inclusion is visible, suggesting that the distribution
of AuNRs within the inclusion was not uniform. This is possible since the small amount of
agar mixture used to create the inclusion cools and sets rapidly making it difficult to achieve
a homogenous distribution of AuNRs while mixing the two together.
The same phantom and inclusion was further imaged with the phased array probe (P9-1)
to determine if the previously discussed (section 5.3.3) potential benefits of the P9-1 array
leads to a more complete photoacoustic image. The B-mode image and PA image was axially
filtered between 4− 9 MHz and 3− 8 MHz, respectively, to improve the image quality, and
figure 5.13b shows the resultant combined B-mode and PA image. The background B-mode
speckle is largely uniform and free of noise and clutter. The recorded PA signal generated
by the inclusion of AuNRs is distributed across the entire volume of the inclusion. This
is in comparison to the image recorded with the L11-4 where large portions were missing.
The enhanced uniformity of the PA signal throughout the inclusion volume can be partly
attributed to the wide bandwidth of the phased P9-1 array. The frequency spectrum of the
PA signal predominately lay within 2− 8 MHz (see figures 5.14 and 5.15) and a significant
proportion came from the lower frequencies (< 5 MHz). The P9-1 is more sensitive at these
lower frequencies compared with the L11-4 and consequently was able to capture the full
range of the signals frequency spectrum while minimising noise. In addition, the contribution
to the PA signal from the upper end of the frequency spectrum was less than that of the
lower frequencies, and both the linear and phased arrays picked up significant noise at this
range. Furthermore, the overall sensitivity of the P9-1 probe is higher than that of the L11-
4. PA signals are weak in amplitude compared with reflected ultrasound pulses generated
by a transducer, and the P9-1 was able to detect these weaker PA signals more easily than
the linear. A combination of these factors led to an overall clearer and more well-defined
image.
118
5.4 Imaging tissue-mimicking phantoms with gold nanorod inclusions
(a)
(b)
(c)
Figure 5.14: The recorded photoacoustic signal is spread across a range of frequencies and
the transducer bandwidth affects signal detection. The photoacoustic signal recorded with
the linear array (L11-4) is filtered between (a) 2−4 MHz, (b) 4−8 MHz, and (c) 8−11 MHz.
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(a)
(b)
(c)
Figure 5.15: The recorded photoacoustic signal is spread across a range of frequencies and
the transducer bandwidth affects signal detection. The photoacoustic signal recorded with
the phased array (L9-1) is filtered between (a) 2−4 MHz, (b) 4−8 MHz, and (c) 8−11 MHz.
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5.5 Conclusions
The possibility of incorporating PA imaging into an EBUS system was explored using the
ultrasound array research platform (UARP) and tissue-mimicking phantoms. The unavail-
ability of an EBUS system meant it was necessary to imitate the technique as closely as
possible with the UARP and the transducers available. Nevertheless, the UARP enabled
a greater degree of flexibility with regards to incorporating and syncing a laser with the
system, in addition to image processing and beamforming. A linear array and two phased
arrays were explored as possible options for this combined modality and a CIRS tissue-
mimicking test phantom provided an accurate and consistent method for investigating the
transducers. The wide field of view (FOV) of EBUS transducers meant that steered focused
beams were the best beamforming method for replicating typical EBUS images. It was found
that the low frequency phased array (P4-2) was not suited for this approach as the narrow
bandwidth meant detection of PA signals would be poor and the B-mode image quality was
sub-optimal. Therefore, the P4-2 probe was discarded. The linear array, while providing
higher resolution image, was poor at deep locations and unable to accurately produce images
with a wide FOV. The wide-band phased array (P9-1) generated accurate B-mode images
and possessed the bandwidth to enhance PA signal detection. Therefore, in the absence of
an EBUS probe, it is suggested that a P9-1 array should be used to closely imitate EBUS.
When recording photoacoustic signals, there are a few important considerations that
must be made. Firstly, the employment of a wide bandwidth transducer is recommended
to ensure that a large proportion of the frequency content of the photoacoustic signals is
detected, and for detecting photoacoustic signals from AuNRs, a transducer that is sensitive
at the lower frequencies (2 − 4 MHz) may be required. Secondly, the post-processing and
receive beamforming of the recorded PA signals was important for producing a clear final
image. Photoacoustic signals are generally weak in amplitude and require multiple averages
to filter out background noise and reveal the ‘true’ photoacoustic signal. Furthermore,
accurate frequency filtering of the photoacoustic signals improved image quality and noise
suppression. Finally, it was shown that AuNR-mediated photoacoustic imaging is possible
at clinically relevant depths for EBUS, since the AuNR inclusions were observable at all the
depths investigated (3 mm, 10 mm, 20 mm), although only the upper portion of the inclusions
was visible for the deepest location. The scattering and loss of directionality of the laser
pulse as the beam propagated through the phantom meant laser intensity diminished with
increasing depths, showing the potential depth limitations of PAI.
Combined ultrasound and PAI of larger AuNR inclusions, with a diameter of approx-
imately 11 mm to replicate a larger tumour volume, were recorded using both the L11-4
and P9-1 in the style of EBUS images with a large FOV (80°). Both probes were able to
discern almost the entire ‘tumour’ region, however the phased array produced the highest
quality image, largely due to its ability to detect low frequency signals with minimal noise.
These results confirmed that a wide-bandwidth transducer is more effective for recording
photoacoustic signals generated by AuNRs since a larger proportion of the emitted signals
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can be recorded and less information is lost. These results highlight the necessary require-
ments for a multimodal transducer for combined ultrasound and PAI in an EBUS device.
EBUS is an already effective biomedical technique that has been shown to be enhanced
further with minimal adaptation. The work presented in this chapter provides the necessary
groundwork for progressing this technique.
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Conclusions
The continued development and advancement of plasmonic nanoparticles is enabling the cre-
ation and sustained improvement of new biomedical modalities that can potentially revolu-
tionise modern medicine. The work presented in this thesis aimed to explore and progress
the use of plasmonic gold nanorods for combined theranostic applications, framed in the
context of translating gold nanorods from a core understanding of their dynamics through
to clinical application, and in particular their use in lung cancer. A summary of the presen-
ted work is provided with some overarching conclusions, followed by a discussion regarding
future work and finally some closing remarks.
6.1 Summary and conclusions
Gold nanorods have the potential to create new combined light-based theranostic modalities
that can improve patient outcome by reducing negative side-effects and increasing diagnostic
and treatment times, in addition to further improving upon already existing clinical routines.
Chapter 2 presented the necessary knowledge to understand the rest of the work in this
thesis. Cancer is a leading cause of death worldwide, and the complex nature of the disease
combined with the large variations between cases make it difficult to diagnose and treat.
One of the biggest issues with current cancer treatments are that they are invasive and
can cause serious side effects for the patient. There is a strong need for new, minimally
invasive procedures that selectively destroy cancerous tissues while leaving healthy tissues
unharmed. Gold nanoparticles have a large set of desirable characteristics that make them
excellent mediators of new and existing biomedicines, and have shown promise for use in
minimally-invasive cancer care. If the final aim is to use gold nanoparticles in routine
medical procedures across the world, then large-scale synthesis is a considerable challenge
that must be addressed. All of the properties of gold nanoparticles - size, shape, SPRs,
surface coating, functionalisation, etc - must be highly controllable en masse to meet the
rigorous criteria required for wide-spread clinical use. Furthermore, the ‘small’ nature of
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nanoparticles, combined with their potentially complex compositions, makes studying their
biological interactions in vivo difficult, and even more-so when translating them for human
use. However, extensive studies that cover all aspects of introducing gold nanoparticles
into the body, such as aggregation, protein adsorption, cellular interactions, biodistribution,
renal clearance, etc, are required to ensure the safety and efficacy of the treatments.
The photoacoustic effect is a powerful phenomenon that enables non-invasive, non-
ionising imaging modalities that combine the high contrast and spectral specificity of optical-
based approaches with the high spatial resolution of ultrasound. Gold nanoparticles can be
used to enhance the photoacoustic effect and provide important additional information that
further extends the potential applications. Functionalised AuNRs targeted to a specific loc-
ation in the body, such as a tumour site, can provide an optical absorption contrast between
the background and malignant tissues, that can be exploited through the use of pulsed
laser irradiation. Furthermore, the exact same AuNRs situated in the tumour volume can
additionally act as photoabsorbers for plasmonic photothermal therapy. This therapeutic
technique - usually conducted with continuous wave lasers - is able to destroy diseased tis-
sues by inducing a bulk temperature increase in target region while minimising damage
to surrounding healthy tissues. It is potentially possible to enhance this therapy further
by substituting continuous wave lasers for pulsed lasers. This seemingly small but crucial
change could open up additional benefits such as the further reduction of damage to healthy
tissues, simultaneous imaging and therapy, and reduced cell toxicity and drug resistance
due to mechanical damage. Gold nanoparticles, and the light-based modalities that rely
on them, have the capacity to provide a combined theranostic approach for the diagnosis
and treatment of lung cancer. For example, endobronchial ultrasound is a routine clinical
procedure that already possesses the underlying technology to be easily combined with such
nanoparticle-mediated techniques, and could provide a way to locate, diagnose, stage and
treat a lung tumour with a single modality.
6.1.1 Chapter 3
The main focus of chapter 3 was to explore the effect of gold nanorod size on a variety of
factors, such as photoacoustic response, photostability, cellular toxicity and uptake. Since
gold nanoparticles can be synthesised into almost any shape and size it is important to
understand what effect this might have on the wide range of aspects related to biomedical
applications. Gold nanorods absorb light based predominately on their aspect ratio, and
since it is desirable for them to absorb light in the near-infrared (due to increased optical
penetration depths) and can be almost any size, there are a large number of AuNR sizes
that are potential candidates as contrast agents. Therefore, four different sized AuNRs
with similar aspect ratios, and consequently similar surface plasmon resonances, were in-
vestigated. Aside from their comparable dimensions, these AuNRs were chosen due to their
commercial access and ‘off-the-shelf’ accessibility. As discussed previously, if AuNRs are to
be used clinically then it is essential that they can be reproduced in large quantities with
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highly controllable properties, and the AuNRs used in this study satisfied these conditions.
Under pulsed laser illumination it was possible to generate a photoacoustic signal from all
of the AuNRs studied (section 3.3). The concentration of AuNRs played a significant part
in determining their photoacoustic response, and more importantly, the way in which the
concentrations were defined was significant. This poses crucial questions as to the governing
factors that control the uptake of AuNRs. For example, if the deliverability of AuNRs to
a tumour is controlled predominately by the number of AuNRs then the best results would
likely be seen with larger AuNRs. If instead it is governed by total mass, then the smal-
lest AuNRs used in the study were the most effective photoacoustic signal generators. In
either case, it is evident that reasonably large numbers of AuNRs are required (upwards
of 1× 109 NP mL−1) to generate a sufficient photoacoustic signal, and improving on the
deliverability of AuNRs to a desired region is a particularly important area that must be
optimised. To address this concern, controlled in vivo studies are required that specifically
consider the dependence of mass or nanoparticle number on the uptake of target tissue.
AuNRs are susceptible to thermal reshaping under pulsed laser illumination and since
their surface plasmon resonances are governed by their specific rod-shape and aspect ratio,
photothermal degradation is a pivotal risk for the efficacy of biomedical modalities that rely
on their ability to absorb light. If they are to be used in a combined theranostic approach,
then it is critical that they are able to withstand the conditions necessary to complete each
of the individual techniques in order for them to maintain their beneficial properties through
to the final treatment. It was found that large AuNRs were less photothermally stable than
their smaller counterparts (section 3.3), and was attributed to a higher peak temperature
under nanosecond pulsed irradiation. The large AuNRs (widths of 40 and 50 nm) saw melt-
ing and reshaping at relatively low fluences (20 mJ cm−2), however the least stable were
the 25 nm wide AuNRs. For theranostic modalities that require AuNRs to maintain their
strong optical absorption, the results suggest that small AuNRs (width ≤ 10 nm) are able to
withstand extended periods of laser illumination and would be more suitable for this applic-
ation. There is a large amount of literature surrounding the photostability of nanoparticles,
however the vast range of nanoparticles and laser parameters used in those studies make it
difficult to draw decisive conclusions. For example, gold nanoparticles of different shapes
and sizes can have a variety of coatings and can be further complicated by the addition of
functionalising ligands. One or a combination of these factors can have a considerable effect
on photothermal degradation (as well as many of the other investigated factors) and so it is
important to understand how simple nanoparticles behave before exploring more complex ar-
rangements. For example, gold nanorods with a reduced graphene oxide coating have shown
enhanced photothermal conversion efficiencies compared with non-coated ones [345], while
silica-coated AuNRs show improved photostability but generated a reduced photothermal
effect [346].
Biocompatibility and toxicity is also critical to the progression and development of
AuNRs for biomedical use. There are a range of factors that can affect the toxicity of
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AuNRs to cells, including surface coating, surface charge, and colloidal stability. In chapter
3, it was found that their size also governed their toxicity to lung cancer cells, with larger
AuNRs exhibiting increased toxicity compared with smaller ones at equivalent concentra-
tions (NP mL−1). It is important to understand that an equivalent number of particles that
have a different amount of mass per particle results in an overall difference in total mass.
Thus, larger AuNRs will have an increased total mass compared with smaller ones, which
may have an affect on overall toxicity to cells. There is a lack of consensus in the literature
surrounding the size-dependent toxicity of AuNRs due to the vast range of variables (coating,
functionalities, experimental methods, cell lines, etc) across each study, however the presen-
ted findings are in agreement with studies on the toxicity of spherical gold nanoparticles
[347, 348], where generally an increase in size lead to an increase in toxicity.
A limitation of the work in chapter 3 is that only four different sized AuNRs were
explored. This was largely due to the availability of different sized AuNRs that absorbed
light at a similar wavelength. Therefore, it would be beneficial to explore an even greater
range of AuNR sizes (that absorb in the near infrared) with respect to the parameters
investigated in chapter 3. Since smaller AuNRs have shown to be the most promising
candidates, it would follow to study a range of even smaller AuNRs for their potential use
in photoacoustic imaging. Nevertheless, clear size-dependent relationships were observed in
the presented work and solid conclusions were able to be drawn.
6.1.2 Chapter 4
The main aims of chapter 4 were to investigate AuNRs with similar dimensions and prop-
erties as in chapter 3 but for use as photoabsorbers for photothermal applications, and to
explore the use of pulsed lasers for therapeutic application. Continuous wave lasers are often
used for plasmonic photothermal therapy as they deliver a steady stream of optical energy
that photothermal absorbers can use to damage tissues by generating heat. It is an effective
way of destroying tissue as it only requires a reasonably small temperature increase in the
target region to begin to cause irreversible damage. However, there are potential problems
with this approach, such as damage to healthy tissues through heat conducting into the sur-
roundings and cells developing a resistance to heat or drugs due to thermal damage. Pulsed
lasers, on the other hand, require photoabsorbers to damage tissues, and result in a rapid
and intense temperature rise in extreme proximity to the absorbers, with no bulk heating.
Using pulsed lasers for therapy would negate the negative effects of continuous wave lasers
while also providing additional benefits, such as simultaneous imaging during therapy via
the photoacoustic effect.
The concentration of absorbers, or in this case gold nanorods, is essential to treatment
success since too few will produce an insufficient temperature rise for thermal damage. In
chapter 4, two different sized AuNRs with SPRs around 850 nm were investigated, and were
chosen due to the 854 nm fixed wavelength of the continuous wave laser. Furthermore,
the AuNRs were from a large-scale synthesis process with repeatable characteristics and
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properties, similarly to the study in chapter 3. It was found that the AuNR size did not affect
the overall peak temperature increase at equivalent concentrations (µg mL−1) achieved under
continuous laser irradiation, while no change in temperature was observed when a pulsed
laser was used. This suggests that, for therapeutic applications, it likely does not matter
what sized AuNR is used to achieve a desired temperature under CW laser irradiation, and
more focus can be placed on the other factors that AuNR size may affect, such as the aspects
discussed in the chapter 3 (deliverability, toxicity, etc.).
The effect that AuNR size has on the toxicity to lung cancer cells under laser irradiation
was explored. Lung cancer was chosen as the treatment target to further the idea that the
techniques discussed in this thesis could be applied for thernostic applications in lung cancer.
Both continuous wave and pulsed lasers were used as optical sources, and the differences in
the number of AuNRs in the path of the laser beam was explored. For continuous wave lasers,
an increase in cell toxicity was observed when AuNRs that had not been taken up by the
cells were still situated around the cells. While, with a pulsed laser, it was only the AuNRs
that had been taken up by the lung cancer cells that were the leading cause of death. This
was attributed to the fact that a larger number of AuNRs absorbing continuous laser light
produced a higher temperature increase in the cell media, and therefore thermal damage was
higher, while the location of the AuNRs was much more significant in determining cell death
for a pulsed laser due to the mechanical stresses induced by the laser pulses and the extreme
heat only occurring within close proximity to the AuNRs. This has important implications
for clinical translation, since if pulsed lasers are to be employed for therapeutic purposes then
the location of the AuNRs in relation to the target cells is important for successful treatment.
Conversely, with continuous wave lasers, the AuNR location may not be as important as
long as there is a sufficient distribution of AuNRs within the target area. The size of the
AuNRs generally did not have a substantial effect on the laser-induced toxicity, except for
the smallest AuNRs considered in the study (width < 10 nm) which produced the highest
photothermal efficacy. In all cases, these small AuNRs were the most effective agents for
cell destruction, regardless of the experimental parameters, and the enhanced therapeutic
effect was attributed to both their ability to be taken up by the cells more proficiently, and
their increased surface-to-volume ratio.
Functionalising and targeting AuNRs to diseased tissue is potentially a highly effective
method for not only ensuring that the AuNRs are delivered to a desired location in the body,
but also to increase the total number that specifically accumulate in that region and con-
sequently improve diagnostic/therapeutic efficacy. Furthermore, targeting has the capacity
to reduce the dose that is administered to a patient and still achieve sufficient uptake at the
target location. This can reduce the negative side-effects caused by large doses, lessening
the need for prohibitively large-scale production, and lowering treatment costs. There is,
however, a debate as to how effective targeting is in a ‘real-world’ scenario where in vivo
results have shown only slight improvements to delivering efficiency. Nevertheless, the body
of work and concepts underpinning targeting - the dynamics of cell growth, proliferation,
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and cellular composition on a molecular level - is solid, and presently appears to be the
only substantial mechanism for improving therapeutic efficacy. The targeting efficiency and
subsequent effect on laser-induced therapy of EGFR-targeting AuNRs was investigated in
chapter 4, and was found to have a positive effect on both cellular uptake and destruction
of lung cancer cells under both continuous and pulsed laser irradiation. Perhaps the most
surprising result was that targeted gold nanorods facilitated an enhanced therapeutic effect
under pulsed laser illumination compared with continuous wave. This significant decrease
in cell viability was further attributed to the location of the AuNRs with respect to the
cells, and the number of AuNRs contributing to cell destruction, facilitated by the enhanced
affinity of the AuNRs to the lung cancer cells. The anti-EGFR-conjugated AuNRs were
situated in close proximity to the membrane of the cells, and were potentially arranged in
clusters, that enabled the mechanical stresses and bubble formations around the AuNRs to
disrupt and damage the cell walls.
Overall, it seems that pulsed lasers can indeed be used for therapeutic (as well as dia-
gnostic and imaging) purposes, and chapter 4 provided a solid understanding of how the
size, location, and targeting of AuNRs can drastically affect the observed outcomes under
pulsed and continuous wave laser generation.
6.1.3 Chapter 5
In the final chapter, the focus was shifted from understanding the principles and effects
that gold nanorods can have on diagnostics, imaging and therapy, to demonstrating the
possibility for improving a clinical diagnostic tool: endobronchial ultrasound. This import-
ant technique is routinely used to guide a needle biopsy for the diagnosing and staging
lung cancer, and does so with exceptional sensitivity. It is currently used as a secondary
method for determining the progress of a lung tumour, however it has the potential to be
a primary investigatory procedure, and one that could facilitate the locating, diagnosing,
staging, and treating of a tumour with a single modality. This theranostic tool could be
achieved by incorporating a laser fibre into an endobronchial device that would allow the
addition of a photoacoustic component to the already existing ultrasound capabilities, and
potentially further enhance the usefulness of the probe by enabling a treatment avenue via
photothermal therapy, all mediated with the aid of AuNRs targeted to the diseased lung
tissue. The technology to accomplish this combined multimodality already exists - except
for the continued development and refinement of AuNRs - and with minimal adaptation
could become a reality.
The unavailability of an endobronchial ultrasound system meant that the technique
needed to be mimicked with a custom, in-house built ultrasound research platform that
enabled a high level of flexibility for combining conventional ultrasound with photoacoustic
imaging. Three transducers were explored for suitability with imitating the typical paramet-
ers associated with endobronchial ultrasound probes, such as frequency, number of elements,
and field of view. It was determined that the wideband phased array was most suited for
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this application due to its ability to be excited at frequencies (5 − 9 MHz) comparable to
EBUS (5− 12 MHz), capacity to record the low amplitude and potentially broad spectrum
of photoacoustic signals, and generate images with a wide field of view (80°). These spe-
cific requirements apply for any future probe that may be implemented into a combined
endobronchial ultrasound and photoacoustic imaging system, since a high frequency enables
high resolution imaging of shallow regions that enable the locating of lymph nodes, and
the wide bandwidth allows the detection of the potentially broad photoacoustic frequency
spectrum to form an image of the entire region emitting the photoacoustic signals.
Plane-wave B-mode images were recorded using a linear array transducer along with
photoacoustic signals generated by small inclusions of gold nanorods at increasing depths
in a tissue-mimicking agar phantom. The ultrasound images of the phantom were formed
without the visibility of the inclusion - as may be the case with a tumour in vivo - and
the inclusion only appeared under pulse laser illumination. Moreover, the inclusion at the
deepest location was able to be resolved, although not entirely, due to the reduction in laser
intensity and loss of directionality as the light penetrated deeper into the phantom. This
is an important aspect to consider in a clinical scenario as tumours that are situated deep
inside tissue will be harder to resolve with photoacoustic imaging since laser penetration will
be reduced. This is the limiting factor with optical-based biomedical approaches and is the
reason that near-infrared light is preferred due to increased penetration in tissues. Accurate
and meaningful filtering of the photoacoustic signals was a crucial aspect to resolving a clear
image. A significant proportion of the photoacoustic signals were located at the lower end
of the frequency spectrum (< 4 MHz) and the wide-band phased array had the bandwidth
to detect these weak, low frequency signals without picking up high levels of noise. Post-
processing and accurate filtering enabled almost the entire volume of the large inclusion to
be resolved.
Chapter 5 demonstrated the ability for successful combination of endobronchial ultra-
sound with photoacoustic imaging, and the potential advantages of doing so. Taking this
body of work forward, the natural next step would to be to acquire an endobronchial ultra-
sound system and look into incorporating a laser fibre into the endoscope to demonstrate
cellular PPTT.
6.2 Future work
There are many routes for investigation that follow-on from the work presented in this thesis,
and some of the more interesting ones will be discussed here.
Firstly, one of the biggest issues to arise from this work, was the lack of knowledge
surrounding the in vivo cellular uptake of gold nanorods dependent on equivalent total mass
or number of nanoparticles. The literature quote nanoparticle concentrations in terms of
equivalent mass (µg mL−1), number of particles (NP mL−1), or number of moles (nmol),
across the vast range of nanoparticle compositions, shapes, sizes, and coatings, and little is
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known regarding whether it is possible to deliver an equivalent concentration of nanoparticles
to a target region across different sizes. Therefore, a size-dependent study for cellular uptake
in vivo is currently in progress across a range of gold nanorod sizes similar to the ones
in the presented work (widths of 10, 25, 40, and 50 nm) to determine whether injections
of equivalent concentrations (mass and number of nanoparticles) affects the total cellular
uptake exhibited by tumour tissues and other vital organs. Furthermore, it would be valuable
to obtain gold nanorods with a range of widths between 5− 25 nm, to determine the effects
of small gold nanorods on the parameters studied in this thesis.
Secondly, due to the promising results observed using a pulsed laser to induce cell death
with EGFR-targeted AuNRs, it would be beneficial to study more closely the route cause of
cell-death, and more specifically, conduct acoustic-monitoring of the potential bubble form-
ation and collapse caused by the pulsed laser-heating of aggregated AuNRs, mediated by the
anti-EGFR targeting ligands. This would provide further understanding of the mechanisms
through which pulsed lasers can induce cell death, and may lead to improved theranostic
modalities.
Finally, to continue the work in chapter 5, it would be useful to acquire a commercial,
clinical endobronchial ultrasound probe to evaluate and develop the integration of a laser
fibre into the existing diagnostic system. This could then be tested in more sophisticated
tissue-mimicking phantoms, with a long-term aim of investigating the newly developed com-
bined endobronchial ultrasound and photoacoustic imaging in vivo, with optimised targeted
gold nanorods.
6.3 Final Remarks
The use of nanotechnology in biomedicine is an exciting area of research with a huge potential
to revolutionise the medical world, however continued research and development into the
many complex aspects of nanoparticles is critical to its success. The work in this thesis has
demonstrated the ability for gold nanorods to be used in combined theranostic applications
and has positive implications for future work. Precision treatments, that are tailored to the
specifics of individual patients and consider the subtle differences between each and every
case, are the future of medicine, and it is only a matter of time before we master the ability
to exploit these differences and ultimately conquer one of the biggest challenges humanity
has ever faced, cancer.
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